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ABSTRACT 
Five studies were designed to characterize the effects of a non-steroidal aromatase inhibitor, 
letrozole, on ovarian function in cattle. The general hypothesis was that non-steroidal aromatase 
inhibitors have potential as a steroid-free option for the control of ovarian function for the 
purposes of fixed-time artificial insemination and embryo production. The specific objectives 
were to determine the effect of route and vehicle, type of aromatase inhibitor, and duration of 
aromatase inhibitor treatment (short vs prolonged) on ovarian follicles in cattle, and to test the 
efficacy of an aromatase inhibitor-based protocol to synchronize ovulation in cattle. In the first 
experiment, heifers were treated with letrozole intravenously (n=10) or intramuscularly (n=10) 
or allocated in iv and im control groups (n=5/group). During the second experiment, heifers were 
divided randomly into two groups (n=15/group) and an intravaginal device containing 1 g of 
letrozole or a blank device (control) was inserted. The third experiment was designed with the 
goal of formulating and testing an intravaginal device that provides biologically active 
circulating concentrations of an aromatase inhibitor for a minimum of 4 days. The biological 
significance of the pharmacokinetic differences between the letrozole intravaginal devices 
resulting from the third study was evaluated during the fourth study. A final study was designed 
to determine the effect of stage of the estrous cycle on the proportion of animals that ovulated 
and the synchrony of ovulation of heifers treated with an aromatase inhibitor-based ovulation-
synchronization protocol and to determine subsequent pregnancy outcomes. In all the studies, the 
effects of aromatase inhibitor on ovarian function were assessed by transrectal ultrasound 
examination of the ovaries, and blood samples were collected for hormone concentration 
determination. Results demonstrated that route of administration, or more precisely, the nature of 
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the vehicle used for the administration of letrozole (intravenous, intramuscular depot, short 
release intravaginal or prolonged release intravaginal) has an impact on the effects of letrozole 
on hormonal profiles and ovarian dynamics. The intramuscular route appeared to provide a 
prolonged release of letrozole from the injection site which had a marked effect on estradiol 
production, dominant follicle lifespan, and CL form and function. Letrozole treatment during the 
ovulatory follicle wave by means of a gel-based intravaginal releasing device during the second 
study resulted in more rapidly growing dominant follicles and larger ovulatory follicles, delayed 
ovulation (by 24 h) of a single follicle and formation of a CL that secreted higher levels of 
progesterone. A wax-based vehicle allowed for a steady and continuous delivery of the active 
compound over the treatment period. During the third study, the addition of a letrozole-
containing gel coating increased the rate of initial absorption and hastened the increase on 
plasma concentrations of the active ingredient, while the letrozole-containing wax-based vehicle 
prolonged drug-delivery from the intravaginal device. When tested in vivo during the fourth 
study, we confirmed that letrozole-impregnated intravaginal devices formulated with a wax base 
plus a gel coat vehicle was most suitable for the application of a letrozole-based protocol for the 
synchronization of ovulation in cattle, since it effectively delivered elevated concentrations of 
letrozole, and reduced estradiol production resulting in increased follicular growth and lifespan, 
without adversely affecting progesterone production. The application of a letrozole-impregnated 
intravaginal device for 4 days, combined with PGF treatment at device removal and GnRH 24 h 
post-device removal increased the percentage of ovulations and synchrony of ovulation in cattle, 
regardless the stage of the estrous cycle at initiation of treatment. As observed in previous 
studies, the effects observed could be associated with an increase in circulating LH 
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concentrations. However, the effects of treatment on gonadotropin concentrations are 
inconclusive, possibly due to inadequate sampling frequency. The impact of letrozole treatment 
of oocyte fertility remains unknown. The results of the five experiments support our general 
hypothesis that non-steroidal aromatase inhibitors have potential as a steroid-free option for the 
control of ovarian function in cattle. However, further research is needed in order to elucidate the 
effects of letrozole treatment during the proestrous on oocyte competence and fertility of the 
resulting ovulations in cattle. 
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CHAPTER 1: GENERAL INTRODUCTION 
Reproductive efficiency is the single most important factor affecting profitability in the cattle 
industry. The impact of methods for controlling the estrous cycle in cattle may be illustrated by 
estimates of the use of artificial insemination (AI) and embryo transfer (ET) in cattle. A 
conservative estimate of the worldwide use of AI is 83 million cows per year – estimated to 
represent about 20% of the breedable cattle population (25% in North America) [1]. Worldwide, 
53% of cows artificially inseminated are of dairy breeds and 39% are of beef breeds, but in 
Canada, the gap is much wider: 94% in dairy and 6% in beef. Regarding ET, just over 120,000 
donor cows are collected each year worldwide and 800,000 embryos are transferred [2]. In 
Canada, those number do not exceed 13,500 and 55,000, respectively [3]. 
Estrogen-based protocols as a treatment for controlling and synchronizing ovulation in 
cattle, have revolutionized breeding practices and enabled beef producers to make use of AI as 
never before because labour and resources could now be pre-scheduled (e.g., fixed-time artificial 
insemination; FTAI). These protocols also allowed for the wider application of superovulation 
and embryo transfer due to their effectiveness to synchronize follicular wave emergence [4-8]. 
Steroid-induced wave synchronization is associated with regression of the dominant follicle 
followed by a surge in circulating FSH and subsequent emergence of a new follicular wave at a 
consistent interval post-treatment. Steroid-induced regression of the dominant follicle is a result 
of a systemic alteration in feedback of estradiol and progesterone on pituitary release of LH and 
FSH [9]. Estradiol suppresses FSH release [10] and has been reported to decrease LH pulse 
amplitude in sheep [11] and cattle [12]. Progesterone has been reported to decrease LH pulse 
frequency and suppress maximal diameter of the dominant follicle in a dose-dependent manner 
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in cattle [13-18]. Once the suppressive effects of estradiol are removed, FSH surges resulting in 
the emergence of a new wave of follicular development approximately 4 days after 
estradiol/progesterone treatment, regardless of the stage of development of the dominant follicle 
at the time of treatment [4, 5, 19].  
However, increasing consumer sensitivity to the possible deleterious effects of estrogens in 
food and in the environment [20] has led to new regulations about the use of estrogenic products 
in livestock. The European Union has already banned the use of estrogenic products in food 
producing animals [21-24]. In United States [25] and Canada [26], estrogens cannot be used for 
synchronization of estrus except by prescription and custom-compounding. In 2007, New 
Zealand and Australia banned use of estrogens in lactating dairy animals [24]. The ban of the use 
of estrogens in livestock and lack of commercially availability of estrogenic preparations 
negatively impacts the implementation of reproductive biotechnologies in cattle production 
systems, limiting potential reproductive efficiency and genetic improvement provided by the use 
of AI or MOET [24]. In this context, the development of alternative methods for controlling 
ovarian function in cattle, with efficacy and predictability comparable with that of estrogen plus 
progesterone treatments [5], and with no toxic or harmful effects on human and animal health is 
needed. 
Another important factor that negatively impacts reproductive efficiency, mainly in dairy 
industry, is the decline in fertility observed in high producing cows. Over a period of 15-20 
years, the rate of decline in fertility has been 0.5% per annum in the USA [27]; in UK herds, 
pregnancy at first insemination has gone from 56% to 40%, approaching a decline rate of 1% per 
annum [28]. The dramatic decline in fertility has been associated with a reduction in expression 
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of heat, failure to ovulate, and poor luteal function. Regarding luteal function, cows that failed to 
carry a pregnancy had lower levels of progesterone at days 14 and 21 post-breeding compared to 
those that remained pregnant [29]. Several research groups have concluded that embryos 
developing under higher levels of progesterone early in the luteal phase grow more rapidly and 
were more likely to prevent prostaglandin F2α (PGF) secretion by the uterus; i.e. prevent 
luteolysis and achieve maternal recognition of pregnancy [30-32]. The development of a 
treatment to improve early luteal function and therefore support the development of a larger 
embryo will be of extreme importance not only for AI in dairy industry but also for the success 
of ET in both beef and dairy herds. 
Aromatase inhibitors prevent the body from producing its own estrogens; thus, they could 
potentially be applied to the management of estrogen-dependent physiologic functions such as 
reproduction. Letrozole (Femara

, Novartis) is a non-steroidal aromatase inhibitor that 
inactivates the aromatase enzyme by reversibly binding to the heme group of the P450 subunit of 
the enzyme. Letrozole is used as an adjuvant treatment for hormone-responsive breast cancer in 
post-menopausal women [33] and has been used as a fertility therapy for women undergoing 
assisted reproduction because of its putative effect on FSH secretion through removal of the 
negative feedback of estradiol [34]. A 5-day regimen of letrozole (2.5 mg/day from 3 to 7 days 
after the beginning of menses) has been used for ovarian stimulation in women [35], and larger 
or increasing doses of letrozole have been used to induce ovarian superstimulation [36, 37]. It 
has also been applied to lower the cost of superstimulatory treatments by reducing the dose of 
FSH required [38]. 
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We conducted two studies to assess the effects of aromatase inhibitors on ovarian function in 
cattle. Contrary to the above mentioned hypothesis proposed to explain the effect of aromatase 
inhibitors in women [34], letrozole treatment of cattle did not induce follicular atresia or hasten 
emergence of a new follicular wave, whether given as a single intravenous dose on Day 3 post-
ovulation [39] or in a 3-day regimen from Days 1-3, 3-5 or 5-7 post-ovulation [40]. Rather, 
letrozole treatment increased mean plasma LH concentrations resulting in a prolonged period of 
dominance of the extant DF and delayed emergence of the next follicular wave. In addition, the 
3-day letrozole treatment was associated with greater corpus luteum (CL) diameters [40]. 
Studies done in cattle in our laboratory established a solid foundation for the development of 
letrozole-based synchronization and fertility treatments:  
• Short or prolonged letrozole treatment extends the lifespan of the dominant follicle 
• Letrozole treatment can be used to delay follicle wave emergence 
• Letrozole treatment induces the formation of a larger dominant follicle  
• Letrozole treatment is luteotrophic (larger CL that secretes more progesterone) 
The set of studies presented in this dissertation aim to provide convincing data that 
aromatase inhibitors can be applied as a safe and effective method to control the estrous cycle 
and improve fertility in cattle. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Reproductive Physiology in Cattle 
2.1.1 Hypothalamus-Pituitary-Ovarian Axis 
The hypothalamus-pituitary-ovarian (HPO) axis is comprised by the anatomic and functional 
relationships existing among the hypothalamus, pituitary gland, and ovaries, thus allowing these 
endocrine glands to act as a single entity. The hormones involved in the control of this axis 
include gonadotropin-releasing hormone (GnRH, produced by the hypothalamus), luteinizing 
hormone and follicle-stimulating hormone (LH and FSH, respectively; produced by the anterior 
pituitary), and estradiol, inhibin and progesterone (synthetized in the ovaries). However, 
numerous other factors and hormones have been linked to the control of the HPO axis in 
mammals. Furthermore, the neuroendocrine nature of the HPO axis integrates external factors 
such as stress, nutrition, and photoperiod, in the control of the reproductive physiology [41]. 
The hypothalamus is located in the ventral brain and comprises groups of cell bodies known 
as hypothalamic nuclei (namely, the paraventricular nucleus, the surge center and the tonic or 
pulsatile center) [41, 42]. The neurons located in the surge and tonic centers secrete GnRH, while 
the neurons of the paraventricular nucleus synthetize oxytocin. Anatomic arrangements are of 
special importance for the communication between the hypothalamus and pituitary gland. 
GnRH-producing neurons release their secretion through long axons located in vicinity to the 
pituitary stalk [43]. Within the pituitary stalk there is highly complex capillary network, the 
hypothalamo-hypophyseal portal system, which allows GnRH to reach the anterior portion of the 
pituitary, the adenohypophysis. It is believed that the main function of this capillary system is to 
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prevent the very small amount of GnRH produced by the hypothalamus from getting diluted in 
the general circulation [42]. Once GnRH binds to its receptors on the gonadotroph cells, LH and 
FSH are produced and secreted into the blood stream in order to reach their target organ, the 
ovaries [43]. 
The gonadotropins (FSH and LH) play an important role in communicating with the ovaries. 
Gonadotropins activate the ovaries to produce different steroid hormones such as estrogen, 
androgens and progesterone which are linked to the regulation the estrous cycle. Positive and 
negative feedback loops are involved in the communication between the ovaries and the 
hypothalamus and pituitary [10, 44-46]. Estrogen receptors (ER) are present in the 
hypothalamus, pituitary and in the ovaries of many species, including cattle [47-50]. Hence, 
alteration in estradiol concentration could have direct and independent effects on all the 
endocrine glands that comprise the HOP axis. Details of the interactions between gonadotropins 
and ovarian sex steroids in cattle will be discussed in later sections of this literature review.  
Non-steroidal ovarian products have also been related to the control of gonadotropin 
secretions [51, 52]. Inhibin is a protein produced by the granulosa cell of growing follicles under 
the influence of FSH. It comprises α and β sub-units and it is known to suppress FSH secretion 
by acting at hypothalamic and pituitary levels [43, 53-55]. The combination of two β sub-units 
results in a related protein, known as activin, which counteracts the effect of inhibin by 
stimulating FSH release [43]. Other factors present in the follicular fluid include follistatin, 
oxytocin, insulin-like growth factor (IGF), epidermal growth factor (EGF) and plasminogen 
activator (reviewed in [56]). 
2.1.1.1 Kisspeptin and the HPO axis 
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Kisspeptins (Kps) are a family of peptide hormones which bind to protein G-coupled receptor 54 
(GPR54) and integrates nutritional and hormonal information which is critical to metabolism and 
regulation of reproduction [57]. All Kps are the product of the KISS-1 gene and contain, at the C-
terminal region, a common deca-peptide sequence (Kp-10) that confers to them biological 
activity [57, 58]. Although Kp receptors (GPR54) have been described in the hypothalamus, 
pituitary, ovaries and placenta, its major role has been postulated as being the neuroendocrine 
regulator of GnRH release [58, 59]. Kisspeptin and hypothalamic GPR54 have been associated 
with the onset of pulsatile GnRH secretion observed at puberty and in seasonal breeders, like 
sheep [57-59]. 
Kisspeptin-secreting neurons contain ER and other sex steroid receptors and are located in 
close vicinity to GnRH-secreting cells in the hypothalamus [59, 60]. Two sub-populations of Kp-
secreting cells have been identified: one is located in the arcuate nucleus (ARC) and the other is 
located in the anteroventral periventricular area (AVPV) [59, 60]. This differentiation of these 
two sub-populations of cells is relevant since the regulatory effects of estrogens are nucleus-
specific. Thus, estrogens inhibit the expression of Kp at the ARC, causing a negative-feedback 
effect on gonadotropin secretion. As expected, reducing circulating E2 concentrations resulted in 
higher Kp mRNA levels and increased GnRH output [58]. In contrast, estrogens enhance Kiss1 
expression at the AVPV in rodents mediated by ERα, which suggests that this population of 
neurons may be involved in the positive-feedback actions of estradiol to generate the 
preovulatory surge of gonadotropins [57, 59]. In cattle, administration of 100 pmole/kg of Kp 
during diestrus, proestrus and estrus resulted in increased circulating LH concentrations during 
diestrous and proestrus, but not during estrous [61].  
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It is important to highlight that, although estrogen plays a key role in the regulation of 
GnRH pulsatile secretion pattern, GnRH-releasing neurons seem to lack ER thus making the 
Kp/GPR54 system pivotal for the normal development of the reproductive functions [59]. 
2.1.2 Ovarian follicular wave development in cattle 
In cattle, ovarian follicles develop in waves [62, 63]. A wave of follicular development begins 
with the synchronous recruitment of a mean of 24 (range of 8 to 41) small follicles (3 to 4 mm in 
diameter), an event that is referred to as wave emergence [64, 65]. Additionally, the growth 
pattern of these follicles at ≤3 mm in diameter has also been describes as occurring in a wave-
like manner [66, 67]. In monovular species such as cattle, a single follicle is selected from this 
cohort of recruited follicles to continue growing (i.e. dominant follicle), while the other follicles 
in the group undergo atresia (i.e. subordinate follicles) [63, 68-70]. This “selection” process is 
confirmed by the deviation in diameter between the now dominant follicle and the largest 
subordinate follicle, which occurs when the dominant follicle is on average 8.5 mm in diameter 
and about 2.5 days after wave emergence [64]. If the dominant follicle is growing during the 
early luteal phase, this follicle becomes anovulatory and regresses. Three different phases of 
follicular growth have been described during anovulatory waves: 1) a growing phase, during 
which the dominant follicle grows actively; 2) a static phase, during which follicular diameter 
does not change significantly; and 3) a regressing phase, during which dominant follicle diameter 
begins to decrease [71]. However, if the dominant follicle is actively growing or in early static 
phase when regression of the corpus luteum begins, it will become the ovulatory follicle and as 
such it has the capability of triggering a gonadotropin surge that will lead to ovulation (reviewed 
in [72]).  
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Two and three of these waves of follicular development have been most commonly reported 
during an estrous cycle in cattle [70, 71, 73, 74]. In animals with two or three waves of follicular 
development, the first wave can be identified, on average, the day of ovulation. The second 
follicular wave emerges about day 10 and day 9 after ovulation in two-wave and three-wave 
cycles, respectively [66, 71]. In animals with three follicular waves per cycle, the last and 
ovulatory wave is detected in average on day 16 post-ovulation [75]. Estrous cycles composed of 
two waves of follicular development are consistently shorter than 3-wave cycles (19 to 20 days 
vs 22 to 23 days, respectively) [75]. 
2.1.3 Gonadotropins and the control of follicular growth 
Follicle-stimulating hormone and LH play crucial roles in the regulation of ovarian follicular 
dynamics. Emergence of a follicular wave and the selection of a dominant follicle have been 
temporally associated with an increase and decrease, respectively, in FSH levels [76]. A transient 
increase in plasma LH concentration has been reported in relation to the time of follicular 
deviation defined as the measured point when a significant difference in diameter between the 
dominant follicle and the largest subordinate follicle is first identified [77]. Additionally, the 
peak in LH concentrations that encompasses ovulation has been well documented [78, 79].  
As mentioned above, each wave of follicular development is preceded by a surge in FSH 
concentration [76]. Inhibiting the increase in FSH concentration by administration of a 
proteinaceous fraction of follicular fluid was followed by a delay in follicular wave emergence. 
Moreover, promotion of a surge of FSH by ablation of the extant DF resulted in the emergence 
of a new wave of follicular development within 2 days [76]. These results also provided evidence 
that intrafollicular factors were, at least in part, responsible for the changes in plasma FSH 
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concentrations related to follicular dynamics. Further clarification of this concept revealed that 
increasing plasma concentrations of intrafollicular components (e.g., estradiol, inhibins, IGF, 
among others), mainly synthesised by the dominant follicle, have a suppressing effect on 
circulating FSH concentrations and that this decrease in FSH levels was crucial for the process of 
dominant follicle selection and to ensure monovulation [45, 53, 68, 80].  
A FSH-follicle coupling system involving all the follicles in the recruited wave is 
responsible for the initial drop in FSH concentrations observed after wave emergence. When the 
dominant follicle reaches a critical stage of development for selection (8.5 mm [81]), it acquires 
the capability to further suppress FSH concentrations to levels that are not compatible with 
continuous development of the subordinate follicles [10]. However, a shift from FSH to LH-
dependency by the dominant follicle (by acquisition of LH receptors in the thecal and granulosa 
cells [77]) allows it to continue growing even under very low levels of plasma FSH [53]. A study 
of the effects of LH suppression by administration of exogenous progesterone before, during and 
after follicular deviation demonstrated that LH was not indispensable for the initiation of 
deviation. There was no difference in follicle diameters between progesterone-treated and control 
animals before and during deviation. However, the dominant follicle was smaller and grew at a 
slower rate when LH secretion was suppressed after deviation was initiated in the progesterone–
treated group [14, 77]. 
The presence of a healthy dominant follicle at the end of the luteal phase leads to ovulation. 
The drop on progesterone concentration that takes place during luteolysis induces an increase in 
LH pulsatility that further feeds the growth of the extant dominant follicle [13]. Additionally, 
high estradiol production by the dominant follicle exerts positive feedback at hypothalamic level 
  
11 
 
to increase LH pulsatility. This loop of positive stimulation by high estradiol and low 
progesterone on GnRH producing cells by estradiol leads to the pre-ovulatory surge of LH 
needed for final oocyte maturation and release [57, 58, 82]. The molecular mechanisms involved 
in this process have been discussed in previous sections in this review. 
The active dominant follicle produces factors that inhibit plasma FSH secretion thus 
preventing the emergence of a new wave of follicular development during the dominance period 
[51, 53, 83]. At the end of the static phase (when the dominant follicle starts to regress) or after 
ovulation (when the source of the follicular components disappears), the negative feedback effect 
of follicular products (mainly estradiol) on gonadotropin secretion is removed. This results in a 
surge of FSH secretion followed by emergence of a new follicular wave [15, 46]. 
In summary, follicle wave emergence is preceded by an increase in plasma FSH 
concentrations. Follicular selection is related to a decline in circulating FSH concentrations 
caused mainly by the production of estradiol by the cohort, and in particular by the dominant 
follicle under the influence of LH. Low FSH concentrations maintained by the dominant follicle 
ensure that no further waves of follicular development occur during the period of dominance. 
When LH pulse frequency is low, the dominant follicle losses dominance and regresses, estradiol 
production declines, FSH surges and a new wave of follicular development is stimulated. 
However, if the dominant follicle is still viable at the end of the luteal phase, LH pulse frequency 
increases and stimulates a greater production of estradiol by the dominant follicle that will, in 
turn, elicit a preovulatory peak of LH and FSH secretion, and ovulation. The disappearance of 
the dominant follicle after ovulation removes the negative feedback effect of estradiol on FSH 
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secretion and a post-ovulatory surge of FSH followed by the emergence of a wave of follicular 
development is observed [84]. 
2.2 Control of the Estrous Cycle 
Based on our knowledge of reproductive physiology gained in the last three or four decades, 
several strategies and protocols to manipulate phenomena related to the estrous cycle (i.e., wave 
emergence, selection, luteolysis and ovulation) have been developed. The ideal method of 
control of the estrous cycle is one that is simple, effective and safe. For the purpose of this 
review, the rationale and implementation of protocols based on prostaglandin F2α (PGF) and 
GnRH, and the use of estrogens alone or in combination with progesterone will be briefly 
discussed.  
2.2.1 Prostaglandin and GnRH-based protocols for estrus synchronization  
The identification of PGF as the luteolysin responsible for the regression of the CL in cattle 
provided a new means for controlling the length of the luteal phase and ovulation (reviewed in 
[85]). Several protocols applying different doses and intervals between doses of prostaglandins 
have since been designed [86, 87]. One of the main limitations of synchronizing ovulation by a 
single PGF treatment is that the state of maturity of the dominant follicle at the time of PGF 
determines the interval to estrus and ovulation. This interval has been described to be, on 
average, of 3 to 3.4 days. However, if the dominant follicle present at the time of PGF treatment 
is in the late static or regressing phase, the dominant follicle of the subsequent follicular wave 
will have to grow in order to reach preovulatory size; in this case the interval from PGF 
treatment to ovulation may take as much as 6 days [86, 87]. Further, newly formed CL during the 
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first 3 to 4 days after ovulation are refractory to the luteolytic effects of PGF; responsiveness 
increases as the CL develops [86]. These important sources of variability in interval from 
treatment to ovulation limit the use of prostaglandin-based protocols for fixed-time artificial 
insemination (FTAI). An alternative approach which uses two doses of PGF 11 to 14 days apart 
is widely accepted and used on many dairy and beef farms. The rationale for this approach is that 
approximately 67% of the animals (those with a CL ≥5 day-old or those experiencing natural 
luteal regression) would respond to the first PGF injection by undergoing luteolysis and 
ovulating. When the second injection of PGF is administered 11 to 14 days later, it is expected 
that 100% of the animals would have functional and PGF-responsive CLs [69]. However, the use 
of luteolytic doses of prostaglandin still relies on estrus detection efficiency to provide 
acceptable outcomes. Consequently, the rate of submission of animals for AI after detected 
estrus may limit the effectiveness of this protocol. Herd heat detection rates are very variable and 
have been reported to be ≤ 50% (range from about 30% to 65%) [88-91] in high producing dairy 
farms and between 53% and 73% in commercial beef farms [90, 92]. 
The use of fixed-time AI (FTAI) can overcome the negative impact of low estrus detection 
efficiency. FTAI eliminates the need for estrus detection but requires synchronous growth and 
ovulation of a viable dominant follicle in order to be successful. Pregnancy rates obtained with 
FTAI are usually comparable to those obtained after AI with high estrus detection rates, because 
all animals are inseminated regardless of whether or not they showed estrus [93]. Gonadotropin 
releasing hormone is commonly used to induce the pituitary release of gonadotropins (LH and 
FSH) which will induce ovulation and/or luteinisation of the dominant follicle [94, 95]. 
Emergence of a new wave of follicular development is expected approximately 2 days after 
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GnRH treatment [94], although its synchrony is highly dependent on the occurrence of ovulation 
after GnRH [95, 96]. The use of GnRH is usually combined with a luteolytic dose of PGF 7 days 
later: GnRH is intended to synchronize wave emergence while PGF synchronizes luteolysis. An 
additional dose of GnRH is used about 48 hours after PGF to induce an LH surge and further 
synchronize ovulation [93, 97]. Finally, animals are inseminated 16 to 20 hours after the second 
GnRH dose. This protocol is known as Ovsynch. Several studies in which Ovsynch protocols 
were used had pregnancy rates similar to those obtained using the two doses of PGF 14 days 
apart with high estrous detection management in lactating dairy cows (38.9% versus 37.8%, 
respectively) [93, 94]. However, after the application of Ovsynch to heifers, pregnancy rates 
were lower than in controls treated with PGF and inseminated after estrus detection (35.1% 
versus 74.4%, respectively). Poor ovulatory response to the first dose of GnRH and consequently 
poor synchronization of wave emergence were identified as the causes of the lack of success of 
the Ovsynch protocols in heifers [96, 98]. Ovulation was induced in 54% of dairy heifers after 
GnRH treatment [94], and it was reported that 27% to 44% of beef heifers treated with a single 
GnRH dose failed to ovulate [95, 96]. 
Alterations to the original Ovsynch protocol were introduced in order to improve the 
ovulatory response and synchronization. Pre-synchronization of follicular wave emergence using 
a double PGF treatment 14 days apart followed 12 days later by an Ovsynch protocol (Presynch), 
or using two consecutives Ovsynch protocol 7 days apart (Double-Ovsynch) improved the 
ovulatory response to first GnRH and therefore more heifers and cows responded to the second 
GnRH with synchronous ovulation [99, 100]. Additional modifications include the addition of a 
progestin device between first GnRH and PGF (to prevent early ovulation, mostly in heifers 
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[101]) and alterations on the timing of the second GnRH and AI (Cosynch [102]). Specifics of 
the application and effectiveness of these protocols are beyond the scope of the present thesis 
and have been reviewed elsewhere [103].  
2.2.2 Estradiol and progesterone-based protocols 
The interval from PGF-induced luteolysis to ovulation and the variability in the ovulatory 
response among animals to GnRH treatment depends on the status of the ovarian follicle at the 
time of treatment. Thus, a method that controls ovarian follicle recruitment would provide the 
advantage of knowing the stage of follicular development when the ovulatory or luteolytic 
treatment is given and would improve the ovulatory response and its synchrony.  
Combinations of progesterone and estradiol have been used to hormonally induce a new 
wave of follicular development in a predictable interval of time [5, 12]. This method of 
synchronizing wave emergence is based on the negative feedback effects that estradiol has on 
FSH secretion during the luteal phase [104] or under the influence of an exogenous source of 
progesterone [4, 5, 19, 105]. Additionally, exogenous progesterone suppresses LH secretion 
leading to the regression of the extant dominant follicle. Reduced secretion of FSH and LH from 
the pituitary gland terminates the growth of both FSH- and LH-dependent follicles. Reduced 
circulating estradiol concentration (most likely due to metabolism and clearance) results in a 
FSH surge and in emergence of a new wave of follicular development about 4 days after 
estradiol and progesterone treatment [4, 106, 107]. This protocol includes, at the time of estradiol 
and progesterone treatment, the insertion of a progesterone releasing device for 7 to 9 days and a 
dose of PGF at the time of progesterone device removal to ensure luteal regression. Animals are 
inseminated 55 to 60 hours after progesterone withdrawal [107]. Additionally, different forms of 
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estradiol have been applied in these progestin-based protocols. It has been reported that the use 
of short-acting preparations such as E-17β or estradiol benzoate (EB) results in more 
synchronous wave emergence and ovulation than long-acting esters such as estradiol cypionate 
[8, 108, 109]. When estradiol is added to increase the synchrony of ovulation, it is recommended 
that it should be administered 24 hours after progesterone device withdrawal and AI should be 
performed 30-36 hours later [107]. 
A synchronized ovulatory response is essential for the efficient use of time, resources, 
labour and the application of reproductive management techniques such as FTAI [5, 109] and 
multiple ovulation and embryo transfer (MOET) [105, 106, 110]. The outcome of a 
superstimulation treatment is strongly influenced by the stage of follicular development at 
initiation of treatment. Optimal ovarian responses were obtained when superstimulatory 
treatments were initiated about the time of follicular wave emergence (day – 1 or 0 of the 
follicular wave) [5, 109]. Since progesterone plus estradiol treatments result in precise 
synchronization of wave emergence (on average 4.3 days after treatment), superstimulatory 
treatments are initiated on day 4 of the protocol, without the need for estrus detection and the 8 
to 12-day waiting period for a natural follicular wave to emerge [4, 111]. 
2.3 Decline in Fertility and its Impact on Reproductive Efficiency 
Fertility can be defined as the ability of the animal to conceive and maintain pregnancy if served 
at the appropriate time in relation to ovulation [112]. This definition implies that fertility can be 
negatively impacted at several different steps in the pathway leading to obtaining a healthy 
offspring: altered ovarian function and cyclicity, poor estrous behaviour or detection, failure to 
ovulate, and embryonic or fetal loss. Strategies to control or modify estrous, ovulation, and 
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ovarian dynamics have been discussed in previous sections of this review. In this section we will 
briefly discuss aspects related to CL dysfunction and pregnancy failure. 
2.3.1 Proposed mechanisms for the decline in fertility 
It is now evident that fertility has declined with rising milk yields [113, 114]. In the USA the rate 
of decline in fertility was 0.5% per annum, over a period of 15-20 years,[27]; in UK herds, 
pregnancy at first insemination has gone from 56% to 40% between 1975-1982 and 1995-1998, 
approaching a decline rate of 1% per annum [28]. However, there is recent evidence that the 
historical decline in fertility has reached a nadir and has now begun to improve, at least in the 
United States [115]. 
This dramatic decline in fertility has been associated with a reduction in expression of 
estrus, failure of ovulation, and poor luteal function [114]. Strategies to control estrus, time to 
ovulation and even eliminate heat detection have already been discussed.  
After ovulation, the CL is formed and secretes progesterone. In a non-bred female, and 
under the influence of estradiol of follicular origin, the endometrium will start secreting PGF 
about 16 days post-ovulation, which will induce the luteolytic process. However, if the animal 
has been bred and a conceptus in present in the uterus by day 16 post-ovulation, the embryo 
signals its presence and prevents the uterine secretion of PGF and luteolysis. Hence, the period 
between days 14 and 21 of the bovine estrous cycle are critical for the establishment of 
pregnancy [116].  
From the process of pregnancy recognition and luteolysis, several steps can be identified in 
which a malfunction could lead to pregnancy failure. In cattle, the natural process of luteolysis is 
driven by estradiol [116]. Estradiol secreted by the growing dominant follicle of each follicular 
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wave in the cycle primes the uterine endometrium and induces the expression of oxytocin 
receptors [117]. Oxytocin, also of follicular origin, acts on the endometrial receptors stimulating 
the synthesis and secretion of PGF. It has been shown that administration of exogenous estradiol 
hastens the process of luteolysis in cattle [117].  
Luteolysis is a default process in cattle, meaning that it has to be actively blocked in order to 
sustain a pregnancy. In cattle, the embryo is responsible for signaling its own presence. 
Embryonic secretion of interferon-τ prevents PGF secretion, although the precise mechanism of 
its action is still unknown. It has been proposed that interferon-τ blocks the effect of estradiol on 
the endometrium, hence preventing the acquisition of oxytocin receptors. An embryo that fails to 
secrete interferon-τ, or that secretes insufficient amounts of the protein, will fail to signal its 
presence and the process of luteolysis will take place [116]. 
Progesterone concentrations are high during the luteal phase of the estrous cycle, which is 
necessary to prepare the uterus for embryonic development. In order to block luteolysis and 
maintain high levels of progesterone, the embryonic trophoblast has to elongate and occupy the 
whole uterine lumen, meaning that larger embryos are more likely to succeed in preventing 
luteolysis. Progesterone levels have been associated with embryonic growth and elongation rate 
and interferon-τ secretion capabilities [116, 118, 119]. However, progesterone does not seem to 
act directly on the embryo in order to influence its growth. Rather, the effects that progesterone 
has on uterine secretion, from which the embryo feeds, are responsible for the increased 
trophoblastic elongation observed in cows supplemented with progesterone during the first week 
post-breeding [118, 120]. It has been shown that cows that failed to carry a pregnancy had lower 
levels of progesterone between days 14 and 21 post-breeding compared to those that remained 
  
19 
 
pregnant [29]. In dairy cows, low circulating progesterone concentrations have been associated 
with increases in metabolic rate and liver clearance of steroid hormones due to high dry matter 
intake [120] and thus, reduced embryonic survival. 
2.3.2 Methods to improve fertility post-AI and embryo transfer 
Several strategies to improve pregnancy rates post-breeding or embryo transfer have been tested. 
The main goals of such strategies can be summarized as follows: (1) to increase the antiluteolytic 
signal from the conceptus (by increasing progesterone concentration post-breeding or embryo 
transfer), and (2) to decrease the effect of estradiol (from the dominant follicle) on endometrial 
secretion of PGF [114, 116]. 
Several research groups have concluded that embryos developing under higher levels of 
progesterone early in the luteal phase grow more rapidly (i.e. trophoblast expansion) and were 
more likely to prevent prostaglandin F2α (PGF) secretion by the uterus; i.e. prevent luteolysis 
and achieve maternal recognition of pregnancy [30-32, 118, 119]. Higher levels of progesterone 
have been achieved by inducing the ovulation of a larger dominant follicle (which results of a 
larger CL) e.g. stimulating follicle growth with eCG, by treating with luteotrophic hormones 
(such as hCG, and GnRH) to induce accessories CLs and stimulate CL growth and progesterone 
secretion [120, 121], or by supplementation with exogenous progesterone (in most cases by the 
use of intravaginal devices) [30, 116, 118, 122]. 
Estradiol of follicular origin has been identified as the stimulus driving the expression of 
oxytocin receptors in the endometrium and, therefore, triggering the mechanism of luteolysis. It 
has been shown that reduction of circulating estradiol concentrations by ablation of the dominant 
follicle delays the occurrence of luteolysis, while estradiol supplementation hastens the initiation 
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of the luteolytic process [117]. In an attempt to reduce estradiol circulating concentrations during 
the critical period of maternal recognition of pregnancy (days 15 to 21 post-ovulation), 
researchers have treated cows with GnRH in order to induce ovulation and remove the estrogenic 
activity of a dominant follicle. It was concluded that increasing the proportion of cows with 3 
waves of follicular development reduces the odds of having a highly estrogenic dominant follicle 
during such period over 2-wave animals, and therefore improves pregnancy rates [116, 117]. 
2.4 Estrogens and Other Sex Steroid Hormones 
Steroid hormones are cholesterol-derivatives commonly classified, based on their physiological 
behaviour, in five groups: glucocorticoids, mineralocorticoids, progestins, androgens, and 
estrogens. The last three groups, also referred to as sex steroid hormones, are associated with the 
mechanisms that govern the reproductive physiology of mammals. 
2.4.1 Steroidogenic pathway for the synthesis of sex steroid hormones 
Estrogens are the final product of a complex biosynthetic pathway that, in ruminants, involves 
five main enzymes: the P450 cholesterol side-chain cleavage enzyme (P450scc), 3β-
hydroxysteroid dehydrogenase (3β-HSD), cytochrome P450 17α-hydroxylase (P45017-OH), 17β-
hydroxysteroid dehydrogenase (17β-HSD), and P450 aromatase (P450arom) [123, 124].  
The rate limiting step in the biosynthesis of sex steroid hormones appears to be the 
incorporation of cholesterol into the mitochondria [125]. Free cholesterol is highly hydrophobic, 
and although it can cross the cellular membrane by diffusion, this process is extremely slow. 
Therefore, the incorporation of cholesterol inside the mitochondria depends on an active (energy 
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dependant) mechanism to transverse the hydrophobic mitochondrial wall. The protein mediating 
the translocation of cholesterol is the “steroidogenic acute regulatory protein” (StAR) [125]. 
Once inside the mitochondria, cholesterol is metabolized to pregnenolone by the P450scc 
enzyme. Pregnenolone is then the substrate for two different enzymes: 3β-HSD and P45017-OH, 
giving rise to progesterone and 17α-hydroxypregnenolone, respectively. In thecal cells of the 
ovarian follicle, P45017-OH is highly expressed and pregnenolone is converted mainly into 17α-
hydroxypregnenolone. The 17α-hydroxypregnenolone is processed into androstenedione by the 
sequential activities of P45017-OH and 3β-HSD and a small amount of androstenedione is 
transformed into testosterone by the enzyme 17β-HSD. Both androgens, androstenedione and 
testosterone, are now available to be either secreted as such or further converted into estrone and 
estradiol, respectively, by the action of the cytochrome P450 aromatase (P450arom) within the 
granulosa cells [123, 126, 127]. The major enzymatic pathway leading to the synthesis of 
estrogens, irrespective of species or tissue, is summarized in Figure 2. 1. 
2.4.2 Source and actions of estrogens 
Estrogen production has an important role in several system and organs, and it is crucial for the 
normal development and function of the whole organism. Some illustrative examples of sources 
and actions of estrogens in mammal species are summarized below. 
The placental is an important, though transient, source of estrogens. Placental production of 
estrogens, mainly during the last portion of gestation, induces the growth of the myometrium, 
induces the production of oxytocin receptors in the myometrium and promotes mammary gland 
development, among other actions [42, 128].  
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During fetal life, estrogens play a key role in sex differentiation in the brain, stimulated by 
the presence of androgens [124]. Testosterone produced by the fetal testis can cross the blood-
brain barrier and be converted into estrogens by the aromatase enzyme present in the brain. This 
local production of estrogen signals the brain of the presence of a male fetus and inhibits the 
development of the pulsatile pattern of GnRH secretion [42].  
At puberty, estrogens induce bone maturation, linear growth, and epiphyseal fusion. In 
young adults, estrogens are important for maintenance of bone density, not only in females but 
also in males [129]. However, estrogens are not as efficient as androgens when it comes to 
stimulation of protein production and muscular growth [128]. 
After puberty, estrogens are produced by the ovaries. Several reports indicate that estrogens 
are in part responsible for the development and maturation of follicles and oocytes in the ovaries. 
Studies have shown that estradiol induces granulosa cells proliferation and expression of LH 
receptor in granulosa and thecal cells of the dominant follicle. Estradiol also promotes the 
formation of gap junctions between granulosa cells to facilitate communication and 
nutritional/hormonal supply from the basal membrane [130]. In females of all species, estrogen 
induces the development of external sexual characteristics and it induces oestrous behaviour 
[128]. Although estrogens were thought as the “female” sex hormone for many years, it is now 
clear that estradiol synthesis in the testis is necessary for a normal spermatogenesis to occur 
[131]. Estrogens of testicular origin can contribute to at least with 15 % of total amount of 
estrogen circulating in blood in the adult male [132]. 
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Figure 2. 1. Synthesis of estrogens in ruminants. Five main enzymes (P450 cholesterol side-chain 
cleavage enzyme (P450scc), 3β-hydroxysteroid dehydrogenase (3β-HSD), cytochrome P450 
17α-hydroxylase (P45017-OH), 17β-hydroxysteroid dehydrogenase (17β-HSD), and P450 
aromatase (P450arom)) are involved in the enzymatic pathway leading to the synthesis of 
estrogens from cholesterol. 
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In post-menopausal women and non-human primates, in which ovarian estrogen production 
is no longer the main source of estrogenic products, peripheral estrogen synthesis (adipose tissue, 
skin, muscle) becomes responsible for the blood levels of estrogens. Adipose tissue contributes 
with the largest amount of extragonadal estrogens due to its wide distribution, and these levels of 
estrogen are necessary to protect cognitive function of the brain and to prevent bone 
demineralization [129, 133].  
Many other actions of estrogens in mammals can be cited: stimulation of hepatic synthesis 
of lipoprotein binding proteins, increasing of the synthesis of coagulation factor, decreasing 
levels of low density lipoproteins (LDL) while increasing high density lipoproteins (HDL), 
among other actions [129, 133, 134]. 
Estrogens, however, are not only related with normal and physiologic functions. These 
steroid hormones are strongly related to the development of pathologic conditions such as 
cardiovascular disease [134], hormone dependant breast cancer, endometrial cancer and 
endometriosis in women [129]. It has been shown that the adipose tissue located in the vicinity 
of breast tumours produces higher amounts of estrogen than normal adipose tissue. In the 
pathologic conditions mentioned above, estrogens exert their actions in a paracrine or autocrine 
fashion, promoting additional estrogen synthesis which stimulates further tumor growth and 
metastasis [133, 134]. 
Estrogens are synthesized in all members of the vertebrate phylum [135, 136]. In more 
developed species i.e. primates, estrogens are synthesized in many different locations in the body 
such as the gonads, adipose tissue, placenta, liver, skin and brain. In ungulates, adipose tissue 
synthesis of estrogens has not been fully demonstrated, and in rats, the placenta does not seem to 
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have the capability to synthesize estrogens [135]. Another characteristic of estrogen synthesis is 
that different tissues can secrete different types of estrogens. For example, it has been described 
that the main estrogen produced in the ovaries is estradiol, while estrone is synthesized in 
adipose tissue and estriol predominates in the placenta. An interesting observation is that the 
P450arom catalyzing these reactions across these different tissues is the same, which confirms the 
notion that different types of estrogens synthesized in different tissues are not the result of the 
activity of alternative P450arom enzymes, but rather the result of the presence of different 
precursors in each location [135]. 
2.4.3 Regulation of steroidogenesis in bovine ovary 
Timely variations in the expression of LH receptors (LHr) and FSH receptors (FSHr) as well as 
differences in cell responsiveness to the activation of such receptors have been described during 
folliculogenesis and maturation of ovarian follicles in cattle [65]. Researchers have been able to 
relate the changes in expression and activity of the gonadotropin receptors with the control of 
steroidogenesis in the bovine ovary, and ultimately, with ovarian follicular dynamics [126, 127]. 
It was shown that granulosa and cumulus cells of small ovarian follicles (≤ 3 mm in diameter) 
express FSHr mRNA, although this stage of follicular development has been thought to be 
gonadotropin-independent. It is now known that these small follicles do respond to surges in 
FSH concentration [66]. The beginning of recruitment of small antral follicles has been 
associated with the expression of P450arom and P450scc mRNA in their granulosa cells. It is 
believed that the surge in FSH related to emergence of each wave [76] could be responsible for 
the induction of such steroidogenic enzymes in granulosa cells. The thecal cells of pre-antral and 
small antral follicles expresses LHr mRNA, P450scc mRNA, 3β-HSD mRNA, StAR mRNA and 
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P45017-OH mRNA, and androgens are available for the newly recruited follicles to begin 
synthesizing and secreting estradiol [126, 127].  
By the time of follicular selection, several follicles in the recruited cohort begin to express 
LHr mRNA and 3β-HSD mRNA on their granulosa cells. It has been hypothesized that estradiol 
and FSH induce these changes, since LHr mRNA and 3β-HSD mRNA are expressed in follicles 
with higher levels of P450arom and P450scc mRNA in their granulosa cells (FSH-induced enzymes 
for the synthesis of estrogens). Forty eight hours after wave emergence, LHr mRNA and 3β-HSD 
mRNA were only found only in granulosa cells of the future dominant follicle [126].  
The dominant follicle of the first follicular wave remains viable for 4 to 5 days, after which 
most mRNAs begin to decline, except for P450arom mRNA which begins to decline 2 days later. 
If progesterone levels decrease 6 or 7 days after wave emergence, this dominant follicle becomes 
preovulatory and all mRNAs, except P450arom mRNA, increase [137]. These observations 
indicate that LH pulsatility may be responsible for the expression of steroidogenic enzymes 
mRNA in the granulosa and thecal cells. Thus, mRNA expression is suppressed under low 
pulsatility of LH observed during the luteal phase and is increased during the pre-ovulatory 
increase in LH pulsatility. These observations also support the notion that P450arom activity does 
not seem to be the rate limiting step in estradiol production. Conversely, it appears that the 
availability of androgenic precursors produced by the thecal cells controls the rate of estrogen 
secretion by granulosa cells of the ovarian follicle (reviewed in [126]). 
2.4.4 Local effects of estrogens in the ovary 
A local effect of estrogens in ovarian follicles is suggested by the presence of estradiol receptors 
in granulosa cells of many mammalian species [43, 130, 138]. Studies have shown that estrogens 
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have paracrine/autocrine effects in the ovary that include prevention of granulosa cell apoptosis, 
stimulation of granulosa cell growth, induction of steroidogenic enzymes and gonadotropin 
receptors, among others [43, 130]. Despite the evidence of a local effect of estrogen in the ovary, 
it is not clear whether estrogen is a major regulator of follicular growth. The use of animal 
models in which estradiol synthesis at follicular level was compromised or inhibited resulted in 
increased follicular atresia and apoptosis. However, it was difficult to determine if the observed 
effects were due to lack of estradiol per se, or to unbalanced gonadotropin secretion cause by 
estradiol deficiency [43, 139]. These observations contradict those in which extremely low levels 
of estradiol (achieved by either suppression of estradiol synthesis or mutational alterations of the 
steroidogenic pathway) did not affect follicular development, oocyte maturation, subsequent 
luteal development and function, oocyte fertilization and cleavage rates; suggesting the estrogens 
are not required, or are required in very low concentrations, for normal ovarian function to occur 
[37, 39, 40, 43, 139-141]. 
2.4.5 Metabolism and elimination of estrogens 
Estrogen bioactivity is regulated through two main mechanisms: metabolism and 
elimination. Estrogens can be either inactivated or converted into compounds with lower 
biological activity before excretion. In ruminants, estradiol-17β is in the most part deactivated in 
the liver by redox reactions (oxidation, reduction and hydroxylation) and it is later conjugated 
with glucuronic or sulphuric acid prior to bile excretion. A small amount is also converted into 
estradiol-17α, which has very low estrogenic activity in cattle. In both pathways, fecal 
elimination is the most important route of excretion in this species, although small amounts of 
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estradiol-17α, and the glucuronic and sulphate conjugates can be isolated from the urine [142-
144]. 
2.5 Aromatase Enzyme 
Aromatization of androgenic precursors represents the very last step of the synthesis of 
estrogens. This reaction is catalyzed by the P450 aromatase enzyme (P450arom); details regarding 
aromatase classification, gene structure and regulation are presented below. 
2.5.1 Classification 
The aromatase enzyme, P450arom, is an enzymatic complex that belongs to the super-family of 
P450 proteins, which includes more than 480 members divided in 74 different families. P450arom 
is the unique member of family 19 [145]. P450arom is located in the endoplasmic reticulum of 
mammalian cells that express the CYP19 gene, such as adipose tissue, brain, adrenal glands, 
gonads, liver and placenta [124, 136, 137, 146-148]. P450arom contains a heme group in its 
structure and is functionally associated with another member of P450 cytochrome family, an 
NADPH reductase, which acts as donor of reductive equivalents [149].  
2.5.2 CYP19 gene: Structure and regulation 
The aromatase gene (CYP19 gene) is a special case of tissue specific regulation of transcription 
by alternative use of different promoters [150]. The gene contains nine exons (from exon II to X) 
that are translated exons, meaning that the sequence of ribonucleotides is actually translated in a 
sequence of amino acids in the protein. Exon X has the sequence that encodes the heme binding 
region and the 3’ untranslated region with alternative poly-adenylation signals. The CYP19 gene 
contains several forms of a first untranslated exon (exon I) located distally from the encoding 
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region. Exon I is present in the mRNA transcripts, but does not encode a sequence of amino 
acids in the aromatase protein [151]. In human, it is estimated that the CYP19 gene has around 
120 kb, where 30 kb include the translated exons and their introns and about 90 kb contains the 
alternative forms of untranslated exons I and their promoters [124, 152]. In cattle, the Cyp19 
gene is estimated to contain at least 56 kb, although the complete length of the gene remains 
unknown [150].  
Exon I is particular in that it can be differentially spliced among several structures located 
upstream from the translational starting site (exon II). These structures are alternative forms of 
exon I, which include their own regulatory signals and promoter regions, and that are activated 
and spliced out in a tissue specific fashion. For instance, in human and bovine ovaries, exon I is 
spliced out and the transcripts start with exon II [150, 152]. In human adipose tissue, exon I.4 is 
activated for the synthesis of P450arom [150]. In the placenta, exon I.1 is expressed [150]. In 
cancer-associated adipose tissue, exon I.3 and II are expressed [133, 136]. 
After transcription, mRNA undergoes the process of maturation, where introns are spliced 
out and exons are arranged together prior to the initiation of translation. In the case of aromatase 
transcripts, this process is crucial to ensure the translation of the same and unique aromatase 
protein even when the original transcripts differ among tissues [135, 146, 152]. Irrespective of 
the tissue of origin, every alternative exon I expresses the same splicing donor sequence (GT) at 
its 3’ end. This donor sequence of exon I matches with the splicing donor sequence (AG) present 
at the 5’ end of exon II. This means that during the process of maturation, exon I becomes 
closely attached to exon II, regardless of the content or the length of the sequence of 
ribonucleotides that were between them in the heteronuclear mRNA [135, 146, 152]. The mature 
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aromatase mRNA is then translated into a sequence of amino acids, starting with the translational 
start signal (ATG) located within exon II. As a result, all the information located upstream from 
the translational start site (exon II) is not translated into the polypeptide chain and the final 
protein is the same in all tissues that have the capability to synthesize estrogens [152]. 
2.6 Estrogen Receptors 
2.6.1 Classification and structure 
The actions of estrogens are mediated through the estrogen receptor (ER), a member of a large 
superfamily of intracellular receptors that function as hormone-activated transcription factors 
[153, 154]. The ER and other steroid hormone receptor proteins have a common structural and 
functional organization, with three distinct regions responsible for ligand/hormone-binding, 
DNA-binding, and transcription activation [153]. 
Specific domains have been identified in the intracellular receptors superfamily. There is an 
A/B domain, located at the N-terminal region of the protein, which contains factors that interact 
with elements of the transcription-initiation complex in the target gene. A highly conserved 
region, domain C, contains two zinc fingers in its structure and is involved in interaction with 
DNA. At the carboxy-terminal region, another highly conserved region known as domain E/F 
binds to the hormone and mediates dimerization, nuclear translocation, and transactivation of 
transcription, being structurally and functionally complex [153, 154].  
To-date, two isoforms of ER have been identified, ERα and ERβ. Structurally, ERα and ERβ 
share high homology on their C domain, suggesting that both isoforms of ER bind to the same 
elements in the DNA by the zinc finger configuration. Their E/F hormone binding domain has 
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less homology (53-60%), although researchers have not found significant differences in affinity 
for E-17β. The main difference between the two known types of ER resides in their A/B domain, 
suggesting that each isoform interacts with different transcription elements and activation factors 
to exert their function [48, 154]. 
The presence of plasma membrane-bound ER has been described more recently [155]. Due 
to the structural similarity between intracellular and membrane ER, it is thought that 
translocation of the intracellular form of ER determines their membrane association [155]. These 
membrane ERs have been associated to E2-induced rapid changes in cellular physiology, as 
these modifications do not require gene up-regulation or down-regulation to take place. Plasma 
membrane ER can also be identified in their ERα and ERβ isoforms [155-157]. 
2.6.2 Mechanism of action 
The “classic” ER is an intracellular transcription factor that exists in inactive apoprotein forms 
either in the cytoplasm or nucleus. Upon binding estrogen, the ER undergoes activation and 
binds to a unique region of the DNA called estrogen-response-element (ERE), often located in 
the 5' flanking region of estrogen responsive genes. The estrogen-occupied receptor is then 
thought to interact with transcription factors and other components of the transcriptional complex 
to modulate gene transcription [154, 158]. 
Since the documentation of the existence of plasma membrane ERs, efforts have been 
directed to describe their mechanism of action. ERs anchored to the cellular membrane are 
unable to establish direct DNA association in order to alter gene transcription. Plasma membrane 
ER appears to be coupled to the G protein second messenger pathways. Activation of these 
pathways may results in calcium influx, cAMP and phosphatidylinositol 3 production, and 
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protein phosphorylation changes. The activation of membrane ER results in changes in cellular 
biology mostly related to kinase activation. Membrane ER activation cascade has also been 
reported to lead to modifications in gene transcriptions mediated by one of the above described 
second messenger pathways [155, 157]. 
It has been proposed that membrane and intracellular ERs have complementary functions in 
order to promote changes in cell biology, due to the nature of the reaction initiated by both ER 
types (signaling vs transcriptional changes). Hence, it is believed that membrane ERs are 
responsible for the initial rapid modification in cellular gene transcription, which is then 
maintained by the activation and long-acting effects of the intracellular ER [155]. 
2.6.3 Distribution of estrogen receptors 
Tissue distribution of intracellular ERα and ERβ is differential in the sense that, even though 
both ER types may be present in a given tissue, one always predominates over the other in 
quantity and transcription signal strength. Thus, ERα appears to be the predominant type in most 
female reproductive tissues (uterus, oviduct, ovaries, mammary gland, and vagina), and the 
hypothalamus, muscle, and liver in cattle, while ERβ has only been found in significant 
quantities in the ovaries, jejunum, kidney and regions of the central nervous system [47]. ERβ 
expression prevails in the lungs, cardiovascular system and male reproductive tissues, such as 
prostate and testis [48, 158, 159]. These differences in tissue distribution between the ER 
subtypes could explain the selective action of estradiol as a stimulant or suppressor of 
physiological activities in different tissues.  
Plasma membrane ER have been described in a number of cell types such as 
cardiomyocytes, endothelial cells, breast cancer cells, osteoblasts and neurons [155, 157]. In all 
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these tissues, they have been associated with effects such as prevention of cardiac hypertrophy 
(cardiomyocytes), vasorelaxation (endothelial cells), growth and proliferation (breast cancer cells 
and osteoblasts) and mood swings (brain nuclei) [156] 
2.7 Use of Estrogens in Food Producing Animals: Regulatory Limitations 
The use of estrogens and other sex steroids have been developed as a tool for controlling and 
manipulating reproductive phenomena in cattle and other farm animals. However, steroid 
hormones have also been extensively applied as growth promotants in food producing animals 
[160]. The first compound approved by the USA Food and Drug Administration (FDA) to be 
used as growth promoter in beef cattle and sheep was diethylstilbestrol (DES), which had 
estrogenic effects. Since then, several compounds have been formulated and approved for use in 
farm animals including estradiol-17β, estradiol benzoate, progesterone, testosterone, 
melengestrol acetate and zeranol, among others [160]. Estrogenic products are used to improve 
the efficiency of meat production as well as the proportion of lean meat. Subcutaneous implants 
are most commonly used and they may contain single steroid hormones or combinations of 
steroid hormones [160-163].  
However, the potential for residues of exogenous steroid hormones in meat and other foods 
originating from treated animals have increased biosafety concerns [22, 164-166]. The main 
issues include the involvement of naturally occurring hormones and synthetic hormonally active 
compounds on the development of different forms of cancer, abnormal growth of prepubertal 
children and altered reproductive function [165, 167]. While several researchers have attributed 
carcinogenic effects to estrogens and estrogenic compounds (i.e., zeranol), other research groups 
have failed to replicate these results [20, 168]. The acceptable levels of estrogens and other 
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steroid hormones in food originating from treated animals have been under consideration for 
many years and consensus has not been reached. The controversy revolves around determining 
acceptable daily intake (ADI) levels, minimum residual levels (MRL) and no-observed-effect 
levels (NOEL) for the different hormones under study [169, 170]. Factors such as method of 
quantification, and age range and physiologic status of the population under consideration have 
made it difficult to determine a common tolerance level for estrogens. Further, the impact of the 
natural occurrence of steroid hormones in food of animal origin is not completely understood 
[170].  
Despite all the uncertainties around the issue of steroid hormone residues in food originating 
from treated animals, the international situation evolved towards the banning of steroid 
hormones and their synthetic analogs for use in food producing animals in all member states of 
the European Union (EU) in January 1989 [21, 171]. The use of E-17β and its ester derivatives 
for reproductive management was prohibited in the EU on October 14, 2006 [23, 171]. The 
position adopted by the EU led to the prohibition of the use of estradiol and its esters in New 
Zealand and Australia in lactating dairy animals in 2007 [24]. In United States and Canada, the 
use of estradiol and zeranol (an estrogen-like compound) as growth promoters is still permitted 
[25, 171, 172]. Estrogens can only be applied for the purpose of reproductive management 
following veterinary prescription and custom compounding. However, compounding has 
recently come under scrutiny in the USA since the FDA declared that it is illegal to compound 
analogs of drugs that are banned from use in food producing animals, which would be the case 
for E-17β and its derivatives [173, 174]. This worldwide situation has created a void in the 
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availability of treatments to efficiently control reproductive function and fertility in food 
producing animals such as cattle. 
2.8 Aromatase Inhibitors 
2.8.1 Classification 
Aromatase inhibitors can be classified based on their chemical structure and mechanism of 
action:  
(1) Steroidal aromatase inhibitors (Type I) are compounds derived from androstenedione 
(Figure 2. 2). These compounds bind irreversibly to the active site of the P450arom inducing a 
covalent change on the structure of the enzyme which results in lasting and selective inhibition. 
Because of their irreversible effects, these compounds are also called “suicide inactivators”. 
Formestane and exemestane are examples of type I inhibitors [175]. 
 
Figure 2. 2. Chemical structure of steroidal aromatase inhibitors Exemestane and Formestane: its 
chemical structure resembles that of androstenedione (see Figure 2.1). 
(2) Non-steroidal aromatase inhibitors (Type II) are compounds that have a hetero-atom (a 
nitrogen containing heterocyclic moiety, the triazole group; Figure 2. 3) as a common 
characteristic in their chemical structure. These inhibitors bind to the heme group in the P450arom, 
occupying part of the active binding site of the enzyme, and interfering with the enzyme activity 
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in a reversible way. All these compounds have been found to be very selective for the estrogen 
synthetase. Examples of these compounds are letrozole, anastrozole, and fradozole [175]. 
 
Figure 2. 3. Chemical structure of non-steroidal aromatase inhibitors letrozole and anastrozole: 
their chemical structures contain a triazole group that selectively binds to the heme group of the 
aromatase enzyme. 
Since steroidal aromatase inhibitors mimic the structure of androstenedione, they have been 
related with undesired mild androgenic effects. Furthermore, the irreversible nature of the 
inhibitor-enzyme interaction implies that recovery of estrogen production will be delayed after 
interruption of treatment, given that di novo synthesis of P450arom protein will be needed [176]. 
Exemestane, letrozole and anastrozole are the most recently developed aromatase inhibitors 
(known as third-generation aromatase inhibitors). The main difference between second and third-
generation aromatase inhibitors is the improved selectivity observed in the third generation, 
which has reduced the secondary effect associated with non-specific enzymatic inhibition [177].  
2.9 Letrozole 
Letrozole [4,4’-(1H-1,2,4-triazol- 1-yl-methylene)-bis-benzonitrile] is a type II, very potent non-
steroidal aromatase inhibitor. Its chemical structure contains a triazole group that selectively 
interacts with the heme group of the P450arom enzyme, thereby reversibly inhibiting the 
bioactivity of the enzyme [178-180]. Letrozole is highly selective for P450arom blocking only 
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estrogen production without altering progesterone or corticosteroid synthesis [181, 182]. In 
North America, letrozole is marketed under the name of FEMARA® (Novartis) and it is 
approved for the treatment of estrogen-dependent breast cancer in postmenopausal women. 
2.9.1 Pharmacokinetic parameters of letrozole 
The pharmacokinetic parameters of letrozole in humans have been described in studies 
conducted on healthy post-menopausal women, breast cancer patients, and in healthy male 
volunteers [182-185]. It was reported that letrozole is rapidly and completely absorbed after oral 
administration [184], with a half-life is approximately 42 hours in healthy subjects [184, 185] 
and 82 hours in breast cancer patients [183]. Breast cancer patients also have been shown to have 
higher area under the curve (AUC) values than healthy individuals which may suggest a reduced 
metabolic clearance and consequently lower elimination rate [183]. Approximately 60% of 
letrozole found in circulation is bound to plasma proteins, mainly albumin [184, 185]. Letrozole 
is eliminated mainly via metabolism by P-450 isozymes (CYP3A4 and CYP2A6) into a 
pharmacologically inactive alcohol metabolite [183, 184]. The main route of excretion of 
letrozole is urine, where 6.8% of the given dose of letrozole was found unchanged [183]. 
A study of the pharmacodynamic characteristics of letrozole in healthy postmenopausal 
women in which three different doses of letrozole were used revealed maximal suppression of 
serum estradiol of 76.5%, 78.5% and 78.8% from baseline at 72 hours post-treatment with 0.1, 
0.5 and 2.5 mg of letrozole given in a single oral dose, respectively [186]. In postmenopausal 
breast cancer patients, in vivo aromatization and plasma estrogen levels were measured after 0.5 
or 2.5 mg of letrozole given orally and daily for at least 6 weeks. Letrozole inhibited aromatase 
activity by 98.4% and >98.9%, respectively; resulting in a reduction in plasma estradiol 
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concentrations of 84.1% and 68.1%, respectively [187]. In a trial conducted in healthy male 
volunteers, estradiol suppression was about 30% at the lowest dose (0.02 mg) and 80-90% at the 
highest dose (30mg) tested [182].  
2.9.2 The use of letrozole in cancer therapy 
Seventy-five percent of women suffering from breast cancer have hormone receptor positive (+) 
disease [188]. This means that circulating hormones, mainly estrogens and progesterone, 
stimulate the division and growth of the tumour tissue. Therefore, several systemic methods of 
treatment have been developed to reduce the effects of estrogens (of any source) on breast cancer 
growth either by irreversibly binding to tumour-estrogen receptors (anti-estrogens) or inhibiting 
estrogen synthesis at the enzymatic level (aromatase inhibitors) [189]. In January 2001, letrozole 
was approved as a first-line treatment for breast cancer in post-menopausal women by the Food 
and Drug Administration (FDA) [33, 190]. Because of its potent inhibition of estradiol 
production, high oral bioavailability, selectivity and mild secondary effects, letrozole has become 
a drug of preference for the treatment of breast cancer, either as a first-line treatment or as a neo-
adjuvant therapy [190-192]  
Letrozole has also been proposed for the treatment of endometrial cancer and endometriosis 
[193, 194]. As both pathologic conditions are steroid hormone-responsive, letrozole and other 
aromatase inhibitors could be beneficial in treatment; promising results have already been 
reported [177, 195-197].  
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2.9.3 Letrozole in the treatment of infertility in women 
Commercially available letrozole (FEMARA
®
) is not labelled for use in any pathologic condition 
other than hormone-dependent breast cancer in post-menopausal women [198, 199]. However, 
there have been numerous reports on the use of letrozole for the treatment of subfertility or 
infertility in women undergoing ovarian superstimulation, intra-uterine insemination (IUI) or 
timed intercourse [194, 200, 201]. Although the effects of estrogen deprivation on the 
reproductive physiology of premenopausal women are not completely elucidated, letrozole has 
been applied in assisted reproduction in women based on its apparent effect of removing the 
negative feedback effects of estradiol on gonadotropin secretion. Theoretically, removal of 
circulating estradiol by means of aromatase inhibition would elicit a surge in FSH concentration 
which would in turn induce the recruitment of a new wave of follicular development, drive 
follicular growth or even trigger the development of more than one ovarian follicle to a pre-
ovulatory size [34, 35]. Letrozole has been used alone as a single or a 5-day regimen for ovarian 
stimulation [35, 202, 203], and in higher or increasing doses to induce ovarian superstimulation 
in women [36, 37]. Letrozole has also been utilized in combination with the administration of 
gonadotropins for ovarian superstimulation treatments prior to intra-uterine insemination. 
Improvements in the ovarian response of gonadotropin-poor responders and a significant 
decrease in the dose of FSH required to achieve an acceptable stimulatory response have been 
reported as the main advantage of the application of letrozole in fertility management treatments 
[38, 204].  
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2.9.4 Letrozole toxicity 
Letrozole has proven to be a well-tolerated drug, practically lacking of toxic effects when used as 
indicated for breast cancer treatment in post-menopausal women. Toxicity studies performed for 
the approval of FEMARA® concluded that repeated dosing caused sexual inactivity and atrophy 
of the reproductive tract in male and female mice, rats and dogs at doses of 0.6, 0.1 and 0.03 
mg/kg, respectively. Although all the reported toxic effects of letrozole have been observed 
during long-term treatment (as used for breast cancer therapy), less is known about its toxicity 
when used in a short-term treatment, as applied for ovarian stimulation. Letrozole is classified as 
embryotoxic, and it is contraindicated in premenopausal and pregnant women [198, 199]. 
In 2005, the safety of letrozole as a treatment for ovulation induction was seriously 
challenged by an abstract published by Biljan et al. [205]. In that retrospective study, the authors 
reported an increased risk for congenital cardiac and bone malformations related to the use of 
letrozole as an infertility treatment. However, the scientific credibility of that study was strongly 
questioned based on the number of letrozole-treated cases versus control cases reported (150 vs 
36,050 babies, respectively) and the inadequacy of the comparison made between these groups. 
Shortly thereafter, another retrospective study reported the absence of teratogenic effects of 
letrozole when used as an ovulation induction therapy [206]. A prospective trial was designed to 
evaluate pregnancy outcomes after ovarian stimulation with aromatase inhibitors, and it further 
confirmed the safety of aromatase inhibitors (letrozole and anastrozole in particular) as a tool for 
infertility management in women [207]. 
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2.9.5 Use of letrozole in cattle 
Based on the use of aromatase inhibitors, mainly letrozole, for the control of reproduction in 
women, we hypothesized that non-steroidal aromatase inhibitors could also be applied to the 
management of ovarian function in cattle, even though the exact mechanism of action of ovarian 
function by letrozole was not clearly understood. 
Two studies were designed to characterize the effects of letrozole on ovarian function in 
cattle. In a first study, post-pubertal beef heifers were given phosphate-buffered saline (control), 
or letrozole at a dose of 500, 250, or 125 µg/kg intravenously 4 days after follicular ablation 
(~2.5 days after wave emergence). In a second study, post-pubertal beef heifers were given no 
treatment (control) or 85 µg/kg of letrozole per day from Days 1 to 3, Days 3 to 5, or Days 5 to 7 
(250 µg/kg total dose, Day 0 = pre-treatment ovulation) corresponding to the periods before, 
during and after selection of the dominant follicle, respectively. In both studies, the diameter 
profile of the dominant follicle was larger in heifers treated with letrozole than in control heifers 
and the intervals to new wave emergence and onset of regression of the extant dominant follicle 
were longer in heifers treated with letrozole than in controls, regardless of the dose (high, 
medium, or low; single vs multiple) or the stage of the follicle wave in which treatments were 
initiated. Furthermore, during the second experiment, the mean CL diameter was larger in 
letrozole-treated heifers, although there were no differences in plasma progesterone 
concentrations between treated and control animals. The effects on dominant follicle and CL 
diameter profiles appeared to be the result of the significantly increased plasma LH 
concentrations observed in letrozole-treated animals during both treatment approaches (single vs 
multiple dose). However, it was concluded that the incomplete and inconsistent inhibition of 
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estradiol production and the lack of a surge on FSH observed in both experiments may be a 
result of insufficient circulating levels of letrozole during the treatment period [39, 40].  
These results suggested that letrozole had potential as a non-steroidal method for controlling 
ovarian function in cattle, but further studies were needed in order to clarify dosage and timing 
of treatment to predictably affect follicular wave dynamics in cattle. Furthermore, the 
prospective use of letrozole as a treatment to improve post-breeding and ET fertility is supported 
by its luteotrophic effect (more progesterone for embryo support, enhanced trophoblast 
elongation and successful maternal recognition of pregnancy) and its effectiveness in reducing 
plasma estradiol concentration (minimizing estradiol-induced expression of endometrial oxytocin 
receptors).  
2.10 The Bovine Model for the Study of Human Reproduction 
Similarities between cattle and women regarding ovarian size, follicular size and endocrine 
regulation of the follicular development, together with the accessibility and adaptability of the 
bovine species, have validated the bovine model as a tool to assess and further investigate human 
reproductive physiology [68, 208-212]. The description of a wave-like pattern of follicular 
growth during the estrous cycle in women, as observed in other mammals (cow, mare, sheep) 
[68, 212], represented a break-through discovery. Two or three waves of follicular development 
were observed during the follicular (ovulatory wave) as well as the luteal phase (non-ovulatory 
waves) of the menstrual cycle in healthy female volunteers [210]. It was also shown that the 
wave-like pattern observed in humans was controlled by the same endocrine mechanisms as 
described in other monovulatory species such as cattle [209]. Consequently, the bovine model 
has been successfully implemented for the study of several features of human reproduction 
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including ovarian senescence [213], oocyte competence after reproductive aging [214] and the 
effect of aromatase inhibitor on ovarian function [40].  
We anticipate that the data generated and included in the present thesis work will be of great 
value to improve our understanding of the effects of aromatase inhibitors when used as infertility 
or subfertility treatment in women.  
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CHAPTER 3: GENERAL HYPOTHESIS 
The overall hypothesis tested in this thesis is that aromatase inhibitors can be used as an 
effective, safe, and steroid-free method for controlling ovarian function and to improve fertility 
in mammals, using a bovine model. 
 
CHAPTER 4: GENERAL OBJECTIVES 
The overall objectives of the studies reported herein were:  
 To determine the effect of aromatase inhibitors on ovarian function in cattle. 
 To determine the effect of vehicle and route of administration of letrozole on ovarian 
function in cattle 
 To determine the effect of duration of aromatase inhibitor treatment on ovarian follicle 
dynamics in cattle 
 To develop an aromatase inhibitor-based protocol to synchronize ovulation in cattle. 
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CHAPTER 5: EFFECT OF VEHICLE AND ROUTE OF 
ADMINISTRATION OF A NON-STEROIDAL AROMATASE INHIBITOR 
ON OVARIAN FUNCTION IN A BOVINE MODEL 
 
 
Relationship of this study to the thesis: 
Previous studies of the effect of aromatase inhibitors on ovarian function in cattle used the 
intravenous route for administration of letrozole treatment. In order to develop a reliable and 
efficient method to synchronize ovulation in cattle, more practical routes of administration need 
to be explored. It this chapter, the effect of route and vehicle for the administration of letrozole 
in ovarian dynamics in cattle are described. 
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5.1. Abstract 
Treatment of cattle with letrozole, a non-steroidal aromatase inhibitor, has been associated with 
elevated mean plasma LH concentrations, prolonged follicular dominance, delayed emergence of 
the next follicular wave, and potential luteotrophic effects. The objective of the present study 
was to determine the effects of vehicle and route of administration of letrozole on ovarian 
function in sexually mature beef heifers. Ovarian follicular function was synchronized among 
heifers using transvaginal ultrasound-guided follicular ablation followed by a luteolytic dose of 
PGF bid 4 days later. The ovaries were examined daily by transrectal ultrasonography until 
ovulation was detected (Day 0=ovulation). On Day 3, heifers were assigned randomly to four 
treatment groups and given letrozole at a dose of 1 mg/kg intravenously (iv, in benzyl alcohol, 
n=10) or intramuscularly (im, in benzyl alcohol plus canola oil 1:1 v/v, n=10), or given a placebo 
iv (benzyl alcohol, n=5) or im (benzyl alcohol plus canola oil 1:1 v/v, n=5). The ovaries were 
monitored daily by ultrasonography and blood samples were collected twice daily from pre-
treatment to post-treatment ovulations. The interovulatory interval did not differ among groups, 
nor did the day-to-day diameter profiles of the dominant follicle of Wave 1 (first follicular wave 
after ovulation). However, the interval between emergence of Waves 1 and 2 was longer in 
heifers treated with letrozole im (11.7±0.3 days) than in placebo-treated controls (10.0±0.4 and 
9.5±0.5 days for iv and im placebo-treated controls, respectively; P<0.05), and intermediate in 
heifers given letrozole iv (10.6±0.30 days). The day-to-day diameter profile of the corpus luteum 
and plasma progesterone concentrations were greater (P<0.03, and P<0.05, respectively) in 
heifers treated with letrozole im vs placebo-treated control im. Plasma estradiol concentrations 
were lower in both letrozole-treated groups, compared to placebo-treated controls (P≤0.03). 
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Plasma LH concentrations tended to be elevated at the time of wave emergence in heifers treated 
with letrozole im compared to other groups (group-by-day interaction, P=0.06), and plasma FSH 
concentrations tended to be greater (P<0.09) in heifers treated with letrozole by either route 
compared to corresponding placebo-treated control groups. In summary, letrozole dissolved in 
benzyl alcohol and given intravenously at a dose of 1 mg/kg on Day 3 did not alter ovarian 
function in cattle, but the same dose given intramuscularly in canola oil vehicle resulted in a 
longer inter-wave interval, a greater CL diameter profile, greater plasma progesterone 
concentrations, and persistent inhibition of estradiol production. We conclude that intramuscular 
administration of letrozole in oil is a feasible route and vehicle for the development of an 
aromatase inhibitor-based treatment protocol for herd synchronization in cattle. 
5.2. Introduction 
Estradiol and its esters, in combination with progesterone, have been used effectively for 
synchronizing follicle wave emergence and ovulation in cattle [4, 5]. The degree of synchrony 
achieved with estradiol has made fixed-time artificial insemination feasible [6, 7] and has 
improved the efficiency of embryo transfer programs [4, 109].  
The use of natural or synthetic estrogens, whether for anabolic purposes, therapeutic 
purposes or for controlling reproductive function, has been the subject of considerable 
controversy in the cattle industry (reviewed in [20, 167]) due to increasing concern about 
potential toxic and carcinogenic effects of steroid hormone use in food producing animals [20, 
22, 170]. As a result, estradiol and other steroid hormones have been banned for use as growth 
promotants and for reproductive management in animals designated for human consumption in 
the European Union [21, 23]. In 2007, New Zealand and Australia have banned the use of 
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estrogens in lactating dairy animals [24]. The use of estradiol and zeranol (an estrogen-like 
compound) as growth promotants is still permitted in the United States [25] and Canada [172], 
but no commercial preparations are available for the purposes of reproductive management. 
Hence, treatments for estrus synchronization must be custom-compounded and used by 
prescription only. In this context, the development of alternative methods for controlling ovarian 
function in cattle is needed.  
Letrozole, a non-steroidal aromatase inhibitor, inactivates the aromatase enzyme responsible 
for the synthesis of estrogens by reversibly binding to the heme group of its P450 subunit. In 
women, letrozole is indicated as an adjuvant or first-line treatment for hormone-dependent breast 
cancer during post-menopause [33] and has also been used for ovarian stimulation and ovulation 
induction in women undergoing assisted reproduction [34, 35, 215]. In women, letrozole is 
commonly used at a dose of 1 to 5 mg per day for 5 days [35, 216]. 
It has been hypothesized that letrozole exerts its ovarian stimulatory effect by removing the 
negative feedback of estradiol on FSH secretion [34]. However, a single intravenous dose of 
letrozole given to beef heifers on Day 3 post-ovulation or in a 3-day regimen from Days 1-3, 3-5 
or 5-7 post-ovulation did not induce an elevation in circulating FSH concentrations and did not 
induce follicular atresia or hasten emergence of a new follicular wave [39, 40]. Rather, letrozole 
treatment increased mean plasma LH concentrations resulting in a prolonged period of 
dominance of the extant dominant follicle and delayed emergence of the next follicular wave. 
Further, a luteotrophic effect was apparent by the observation of larger diameter corpora lutea in 
heifers treated with letrozole in a 3-day regimen.  
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The objectives of the present study were to test the hypothesis that letrozole will terminate 
dominant follicle growth and result in the emergence of a new follicular waves at predictable 
intervals thereafter when administered at a higher dose than previously tested (1 mg/kg vs 
0.5mg/kg) and to determine the effect of vehicle and route of administration of letrozole on 
ovarian and endocrine function in cattle.  
5.3. Materials and Methods  
5.3.1. Cattle 
Hereford-cross beef heifers, 14 to 20 months of age and weighing between 340 and 482 kg, were 
chosen randomly from a herd of 50 heifers maintained in outdoor corrals at the University of 
Saskatchewan Goodale Research Farm (52° North and 106° West). Heifers were fed alfalfa/grass 
hay and grain to gain approximately 1.3 Kg per day and had water ad libitum during the 
experimental period from October to December. Heifers were initially examined by transrectal 
ultrasonography (7.5 MHz linear-array transducer, Aloka SSD-900; Tokyo, Japan) to confirm 
that they were post-pubertal by detection of the presence of a CL [217]. Animal procedures were 
performed in accordance with the Canadian Council on Animal Care and were approved by the 
University of Saskatchewan Protocol Review Committee. 
5.3.2. Treatments and examinations 
Heifers in which a CL was detected during the initial examination underwent transvaginal 
ultrasound-guided follicular ablation of the two largest ovarian follicles to synchronize follicular 
wave emergence. New wave emergence was expected to occur 1 to 1.5 days later [218, 219]. 
Four days after follicular ablation, two doses of 500 µg of cloprostenol (PGF, Estrumate, 
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Schering-Plough Animal Health, Pointe-Claire, QC, Canada) were administered intramuscularly 
(im) 12 h apart to induce regression of the CL and synchronize ovulation [220]. Heifers were 
assigned randomly at the time of ovulation (Day 0) to the following groups and given 1 mg/kg of 
letrozole on Day 3 either intravenously (iv, n=10) or im (n=10), or placebo treatment iv (n=5) or 
im (n=5). For iv administration, letrozole was prepared in 95% benzyl alcohol to a final 
concentration of 100 mg/mL resulting in an injection volume of 4-5 mL. For im administration, 
letrozole was prepared in 95% benzyl alcohol mixed with sesame oil 1:1 v/v to a final 
concentration of 50 mg/mL resulting in an injection volume of 8-10 mL applied in two injection 
sites. Intravenous and im placebos were prepared using benzyl alcohol and benzyl alcohol plus 
sesame oil 1:1 v/v, respectively and the volumes were similar to those injected in the letrozole-
treated groups.  
5.3.3. Ovarian ultrasonography 
The observations from ultrasound examination were recorded on a sketch sheet in which each 
ovary and its structures (CL and follicles ≥ 4 mm in diameter) were represented in size and 
location [73]. Ovulation was defined as the disappearance of a follicle ≥8 mm between two 
consecutive daily examinations and confirmed by subsequent development of a CL [217]. 
Follicular wave emergence was taken as day of ovulation for Wave 1 (first wave of the 
interovulatory interval) or defined retrospectively as the day when the dominant follicle was first 
identified at a diameter of 4 or 5 mm for Wave 2 [45, 64]. If the dominant follicle was not 
identified until it reached 6 or 7 mm, the previous day was considered day of the follicular wave 
emergence [87]. The dominant follicle of a wave was defined as the largest antral follicle of that 
wave [221]. The day of onset of follicular and luteal regression was defined as the first day of an 
  
51 
 
apparent progressive decrease in diameter that terminated in their disappearance or loss of 
individual identity [45].  
5.3.4. Collection of blood samples 
Daily blood samples were collected by jugular or coccygeal venipuncture into 10 mL 
heparinized vacuum tubes (Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA). 
Additionally, blood samples were collected twice daily from treatment (Day 3) until emergence 
of the first post-treatment wave was detected, and daily thereafter until ovulation occurred. A 
subset of heifers in the letrozole treated groups (n=4 for iv and im each) underwent more 
frequent blood sampling via indwelling jugular catheter, as previously described to determine 
letrozole concentration and pharmacokinetic parameters [84]. Samples were taken at the time of 
catheter placement and at 0, 10, 20, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-treatment. 
Blood samples were centrifuged at 1500 x g for 20 minutes and plasma was separated and stored 
in plastic tubes at -20 °C. 
5.3.5. Hormone assays 
Plasma LH concentrations were determined in duplicate in a single assay using a double-
antibody radioimmunoassay (NIDDK-bLH4) [11, 222]. The minimum and maximum values 
along the standard curve were 0.06 and 8 ng, respectively. The intra-assay coefficient of 
variation was 9.8% for low reference samples (mean, 1.1 ng/mL) and 14.4% for high reference 
samples (mean, 2.7 ng/mL).  
Plasma FSH concentrations were determined in duplicate with a double-antibody 
radioimmunoassay using NIDDK-anti-oFSH-1 primary antibody and expressed as USDA bovine 
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FSH-Il units [11, 222]. The minimum and maximum values along the standard curve were 0.12 
and 16 ng, respectively. The intra- and inter-assay coefficients of variation were 10.6% and 
10.7%, respectively, for low reference samples (mean, 2.3 ng/mL) and 5.7% and 5.6%, 
respectively, for high reference samples (mean, 5.5 ng/mL).  
Plasma concentrations of estradiol were determined using a commercial radioimmunoassay 
kit (Double Antibody Estradiol; Diagnostic Products, Los Angeles, CA, USA). The procedure 
was carried out at the Department of Animal Health and Biomedical Sciences, University of 
Wisconsin–Madison, as described elsewhere [79, 223] with the following modifications: 
Standards (0.78–100 pg/mL) were prepared in steroid-free (charcoal-treated) bovine plasma. The 
standards (250 µL in duplicate) and plasma samples (500 µL in duplicate) were extracted with 3 
mL of diethyl ether, frozen in a dry-ice/methanol bath, decanted into assay tubes, and dried 
overnight under a fume hood. The dried samples and standards were re-suspended with 100 µL 
of assay buffer (0.1% gelatin in PBS). The intra-assay and inter-assay coefficients of variation 
were 10.5% and 10.6% for high reference samples (mean, 11.1 pg/mL), and 14.8% and 12.3% 
for low reference samples (mean, 2.6 pg/mL), respectively. The sensitivity of the assay was 0.1 
pg/mL. 
Plasma progesterone concentrations were determined in duplicate in a single assay using a 
commercial solid-phase radioimmunoassay kit (Coat-A-Count; Diagnostic Products 
Corporation). The range of the standard curve was 0.1 to 40.0 ng. The intra-assay coefficient of 
variation was 3.9% for low reference samples (mean, 1.4 ng/mL) and 3.9% for high reference 
samples (mean, 14.6 ng/mL). 
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5.3.6. Letrozole concentrations 
Plasma concentrations of letrozole were determined using high performance liquid 
chromatography tandem mass spectrometry (LC/MS/MS). Letrozole was extracted from 250 µL 
of plasma with 250 µL of 0.1 M ammonium acetate followed by the addition of 5 mL of methyl 
t-butyl ether (MTBE) and vortexed for 15 sec. The organic layer was removed and transferred to 
a fresh 15 mL plastic tube and dried by gentle nitrogen gas flow. The dried extract was 
reconstituted in 1 mL of 100% ethanol, sonicated for 5 min and transferred to a labelled vial for 
further analysis. Separation was accomplished by HPLC (Agilent 1200, Santa Clara, CA, USA) 
fitted with an analytical column (50x2.1 mm, 3 µm particle size; Thermo Scientific Betasil C18, 
Waltham, MA, USA) operated at 35ºC. Gradient conditions were used at a flow rate of 250 
µL/min, starting at 85% A (0.1% acetic acid) and 15% B (0.1% acetic acid in acetonitrile). Initial 
conditions were held for 2 min and then ramped to 100% B at 6 min, held until 9 min, decreased 
to 0% B at 11 min, returned to initial conditions at 13 min, and then held constant until 15 min. 
Mass spectra were collected using a tandem mass spectrometer (Applied Bioscience SCIEX 
3000, Foster City, CA, USA) fitted with an electrospray ionization source, operated in the 
negative ionization mode. Chromatograms were recorded using multiple reaction monitoring 
(MRM) mode, where at least two transitions per-analyte were monitored. The following 
instrument parameters were used: desolvation temperature 450ºC, desolvation (curtain) gas 6.0 
arbitrary units (AU), nebulizer gas flow 4 AU, ion spray voltage 4500 V, collision gas 12 AU, 
collision energy 46 AU, declustering potential 30 AU, and a dwell time of 100 msec. 
Quantification using these transitions was performed using Analyst 1.4.1 software provided by 
SCIEX (Applied Bioscience, Foster City, CA, USA). The minimum and maximum values along 
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the standard curve were 0.25 and 500 ng/mL respectively. The limit of quantification used in this 
method was 0.25 ng/mL and the mean recovery was 70%. 
Plasma concentration-time profiles were generated for letrozole given intravenously and 
intramuscularly. Concentrations below the limit of quantification were considered non-detectable 
and were taken as zero. The following pharmacokinetic parameters were determined: Cmax 
(maximum observed plasma concentration of letrozole), tmax (time to reach Cmax), t1/2 (terminal 
elimination half-life), AUC (area under the plasma letrozole concentration-time curve from zero 
to infinity calculated as AUClast). The concentration of letrozole in plasma as a function of time 
(C–t) data for each heifer was analyzed by non-compartmental techniques using a computer 
modeling program (WinNonLin Standard Edition Version 2.1, Pharsight Corporation, Mountain 
View, CA, USA). Peak letrozole concentration in plasma (Cmax) and time to peak letrozole 
concentration (tmax) were determined using observed values. The apparent terminal rate 
constant (λ) was determined by linear regression of the last 6–8 points on the terminal phase of 
the logarithmic plasma concentration vs time curve. The area under the C–t curve until the final 
plasma sample (AUClast) was determined using the linear trapezoidal rule. The total area under 
the curve extrapolated to infinity (AUC0-∞) was calculated by adding the Clast obs/λ + AUClast. The 
terminal half-life (T1/2λ) was calculated as ln2 ⁄λ. The mean residence time (MRT) was calculated 
as the area under the moment curve extrapolated to infinity (AUMC0-∞) ⁄AUC0-∞. Systemic 
clearance (ClS) was determined using the dose divided by AUC0-inf. The apparent volume of 
distribution (Vλ/f) was calculated by clearance divided by λ. 
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5.3.7. Statistical analyses 
Statistical analyses were done using the Statistical Analysis System software package (SAS 
Learning Edition 9.1, 2006; SAS Institute Inc., Cary, NC, USA). Time-series hormone data and 
follicular and CL diameter profiles were analyzed by repeated measures using the PROC 
MIXED procedure. The main effects were treatment (letrozole im, letrozole iv, placebo-treated 
control im and placebo-treated control iv), time, and their interactions. Data were combined and 
re-analyzed as a single letrozole treatment group and/or a single placebo-treated control group 
when no differences were detected between routes of administration. Single point measurements 
(inter-wave interval, interovulatory interval, dominant follicle diameter at treatment, and 
treatment to onset of CL regression) were analyzed by one-way analysis of variance. 
Gonadotropin data were centralized to the day of post-treatment wave emergence to adjust for a 
delay in new wave emergence caused by letrozole treatment. Estradiol concentrations between 
two given points in time within each treatment group were assessed using paired t-tests. 
Individual time point comparisons between treatment groups were performed using least 
significant difference (LSD) test. 
5.4. Results 
The mean diameter of the dominant follicle at the time of treatment (Day 3; Day 0 = ovulation), 
did not differ among groups (Table 5. 1). No effect of route of treatment (im vs iv) was detected 
on the day-to-day dominant follicle diameter profiles in either the letrozole-treated or placebo-
treated control groups (Figure 5. 1); therefore, data were combined into a single letrozole group 
for comparison with the single placebo-treated control group. No differences in day-to-day 
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dominant follicle diameter profiles were observed in letrozole-treated heifers compared to 
placebo-treated controls from Days 0 to 13 (Figure 5. 1). 
Table 5. 1. Follicle dynamics (mean ± SEM) in heifers treated intravenously (iv) or 
intramuscularly with letrozole (1mg/kg of body weight) or placebo (control). Data are presented 
as mean ± SEM. 
 End point 
Control im 
(n=5) 
Letrozole im 
(n=10) 
Control iv 
(n=5) 
Letrozole iv 
(n=10) 
Interwave interval 
(days) 
9.5 ± 0.50 
a
 11.7 ± 0.34 
b
 10.0 ± 0.43 
a
 10.6 ± 0.30 
a,b
 
Interovulatory interval 
(days) 
18.2 ± 1.10 
a
 19.7 ± 0.83 
a
 17.5 ± 1.10 
a
 18.9 ± 0.70 
a
 
Dominant follicle at 
treatment (mm) 
11.0 ± 0.86 
a
 10.2 ± 0.61 
a
 11.2 ± 0.86 
a
 10.9 ± 0.61 
a
 
ab
 Within rows, values with different superscripts are different (P<0.05) 
 
Dominant follicle diameter profiles did not differ between letrozole-treated and placebo-
treated control heifers. However, the interval from treatment to emergence of a new follicular 
wave was significantly longer in heifers treated with letrozole im compared with either of the 
placebo-treated control groups while the letrozole iv group was intermediate (Table 5. 1). The 
inter-ovulatory interval did not differ among groups nor did the variability in interwave interval 
(i.e., degree of synchrony; Table 5. 1). 
Corpus luteum diameter profiles were larger in heifers treated with letrozole im than in the 
respective control group (P=0.04) while that of letrozole iv and placebo-treated control iv groups 
did not differ and were intermediate (Figure 5. 2). There was a tendency for a treatment effect on 
plasma progesterone concentration (P=0.06) that was determined to be a reflection of 
numerically higher concentrations in the letrozole im group on all but two days from Day 5 
onward (Figure 5. 2). The day-to-day CL diameter and progesterone profiles were significantly 
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larger in letrozole-treated heifers when data were combined into a single letrozole-treated group 
and a single placebo-treated control group (Figure 5. 3). 
 
 
Figure 5. 1. Dominant follicle diameter profile (mean ± SEM) in heifers treated with letrozole 
intramuscularly (im, n=10) or intravenously (iv, n=10), and their respective placebo-treated 
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controls (n=5 per group). In the bottom panel, im and iv routes were combined within letrozole 
and control groups. The arrow indicates the day of treatment. 
 
 
Figure 5. 2. Corpus luteum diameter and plasma progesterone concentration (mean±SEM) in 
heifers treated with letrozole intramuscularly (im, n=10) or intravenously (iv, n=10), and their 
respective placebo-treated controls (n=5 per group). The arrow indicates the day of treatment. 
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Figure 5. 3. Corpus luteum diameter and plasma progesterone concentration (mean ± SEM) in 
heifers treated with letrozole (intravenous and intramuscular routes combined, n=20) or a 
placebo (intravenous and intramuscular routes combined, n=10). (*) indicates P≤0.05 between 
groups for that specific time point (analyzed by LSD). The arrow indicates the day of treatment. 
 
Plasma estradiol concentrations were not different among groups at the time of treatment (P 
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between the placebo-treated control groups hence data were combined. In the letrozole im group, 
plasma estradiol concentrations started to decline immediately after treatment and became 
significantly lower on Day 5 (P = 0.013, Figure 5. 4). Estradiol concentration remained low until 
the end of the observational period (Day 9). In the letrozole iv group, estradiol concentration 
dropped rapidly and were significantly lower by 24 h after treatment (P = 0.03, Figure 5. 5). 
However, estradiol concentration returned to pre-treatment levels within 3 days of treatment and 
did not differ from the placebo-treated control iv group by Day 6 (P = 0.64, Figure 5. 5).  
 
 
Figure 5. 4. Plasma estradiol concentration (mean ± SEM) in heifers treated with letrozole 
intramuscularly (im, n=10) compared to placebo-treated controls (iv and im combined; n=10). 
(*) indicates P≤0.05 between groups for that specific time point (analyzed by LSD test). The 
arrow indicates the day of treatment. 
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Figure 5. 5. Plasma estradiol concentration (mean ± SEM) in heifers treated with letrozole 
intravenously (iv, n=10) compared to placebo-treated controls (iv and im combined; n=10). (*) 
indicates P≤0.05 between groups for that specific time point (analyzed by LSD test). The arrow 
indicates the day of treatment. 
 
Plasma FSH concentrations were centralized to the day of post-treatment wave emergence. 
No differences were detected for route of administration so data were combined in the respective 
treatment groups. Plasma FSH concentrations increased as the day of wave emergence neared 
and tended to be higher in the letrozole group than in the placebo-treated control group (P = 0.09, 
Figure 5. 6). 
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Figure 5. 6. Plasma FSH concentration (mean ± sem) in heifers treated with letrozole 
(intravenous and intramuscular routes combined; n=20) compared to pacebo-treated controls 
(intravenous and intramuscular routes combined; n=10). Data were centralized to the day of post-
treatment wave emergence. (*) indicates P≤0.05 between groups for that specific time point 
(analyzed by LSD test). 
 
There was a tendency for a treatment-by-day interaction on plasma LH concentrations 
(P<0.06) as a result of higher concentrations in the letrozole im group than other groups on the 
day of new wave emergence (Figure 5. 7). 
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Figure 5. 7. Plasma LH concentration (mean ± SEM) in heifers treated with letrozole 
intravenously (n=10) and intramuscularly (n10) compared to placebo-treated controls 
(intravenous and intramuscular routes combined; n=10). Data were centralized to the day of post-
treatment wave emergence.  
 
No adverse effects were observed in any heifers after iv or im letrozole administration. The mean 
plasma letrozole concentration vs time curves for both letrozole groups are depicted in Figure 5. 
8. The pharmacokinetic parameters of letrozole are presented in  
Table 5. 2. The mean bioavailability of letrozole after im administration was 54%.  
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A
 
B 
 
Figure 5. 8. Plasma letrozole concentration (mean ± SEM) during the first 12 h (A) and 8 d (B) 
in heifers after a single administration of 1 mg/kg of body weight intravenously (iv, n=4) or 
intramuscularly (im, n=4). 
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Table 5. 2. Pharmacokinetics of letrozole after intravenous administration and AUClast after 
intravenous and intramuscular administration of 1mg/kg in cattle. 
Parameter 
Heifers
1 
Heifers
2 
Heifers
3 
Heifers
4 
Mean SEM 
Maximal concentration (Cmax) 
(ng/mL) 
542.6 412.9 1938.5 1030.9 981.2 345.73 
Half-life (T1/2) (hours)  33.6 37.4 30.2 32.0 33.3 1.52 
Volume of distribution (Vz/f) (L/kg) 9.4 9.7 6.4 6.8 8.1 0.84 
Systemic clearance (ClS) (L/hour/kg) 0.2 0.2 0.1 0.1 0.2 0.01 
iv - area under the curve (AUClast) 
(hours x ng/mL) 
4896.5 5441.0 6716.0 6522.0 5893.9 434.96 
im - area under the curve (AUClast) 
(hours x ng/mL) 
2776.0 2371.7 4361.3 3191.1 3175.0 429.34 
Bioavailability after im treatment     
54% 
 
 
5.5. Discussion 
Previous studies on the effects of letrozole on ovarian function in women have been interpreted 
to mean that aromatase inhibitor treatment stimulated follicular growth by removing the negative 
feedback effect of estradiol on FSH secretion [34, 141]. However, results of the present study 
and studies previously conducted by our group [39, 40] support the hypothesis that the hormone 
responsible for the effects of letrozole on ovarian function in cattle is LH rather than FSH. 
Two previous studies conducted in cattle showed that letrozole has a stimulatory effect on 
the growth and lifespan of the dominant follicle [39, 40]. Similarly, women treated with letrozole 
from Days 3 to 7 of the menstrual cycle had larger dominant follicles than untreated controls 
[224]. Although an effect on dominant follicle diameter was not evident in the present study, the 
prolonged interval from treatment to new wave emergence in both letrozole-treated groups 
suggests that the functionality of the dominant follicle was indeed prolonged. However, this 
effect on dominant follicle lifespan was more evident in heifers given letrozole intramuscularly 
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than in those treated intravenously. This observation may be related to the longer residence time 
of letrozole in circulation in the im group, given that the oil-based formulation probably served 
as a depot, delaying and prolonging drug release from the injection site.  
In the present study, letrozole treatment had a luteotrophic effect. The effect was evidenced 
by larger CL diameter profiles and increased plasma progesterone concentrations in the 
letrozole-treated heifers. The effect seemed to be more evident in the letrozole im group. Similar 
findings have been reported in women, where enhanced luteal function was associated with 
increased circulating LH concentrations but no difference in FSH concentrations [225]. Our 
present results are consistent with those of previous studies in cattle in which luteotrophic effects 
were observed after treatment with a single or a 3-day regimen of letrozole; circulating LH was 
increased and FSH remained unchanged [39, 40]. 
Plasma estradiol concentrations were significantly reduced by letrozole treatment and the 
magnitude and duration of estradiol reduction was significantly greater in heifers treated 
intramuscularly than in those treated intravenously. The vehicle formulated for intramuscular 
administration of letrozole appeared to result in a steady and prolonged released of letrozole 
from the injection site. Plasma estradiol concentrations in heifers treated intramuscularly took 24 
h longer than in those treated intravenously to reach minimum and remained low until the end of 
the observational period (6 days after treatment). In the letrozole iv group, estradiol levels 
reached the minimum concentration between 12 and 24 h after treatment but returned to placebo-
treated control levels within 2 days. Given that the half-life of letrozole in cattle is about 32 h, 
the differences observed between routes of administration may be attributable to a function of the 
absorption pattern after intramuscular administration. 
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The pharmacokinetic parameters presented in the present study are in accordance with those 
reported previously [40]. As anticipated, the intramuscular vehicle acted as a depot, releasing 
letrozole from the injection site at a slow and steady rate. Although the effects of the im letrozole 
treatment on ovarian function were more consistent and reliable that those obtained with the iv 
route, the fact that withdrawal of the circulating concentration of letrozole depends entirely on 
absorption and clearance, making it is difficult to manipulate the length of the treatment, remains 
to be a strong limitation for this route and vehicle of administration. It is important to note the 
limited information provided by the AUClast and the bioavailability data for the letrozole im 
group since the observational period was not prolonged enough as to determine volume of 
distribution and systemic clearance for letrozole im formulation. 
Gonadotropin concentration data were centralized to day of post-treatment wave emergence 
to permit direct comparison among groups since letrozole treatment was associated with delayed 
wave emergence. Plasma FSH concentrations tended to be higher around the time of wave 
emergence in the letrozole-treated group. A surge on LH concentration was observed on the day 
of wave emergence on the letrozole im group while no such increase was detected in the 
letrozole iv and combined placebo-treated control groups. It is unclear as to what led to the LH 
surge although we speculate that it may be related to the suppressed circulating concentrations of 
estradiol in letrozole-treated heifers. 
In summary, our results demonstrate that route of administration, or more precisely, the 
nature of the vehicle used for the administration of letrozole (depot vs intravenous) has an impact 
on the effects of letrozole on ovarian dynamics and hormonal profiles. The intramuscular route 
provided a prolonged release of letrozole from the injection site which had a marked effect on 
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estradiol production, dominant follicle lifespan, and CL form and function. As observed in 
previous studies [39, 40], the effects observed were associated with an increase in circulating LH 
concentrations. We concluded that letrozole treatment given intramuscularly on Day 3 post wave 
emergence lengthens the lifespan of the dominant follicle, delays post-treatment wave 
emergence, and has a luteotrophic effect as evidenced by a larger CL and higher circulating 
progesterone concentrations. However, the same dose of letrozole given intravenously was less 
effective in altering ovarian function. Our results further support the working hypothesis that 
letrozole has potential as a steroid-free option for the control of ovarian function for the purposes 
of fixed-time artificial insemination and embryo production. 
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CHAPTER 6: NON-STEROIDAL AROMATASE INHIBITOR 
TREATMENT WITH AN INTRAVAGINAL DEVICE AND ITS EFFECT 
ON PRE-OVULATORY OVARIAN FOLLICLES IN A BOVINE MODEL 
 
 
Relationship of this study to the thesis: 
In chapter 5, we demonstrated that intramuscular administration of aromatase inhibitors is a 
feasible route for the control of ovarian function in cattle and allows for extended letrozole 
release from the injection site when a depot (oil based) vehicle was employed. However, one 
of the main limitations of the intramuscular route is the difficult control of the length of 
treatment, which is crucial to minimize variability and to control timing during an ovulation 
synchronization protocol. An alternative technology that allows not only for prolonged 
treatments but also for controlled treatment termination or withdrawal is the use of 
intravaginal devices. Additionally, past experiments have only assessed the effect of 
aromatase inhibitor on ovarian activities when given during non-ovulatory follicular waves. 
In this chapter, we described the effects of a prototype letrozole-containing intravaginal 
device formulated for cattle on pre-ovulatory ovarian follicles. 
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6.1. Abstract  
Letrozole, a non-steroidal aromatase inhibitor, prevents the body from producing its own 
estrogen. The objectives of the present study were to test the hypotheses that letrozole treatment, 
initiated prior to selection of the preovulatory dominant follicle, will induce the growth of more 
than one follicle to a pre-ovulatory size, and will delay ovulation. Post-pubertal beef heifers were 
given two luteolytic doses of PGF (12 h apart) and monitored by ultrasonography for ovulation. 
Five to eight days later, ovarian follicular wave emergence was synchronized by ultrasound-
guided transvaginal follicular ablation (Day 0=wave emergence) and a luteolytic dose of PGF 
was given 60 and 72 h later. On Day 1, heifers were divided randomly into two groups 
(n=15/group) and an intravaginal device containing 1 g of letrozole or a blank device (control) 
was inserted. The intravaginal devices were removed on Day 7, or at the time of ovulation, 
whichever occurred first. Transrectal ultrasonography and blood sample collection was 
performed daily from the day of ablation to 12 days after subsequent ovulation. The mean 
(+SEM) interval from device placement to ovulation was longer in letrozole-treated animals 
compared to controls (6.1±0.25 vs 5.1±0.26 days, respectively; P<0.01). Single dominant 
follicles were present in both groups. The day-to-day diameter profiles of the dominant follicles 
of the ovulatory wave were larger (P<0.05) and the maximum diameters greater in letrozole-
treated heifers (14.6±0.51 vs 12.4±0.53 mm, respectively; P<0.01). The diameter profile of the 
corpus luteum (CL) that formed after treatment did not differ between groups; however, plasma 
progesterone concentrations were higher (P<0.01) in heifers treated with letrozole. Estradiol 
concentrations were reduced following letrozole treatment (P<0.05), although a preovulatory rise 
of estradiol occurred in both groups. Administration of letrozole with an intravaginal device 
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during growth of the ovulatory follicle delayed ovulation by 24 h and resulted in the formation of 
a CL that secreted higher levels of progesterone. A sustained-release intravaginal device may be 
useful for the development of an aromatase inhibitor-based protocol to control ovulation for herd 
synchronization and to enhance fertility by increasing circulating progesterone concentrations 
during the first 7 days post-ovulation in cattle. 
6.2. Background  
Estrogen-based protocols, as a treatment for synchronizing ovulation in cattle, have modernized 
breeding practices and allowed producers to reliably control the timing of ovulation, thus 
enabling efficient use of time, labour and resources by allowing pre-scheduled insemination. 
Estradiol-based protocols also allow wider application of superovulation and embryo transfer by 
enabling effective synchronization of follicular wave emergence [4-8]. However, increasing 
consumer sensitivity to the possible deleterious effects of estrogens in food and in the 
environment [20] has led to new regulations about the use of estrogenic products in livestock. 
The European Union has already banned the use of estrogenic products in food producing 
animals [21-24]. In the United States [25] and Canada [26], estrogens cannot be used for 
synchronization of estrus except by prescription and custom-compounding. In 2007, New 
Zealand and Australia banned use of estrogens in lactating dairy animals [24]. These policies 
have created a void in methods to control reproductive function for breeding management in 
cattle. 
Non-steroidal aromatase inhibitors prevent the body from producing its own estrogen. 
Letrozole, a non-steroidal aromatase inhibitor, is used as an adjuvant treatment for hormone-
responsive breast cancer in post-menopausal women [33] and has been used as a fertility 
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treatment for women undergoing assisted reproduction [34]. The putative effect of letrozole on 
ovarian function in women is through elevated FSH secretion by removal of the negative 
feedback of estradiol [34]. Tests of this hypothesis in a bovine model, however, were not 
supportive of an effect on FSH. In cattle, a single intravenous dose given on Day 3 post-
ovulation, or a 3-day regimen given on Days 1-3, 3-5 or 5-7 post-ovulation did not induce an 
elevation in circulating FSH concentration but did increase mean plasma LH concentrations. The 
effect on LH secretion resulted in a prolonged period of dominance of the extant dominant 
follicle and delayed emergence of the next follicular wave [39, 40]. Further, a luteotrophic effect 
was inferred from the observation that heifers treated with letrozole for 3 days had larger corpora 
lutea following treatment. Similar results were observed when letrozole was prepared in an oil-
based vehicle and administered intramuscularly (Chapter 5).  
To date, studies on the effects of letrozole on ovarian function in cattle have been focused on 
non-ovulatory follicular waves [23-25]. The present study was designed to determine the effect 
of an extended period of treatment with letrozole on the pre-ovulatory follicle in cattle. We 
hypothesized that letrozole treatment initiated before selection of the dominant ovulatory follicle 
and extended over the follicle growing phase will induce the development of more than one 
follicle to a preovulatory size, and delay ovulation. Additionally, we hypothesized that the CL 
resulting from ovulations after letrozole treatment will be larger and secrete more progesterone 
than those from control heifers. 
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6.3. Methods  
6.3.1. Cattle 
Hereford-cross beef heifers (n=30), 15 to 20 months of age and weighing between 235 and 405 
kg (average 336 kg), were chosen from a herd of 51 heifers maintained in outdoor pens at the 
University of Saskatchewan Goodale Research Farm (52° North and 106° West). Heifers were 
fed alfalfa/grass hay and concentrate to gain approximately 1.3 Kg per day and had water ad 
libitum during the experimental period from October to December. Heifers were initially 
examined by transrectal ultrasonography (MyLab5 VET, Canadian Veterinary Imaging, 
Georgetown, Ontario Canada) to detect the presence of a CL (i.e., confirm post-pubertal status; 
[217]. Animal procedures were performed in accordance with the Canadian Council on Animal 
Care and were approved by University of Saskatchewan Protocol Review Committee. 
6.3.2. Treatments and examinations 
Heifers in which a CL was detected were given two luteolytic doses of PGF (12 h apart) and 
monitored by ultrasonography for ovulation. Five to eight days later, the two largest ovarian 
follicles were ablated by transvaginal ultrasound-guided follicular aspiration to synchronize 
follicular wave emergence which was expected to occur 1 to 1.5 days later [218, 219]. 
Prostaglandin (500 µg cloprostenol, Estrumate, Schering-Plough Animal Health, Pointe-Claire, 
QC, Canada) was given intramuscularly at 60 and 72 h after follicular ablation to induce 
regression of the CL and shift from a non-ovulatory to an ovulatory follicular wave [87]. At the 
time of follicular wave emergence (Day 0; i.e., 1.5 days after follicle ablation), heifers were 
assigned randomly to two groups and given an intravaginal device containing 1 g of letrozole 
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(letrozole group, n=15) or a placebo (letrozole-free) intravaginal device (control group, n=15). 
Devices were inserted on Day 1 and were kept in place until Day 7 or until ovulation was 
detected, which ever occurred first.  
Intravaginal devices were prepared using a Cue-Mate spine (Bioniche Animal Health, 
Bellville, ON, Canada) assembled with two blank (progesterone-free) silicone pods that were 
coated with a gel-based vehicle containing letrozole or vehicle only (control). The vehicle 
contained the following (all ingredients % w/w): letrozole 10%, gelatin 20% (Gelatin type B, 
Fisher Scientific, Pittsburgh, PA, USA), polymer 65% (prepared by mixing distilled water 68%, 
Poloxamer 188 12% and Poloxamer 407 20%, both from Spectrum Chemical, New Brunswick, 
NJ, USA) and distilled water 5%. 
6.3.3. Ovarian ultrasonography 
The observations from ultrasound examinations were recorded on a sketch sheet in which each 
ovary and its structures (CL and follicles ≥ 4 mm in diameter) were represented by size and 
location [73]. Ovulation was defined as the disappearance of any follicle ≥8 mm between two 
consecutive daily examinations and was confirmed by the subsequent development of a CL 
[217]. Follicular wave emergence was defined as occurring 1.5 days after follicular ablation 
[218]. The dominant follicle of a wave was defined as the largest antral follicle of that wave [45].  
6.3.4. Collection of blood samples 
Blood samples were collected by coccygeal venipuncture into 10 mL heparinized vacuum tubes 
(Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA). Samples were collected daily 
from pre-treatment follicular wave emergence (Day 0) to 12 days after the subsequent ovulation. 
  
75 
 
In a subset of letrozole-treated animals (n=4), frequent blood samples were collected using an in-
dwelling jugular catheter, as previously described [84], at the time of catheter placement and 0, 
10, 20, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h after treatment for measurement of plasma 
letrozole concentration. Blood samples were centrifuged at 1500 x g for 20 min and plasma was 
separated and stored in plastic tubes at -20°C. 
6.3.5. Hormone assays 
Plasma LH concentrations were determined in duplicate using a double-antibody 
radioimmunoassay (NIDDK-bLH4) [11, 222]. The minimum and maximum values along the 
standard curve were 0.06 and 8 ng/mL, respectively. All samples were analyzed in a single 
assay; the intra-assay coefficient of variation was 11.4% for low reference samples (mean, 0.9 
ng/mL) and 12.2% for high reference samples (mean, 2.1 ng/mL).  
Plasma FSH concentrations were determined in duplicate using a double-antibody 
radioimmunoassay using NIDDK-anti-oFSH-1 primary antibody and expressed as USDA bovine 
FSH-Il units [11, 222]. The minimum and maximum values along the standard curve were 0.12 
and 16 ng/mL, respectively. All samples were analyzed in a single assay; the intra-assay 
coefficients of variation were 7.9 and 6.5%, for low (mean, 2.4 ng/mL) and high reference 
samples (mean 4.9 ng/mL), respectively.  
Plasma concentrations of estradiol were determined using a commercial radioimmunoassay 
kit (Double Antibody Estradiol; Diagnostic Products Corp., Los Angeles, CA, USA). The 
procedure was carried out at the Department of Animal Health and Biomedical Sciences, 
University of Wisconsin–Madison, as previously described [79, 223], with the following 
modifications: Standards (0.78–100 pg/mL) were prepared in steroid-free (charcoal-treated) 
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bovine plasma. The standards (250 µL in duplicate) and plasma samples (500 µL in duplicate) 
were extracted with 3 mL of diethyl ether, frozen in a dry-ice/methanol bath, decanted into assay 
tubes, and dried overnight under a fume hood. The dried samples and standards were re-
suspended with 100 µL of assay buffer (0.1% gelatin in PBS). The intra- and inter-assay 
coefficients of variation were 10.5 and 10.6% for high reference samples (mean 11.1 pg/mL), 
and 14.8 and 12.3% for low reference samples (mean 2.6 pg/mL), respectively. The sensitivity of 
the assay was 0.1 pg/mL. 
Plasma progesterone concentrations were determined in duplicate using a commercial solid-
phase radioimmunoassay kit (Coat-A-Count; Diagnostic Products Corporation, Los Angeles, 
CA, USA). The range of the standard curve was 0.1 to 40.0 ng/mL. All samples were analyzed in 
a single assay; the intra-assay coefficients of variation were 9.7% and 5.8 % for low- (mean, 1.7 
ng/mL) and high-reference samples (mean, 18.7 ng/mL), respectively.  
6.3.6. Letrozole concentrations 
Plasma letrozole concentrations were quantified using liquid chromatography tandem mass 
spectrometry (LCMS/MS), as described [39]. Briefly, letrozole was extracted from 250 mL 
plasma with 250 mL of 0.1M ammonium acetate followed by the addition of 5 mL methyl t-
butyl ether (MTBE) and vortexed for 15 s. The organic layer was removed and transferred to a 
fresh 15-mL plastic tube and dried by gentle nitrogen gas flow. The dried extract was 
reconstituted in 1 mL of 100% ethanol. Separation was accomplished by HPLC (Agilent 1200; 
Agilent, Santa Clara, CA, USA) fitted with an analytical column (50 x 2.1 mm, 3 mm particle 
size; Betasil C18; Thermo Scientific, Waltham, MA, USA) operated at 35ºC. Mass spectra were 
collected using a tandem mass spectrometer (SCIEX 3000; Applied Bioscience, Foster City, CA, 
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USA) fitted with an electrospray ionisation source, operated in the negative ionisation mode. 
Quantification was performed using Analyst 1.4.1 software provided by SCIEX (Applied 
Bioscience). The minimum and maximum values along the standard curve were 0.25 and 500 
ng/mL, respectively. The limit of quantification used in this method was 0.25 ng/mL and the 
mean recovery was 70%. 
The following pharmacokinetic parameters were determined: Cmax (maximum observed 
plasma concentration of letrozole), tmax (time to reach Cmax), t1/2 (terminal elimination half-life), 
AUC (area under the plasma letrozole concentration-time curve from zero to infinity calculated 
as AUClast). The concentration of letrozole in plasma as a function of time (C–t) data for each 
heifer was analyzed by non-compartmental techniques using a computer modeling program 
(WinNonLin Standard Edition Version 2.1, Pharsight Corporation, Mountain View, CA, USA). 
Peak letrozole concentration in plasma (Cmax) and time to peak letrozole concentration (tmax) 
were determined using observed values. The apparent terminal rate constant (λ) was determined 
by linear regression of the last 6–8 points on the terminal phase of the logarithmic plasma 
concentration vs time curve. The area under the C–t curve until the final plasma sample (AUClast) 
was determined using the linear trapezoidal rule. The total area under the curve extrapolated to 
infinity (AUC0-∞) was calculated by adding the Clast obs/λ + AUClast. The terminal half-life (T1/2λ) 
was calculated as ln2 ⁄λ. The mean residence time (MRT) was calculated as the area under the 
moment curve extrapolated to infinity (AUMC0-∞) ⁄AUC0-∞. Systemic clearance (ClS) was 
determined using the dose divided by AUC0-inf. The apparent volume of distribution (Vλ/f) was 
calculated by clearance divided by λ. Absolute bioavailability was calculated by comparing 
letrozole AUClast obtained using intravaginal devices to the AUClast obtained after a single iv 
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injection of letrozole (Chapter 5), corrected by dose (Bioavailability = (AUClast 
intravag/Doseintravag)/(AUClast iv/Doseiv) x 100). 
6.3.7. Statistical analyses 
Statistical analyses were done using the Statistical Analysis System software package (SAS 
Learning Edition 9.1, 2006; SAS Institute Inc., Cary, NC, USA). Time-series data (hormone 
concentrations, follicle and CL diameter profiles) were analyzed by repeated measures using the 
PROC MIXED procedure. The main effects were treatment (letrozole and control), time, and 
their interactions. Single-point measurements (dominant follicle diameter at device placement, 
maximum diameter of extant dominant follicle, intervals from ablation to wave emergence, and 
from device placement to ovulation) were analyzed by t-tests. Individual time point comparisons 
between treatment groups were performed using least significant difference (LSD) test. 
Significance was defined as P ≤ 0.05. 
6.4. Results 
The diameter of the dominant follicle at the time of intravaginal device placement on Day 1 (Day 
0 = wave emergence) did not differ between groups (Table 6.1). The day-to-day diameter profile 
of the dominant follicle during treatment and the maximum diameter of the ovulatory follicle 
were larger in the letrozole-treated group (P=0.05 and P=0.01; respectively; Figure 6. 1 and 
Table 6.1; respectively). The interval from device placement to ovulation was longer in heifers 
treated with letrozole than in controls (P=0.01, Table 6.1). Single ovulation occurred in all 
heifers, regardless of treatment. 
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Table 6. 1. Effects of a letrozole-containing intravaginal device on ovarian function in heifers 
(mean±SEM). 
End point 
Control 
(n=15) 
Letrozole 
(n=15) 
P-value 
Device placement to ovulation (days) 5.1±0.26 6.1±0.25 <0.01 
Max. diameter of extant dominant 
follicle (mm) 
12.4±0.53 14.6±0.51 <0.01 
Dominant follicle diameter at device 
placement (mm) 
3.9±0.47 4.2±0.46 0.68 
 
 
 
Figure 6. 1. Dominant follicle diameter (mean±SEM) in heifers treated with a blank (control, 
n=15) or a letrozole-containing intravaginal device (letrozole, n=15). Devices were inserted on 
Day 1, indicated by the arrow (Day 0 = wave emergence). * On indicated days, values differed 
between groups (P≤0.05). 
 
Corpus luteum diameter profiles were not different between letrozole and control groups 
(P=0.82, Figure 6. 2). However, progesterone concentrations were higher during the 
observational period (first 12 days post-ovulation) in the letrozole-treated heifers compared to 
control heifers (P=0.01, Figure 6. 3). 
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Figure 6. 2. Corpus luteum diameter (mean±SEM) following post-treatment ovulation in heifers 
treated with a blank (control, n=15) or a letrozole-containing intravaginal device (letrozole, 
n=15). 
 
Figure 6. 3. Plasma progesterone concentrations (mean±SEM) following post-treatment 
ovulation in heifers treated with a blank (control, n=15) or a letrozole-containing intravaginal 
device (letrozole, n=15). * On indicated days, values differed between groups (P≤0.05). 
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Plasma estradiol concentrations were lower in the letrozole-treated group than in the control 
group (P=0.04, Figure 6. 4). Treatment with letrozole did not prevent a pre-ovulatory rise in 
estradiol but the rise was delayed in the letrozole group (Figure 6. 4). 
 
Figure 6. 4. Plasma estradiol concentrations (mean ±SEM) in heifers treated with a blank 
(control, n=15) or a letrozole-containing intravaginal device (letrozole, n=15). Devices were 
given on Day 1, indicated by the arrow (Day 0 = wave emergence) of the ovulatory wave. * On 
indicated days, values differed between groups (P≤0.05). 
 
There was a tendency for lower plasma FSH concentrations in the letrozole group compared 
to the control group (P = 0.1; Figure 6. 5). Mean plasma LH concentrations did not differ 
between groups (P = 0.61; Figure 6. 6). 
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Figure 6. 5. Plasma FSH concentrations (mean ±SEM) in heifers treated with a blank (control, 
n=15) or a letrozole-containing intravaginal device (letrozole, n=15). Devices were given on Day 
1 (Day 0 = wave emergence) of the ovulatory wave. 
 
 
Figure 6. 6. Plasma LH concentrations (mean ±SEM) in heifers treated with a blank (control, 
n=15) or a letrozole-containing intravaginal device (letrozole, n=15). Devices were given on Day 
1, indicated by the arrow (Day 0 = wave emergence) of the ovulatory wave. 
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Plasma letrozole concentrations are shown in Figure 6. 7. The half-life of letrozole in plasma 
was 33.3±4.56 h. Maximal concentrations in plasma (Cmax 31.7±1.65 ng/mL) occurred at 24 h 
post-device insertion (Table 6. 2). Additional letrozole pharmacokinetic parameters are 
summarized in Table 6. 2. 
 
Figure 6. 7. Plasma letrozole concentration (mean±SEM) in heifers (n=4) given an intravaginal 
letrozole-releasing device for 6 days. * Between indicated time points, values differed (P≤0.05).  
Table 6. 2. Pharmacokinetics of a letrozole-containing intravaginal device in heifers. 
Parameter Heifer 1 Heifer 2 Heifer 3 Heifer 4 Mean SEM 
Maximal concentration (Cmax) 
(ng/mL) 
32.4 35.3 27.3 31.7 31.7 1.65 
Half-life (T1/2) (hours) 35.1 20.4 41.9 35.7 33.3 4.56 
Area under the curve (AUClast) 
(hours x ng/mL) 
3538.1 2697.7 2583.1 1698.0 2629.2 376.39 
Volume of distribution (Vz/f) 
(L/kg) 
6.2 4.9 9.9 13.2 8.5 1.87 
Systemic clearance (ClS) 
(L/hour/kg) 
0.1 0.2 0.2 0.3 0.2 0.03 
Mean residence time (MRT) 
(hours)  
71.5 56.2 65.5 48.7 60.5 5.03 
Bioavailability     16%  
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6.5. Discussion 
Previous studies of the effects of letrozole on ovarian function in cattle were focused on the non-
ovulatory portion of the estrous cycle in cattle [39, 40]; hence, the effect of letrozole treatment 
on pre-ovulatory follicles was the subject of the present study. Letrozole treatment during the 
pre-ovulatory follicular wave resulted in a greater diameter of the ovulatory follicle. This 
observation is consistent with the results of previous studies in which larger dominant follicles 
were observed when letrozole treatment was administered during non-ovulatory follicular waves 
[39, 40]. The hypothesis that letrozole treatment initiated prior to the onset dominant follicle 
selection would result in multiple ovulatory follicle development [40] was not supported by the 
results of the present study; single ovulations were detected in both groups. However, ovulation 
was delayed by 24 h in the letrozole-treated group. The larger ovulatory follicle diameter 
observed in the letrozole-treated heifers may have been affected by the length of the growing 
phase of these follicles due to delayed ovulation. However, ovulatory dominant follicle diameters 
in the letrozole-treated group were already larger than the control group when compared 5 days 
after initiation of treatment (Day 6 post-wave emergence). The stimulus driving the accentuated 
follicular growth is unclear. However, daily sampling has limitations when attempting to 
interpret gonadotropin concentrations and its correlation to ovarian dynamics. Perhaps changes 
in gonadotropin pulse-frequency would have been detected using more frequent sampling.  
Estradiol concentrations were reduced following treatment with letrozole-impregnated 
intravaginal devices, and the preovulatory rise in estradiol concentrations occurred 24 h later 
than in the control group. However, the follicles maintained ovulatory capability. We infer that 
the delay in estradiol rise observed in the letrozole-treated group is responsible for the delay in 
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ovulation in this group. The notion is further supported by plasma LH concentrations which, 
although not significantly different between groups, appeared to increase 24 h later in the 
letrozole-treated group than in the control group. 
In the present study, a letrozole-impregnated intravaginal device was used to provide 
extended estradiol suppression during the ovulatory wave. The intravaginal route of 
administration provides the advantage of reducing animal handling and distress caused by daily 
injections [226]. The duration of estradiol inhibition was influenced by the pharmacokinetic 
characteristics of the intravaginal device, and accounts for the occurrence and timing of the 
estradiol rise observed in the letrozole-treated group. The half-life of letrozole observed 
following administration via an intravaginal device (33 h) corresponded to that reported 
previously after single intravenous administration in beef heifers (Chapter 5). Hence, the profile 
of letrozole concentration over time obtained in the present study was affected primarily by the 
absorption characteristics of the formulation used in the intravaginal devices. Based on the 
plasma letrozole concentration profile, the intravaginal devices released letrozole for only 24 h 
post-insertion, and elimination and plasma clearance took place thereafter. Therefore, letrozole 
concentrations may have dropped below a critical level relatively rapidly, allowing for the pre-
ovulatory estradiol rise to occur after only a 24 h delay. Bioavailability has been defined as the 
amount of a drug given by any route, other than intravenously, that reaches general circulation 
and is available at the site of action [227]. The low bioavailability observed with the intravaginal 
devices (16%) may be explained in part by the melting point of the gel-vehicle used. This gel-
based vehicle is commonly used for intravaginal suppositories for women, in which body 
temperature is lower than that of cattle (37° vs 39° C) [228, 229]. Rapid liquefaction of the 
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letrozole-containing gel resulted in loss of the preparation through the vulvar opening during 
micturition, defecation, or ultrasound examinations (the latter was observed by the author). 
Letrozole treatment during the growing phase of the ovulatory follicle resulted in the 
ovulation of a larger follicle. Although larger follicles did not result in larger CL, elevated 
plasma progesterone profiles were observed over the first 12 days post-ovulation in the letrozole-
treated group. Preovulatory letrozole treatment may have affected the number or proportion of 
large luteal cells (granulosa cell origin) and small luteal cell (thecal cell origin) contained within 
the CL [230], resulting in an increase in progesterone production per CL volume. Small and 
large luteal cells are present in the bovine CL in a ratio of 7.6:1 [231]. Small luteal cells respond 
directly to LH stimulus to secrete progesterone [232, 233], while large luteal cells appear to be 
responsible for sustained secretion of progesterone in the absence of a stimulus [233]. Treatment 
with letrozole may have resulted in an increase in luteal cell numbers or an alteration in the 
proportion of small and large luteal cells within the CL and an increase in progesterone-
producing capability per CL volume. In this regard, treatment of cows with equine chorionic 
gonadotropin resulted in increased density and number of large luteal cells which increased the 
capacity of the CL to produce progesterone [234]. Although we were unable to document the 
effect of letrozole treatment on gonadotropin secretion in the present study, previous studies have 
shown an increased in gonadotropin secretion after single or 3-day letrozole regimen [39, 40].  
In summary, letrozole treatment during the ovulatory follicle wave resulted in more rapidly 
growing dominant follicles and larger ovulatory follicles, delayed ovulation (by 24 h) of a single 
follicle and formation of a CL that secreted higher levels of progesterone. The effects of 
treatment on gonadotropin concentrations are inconclusive, possibly due to inadequate sampling 
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frequency. However, results confirmed that letrozole treatment effectively reduces estradiol 
production in cattle. Finally, the formulation used for the development of an intravaginal device 
containing letrozole impacts on the effect of treatment on ovarian function. Based on these 
observations, we hypothesize that a letrozole-releasing device capable of a more sustained drug 
release may delay ovulation even further, while allowing more than one follicle to develop to a 
pre-ovulatory size when treatment is initiated prior to dominant follicle selection. 
We conclude that a sustained-release intravaginal device has potential in the development of 
an aromatase inhibitor-based protocol for control of ovulation for herd synchronization. The 
enhanced effects of letrozole treatment on CL function has the potential of enhancing fertility by 
increasing circulating progesterone concentrations during the first 7 days post-ovulation in cattle. 
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CHAPTER 7: FORMULATION AND PHARMACOKINETIC 
CHARACTERISTICS OF AN INTRAVAGINAL DEVICE FOR 
AROMATASE INHIBITOR DELIVERY IN CATTLE 
 
 
Relationship of this study to the thesis: 
Chapters 5 and 6 provide evidence that extended aromatase inhibitor treatment predictably 
affects ovarian function and has potential as a method to synchronize ovulation in cattle. 
However, the advantages of intravaginal administration over im treatments (reduce animal 
distress, user friendly, no negative impact in meat quality, controlled length of treatment) led us 
to pursue this route of administration further. During chapter 6, we identified the short-comings 
of the intravaginal vehicle tested, namely low melting point and loss of the formulation through 
the vulvar opening. We concluded that prior to successfully applying aromatase inhibitors to the 
synchronization of ovulation, formulation adjustments are needed in order to provide 
biologically relevant levels of aromatase inhibitor during the desired period of time. In chapter 7 
we describe the steps taken towards the development of an aromatase inhibitor-releasing 
intravaginal device to be applied in the development of an aromatase inhibitor-based method for 
the synchronization of ovulation in cattle. 
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7.1. Abstract: 
The goal of this study was to formulate and test an intravaginal device that provides biologically 
active circulating concentrations of an aromatase inhibitor for a minimum of 4 days. Three 
compounds with estradiol inhibitory capability (letrozole, anastrozole and fenbendazole) were 
tested in vitro using a bovine granulosa cell culture. Letrozole was found to be the most efficient 
and potent estradiol inhibitor. Liposome-based and a wax-based formulations were used to assess 
letrozole diffusion through bovine vaginal mucosa in a diffusion chamber study. Samples were 
collected over a 24 h period. The wax-based vehicle was selected for further development of a 
letrozole intravaginal device based on its steady release rate. In an in vivo study in cattle, three 
different intravaginal devices containing 3 g of letrozole were tested: Wax (with 1,2-Dioleoyl-sn-
Glycero-3-Phosphoethanolamine, DOPE) + gel coat (n=2), Wax + gel coat (n=4) and Wax (n=4). 
Blood samples were collected serially from 0 to 120 h, and daily thereafter to measure 
circulating concentrations of letrozole by LC/MS/MS. The addition of a letrozole-containing gel 
coating improved initial absorption and hastened the increase on plasma concentrations of the 
active ingredient, while the letrozole-containing wax-based vehicle maintained prolonged 
delivery from the intravaginal device. 
7.2. Introduction 
Control of the estrous cycle in animal species of commercial interest, such as cattle, has a great 
impact on the efficiency of meat and milk production. Numerous treatments and protocols have 
been successful in achieving the goal of timely control of the occurrence of several reproductive 
events such as luteolysis, estrus and ovulation [107, 235, 236]. However, the application of many 
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of these protocols involves the administration of hormonal combinations in food producing 
animals, many of which are perceived as having a negative impact on consumer health [22, 237, 
238]. The situation has led to the legal banning of steroid hormones within particular geographic 
locations (i.e., European Union, New Zealand, and Australia) or physiological categories of 
animals (i.e., lactating dairy cattle; [23, 24]). 
Non-steroidal aromatase inhibitors are compounds that prevent the body from producing 
estradiol by inhibiting the activity of the aromatase enzyme that is responsible for the conversion 
of androgens into estrogens [239, 240]. Aromatase inhibitors are used widely for the treatment of 
estrogen-responsive breast cancer in postmenopausal women [241, 242]. However, the potential 
benefits of these drugs for the treatment of other pathological conditions, such as endometriosis 
or unexplained infertility, has gained attention [194, 197].  
Recent studies have revealed the potential of aromatase inhibitors as a tool to control the 
estrous cycle in cattle [39, 40]. These studies have focused on the use of letrozole, which has 
been the compound of choice for treatment of sub-fertility or infertility in women [34]. Letrozole 
treatment in cattle extended the lifespan of the dominant follicle, delayed the emergence of the 
next ovarian follicular wave, and altered the timing of ovulation. Letrozole treatment also had a 
consistent luteotrophic effect; i.e., development of a larger corpus luteum that produced more 
progesterone. This latter effect was unexpected and may be of particular interest for the purposes 
of enhancing embryo development and reducing embryonic loss. Effective circulating 
concentrations of letrozole in cattle have been achieved by intravenous, intramuscular or 
intravaginal administration. Collectively, these results provide impetus for the development of an 
aromatase inhibitor-based synchronization and fertility treatment in cattle. 
  
91 
 
The intravaginal route of administration of letrozole is of particular interest because it allows 
for extended treatment protocols, it is minimally invasive for the animal, it reduces animal 
handling and treatment-associated stress, and is most likely to be accepted by practitioners and 
producers [243]. In a previous study (Chapter 6), we tested a prototype of an intravaginal device 
for providing extended treatment with letrozole. However, it appeared that the formulation was 
released too rapidly and plasma levels of letrozole declined significantly within 24 h after device 
insertion. We determined that adjustments in vehicle formulation were needed to provide more 
extended and uniform release of aromatase inhibitor for controlling ovarian function in cattle.  
The objective of the present study was to formulate and test an intravaginal device that 
provides biologically active circulating concentrations of an aromatase inhibitor for a minimum 
of 4 days. 
7.3. Materials and Methods 
The development of an effective formulation for intravaginal administration of an inhibitor of 
estradiol production in cattle in the present study involved three stages. Firstly, the inhibitory 
effects of three different compounds on estradiol production were examined using bovine 
granulosa cells in culture. Secondly, the absorbability of the selected aromatase inhibitor 
prepared in two different vehicles was tested in diffusion chamber studies of bovine vaginal 
mucosa. Thirdly, an in vivo study was done in cattle to determine the pharmacokinetic 
characteristics of the respective formulations developed in the diffusion chamber studies. 
  
92 
 
7.3.1. In vitro testing of different inhibitors of estradiol production 
Inhibition of estradiol production by two aromatase inhibitors (letrozole and anastrozole) and a 
benzimidazole (fenbendazole) was tested in vitro using a bovine granulosa cell culture. The 
commonly used anthelmintic, fenbendazole, was added as the third possible estradiol inhibitor 
based on reports that benzimidazole drugs have mild anti-estrogenic effects in mammals and 
may disturb reproductive events [244, 245], and that deworming treatment with another 
benzimidazole (albendazole) in ewes resulted in decreased estradiol concentrations in follicular 
fluid [246]. 
The granulosa cell culture protocol has been described previously [247]. Briefly, bovine 
ovaries were obtained at a local abattoir and transported to the lab where granulosa cells of antral 
follicles were collected by rinsing the follicle wall with Dulbecco’s Modified Eagle Medium 
Nutrient Mixture F-12 (DMEM/F12, Invitrogen Life Technologies, Burlington, ON, Canada). 
Granulosa cells were maintained in culture for 6 days at 37°C in 5% CO2, in 700 uL of culture 
medium [247] which was replaced every 2 days. Cells were maintained in culture from Days 0 to 
2, followed by the addition of 1 ng/mL of FSH from Days 2 to 4. On Day 4, depending on the 
treatment group, the culture medium was supplemented with 1 ng/mL FSH plus the estrogen 
inhibitor of interest, with FSH alone (positive control) or no FSH (negative control). On Day 6, 
the culture medium was collected and total protein was measured by the Bradford method (Bio-
Rad, Mississauga, ON, Canada). Estradiol levels were determined by radioimmunoassay and 
expressed as total pg of estradiol per ug of protein.  
Three different levels of each compound were tested. The standard concentration used for 
letrozole was 20 ng/mL, based on previously determined plasma concentrations observed after 
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placement of an intravaginal device containing 1 gram of letrozole in cattle (Chapter 6). The half 
maximal inhibitory concentration (IC50) values in MCF-7 cancer cell preparations have been 
reported to be 0.07 and 0.82 ng/mL for letrozole and anastrozole, respectively [192, 248]. Based 
on this, we considered letrozole to be approximately 11 times more potent than anastrozole; 
therefore, the standard dose of anastrozole was set at 200 ng/mL. The standard dose of 
fenbendazole was based on a reported maximum concentration 160 ng/mL fenbendazole in 
plasma after a single oral administration of 7.5 mg/kg of body weight in cattle [249]. Low and 
high doses of each aromatase inhibitor were arbitrarily set at standard concentration x 1/10 and 
standard concentration x10, respectively (Table 7. 1).  
Table 7. 1. Treatment groups tested for estradiol inhibitory capability using an in vitro bovine 
granulosa cell culture. 
Treatment 
Low dose 
(1/10 x standard) 
Standard dose 
 
High dose 
(10 x standard) 
Letrozole 2 ng/mL 20 ng/mL 200 ng/mL 
Anastrozole 20 ng/mL 200 ng/mL 2000 ng/mL 
Fenbendazole 15 ng/mL 150 ng/mL 1500 ng/mL 
Positive Control FSH + no estradiol inhibitor 
Negative Control No FSH + no estradiol inhibitor 
  
7.3.2.  In vitro diffusion chamber studies 
Based on the results of in vitro testing of different aromatase inhibitors on granulosa cells, 
letrozole was chosen for further testing and development. Letrozole was prepared in two 
different formulations (liposome and wax-based) for testing in in vitro diffusion chamber studies. 
The liposome formulation contained the following ingredients (% w/w): 10% letrozole (Xian 
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Huayang Biological Science and Technology; Xian, China); 10% hydrogenated soy 
phosphatidylcholine (Phospholipon 90H; American Lecithin Company, Oxford, CT, USA); 5% 
cholesterol (Spectrum Chemical and Laboratory Products, New Brunswick, NJ, USA); 2% 1,2-
Dioleoyl-sn-Glycero-3-Phosphoethanolamine (DOPE, Avanti Polar Lipids Inc., Alabaster, AL, 
USA); 20% propylene glycol and water qs to 100% [250]. The wax-based formulation contained 
the following ingredients (% w/w): 10% letrozole; 10% Phospholipon 90H; 5% cholesterol; 2% 
DOPE; and Suppocire D (Gattefosse, Paris, France) q.s. to 100%. Both preparations were heated 
to 65°C and vortexed to obtain a uniform mixture. 
Bovine vaginal mucosa samples were collected from cows within 3 h of slaughter at a local 
abattoir. In vitro absorption studies were performed in flow-through diffusion chambers [251]. 
Full-thickness bovine vaginal mucosa was set up in the diffusion chambers (9 mm diameter) and 
maintained at 39.0°C. The perfusion buffer (0.01 M Na-phosphate buffer) was circulated under 
the mucosa at a flow rate of 112 uL/min, at 39°C. The mucosal samples were treated with 100 uL 
of liposome formulation (n=3) or wax-based formulation (n=3) for 24 h. The vaginal mucosa in 
one chamber remained untreated to serve as a negative control. The perfusion fluid was collected 
from each chamber into a single container, and 500 uL samples were collected from this 
container at 0, 1, 2, 3, 4, 5, 6, 8, 12, and 24 h after initiation of treatment to determine cumulative 
concentration. Samples were stored at -20ºC until extraction for LC/MS/MS quantification of 
letrozole concentration. 
7.3.3. Preparation of letrozole-impregnated intravaginal devices  
Based on the results from diffusion chamber studies, the wax-based formulation of letrozole was 
selected for the formulation of the intravaginal devices. Three different devices containing a total 
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of 3 grams of letrozole were tested in vivo: Wax (DOPE) + gel coat, Wax + gel coat, and Wax. 
The Wax (DOPE) + gel coat device was formulated with 2 grams of letrozole contained in the 
wax-based vehicle covered by a gel coat containing 1 gram of letrozole per device. The wax-
based vehicle contained the following (all ingredients % w/w): 10% letrozole; 10% 
Phospholipon 90H; 5% cholesterol NF; 2% DOPE; and Suppocire D q.s. to 100%. The gel coat 
contained the following (all ingredients % w/w): 10% letrozole, 20% gelatin (Gelatin type B, 
Fisher Scientific, Pittsburgh, PA, USA), 65% polymer (prepared by hydrating 12% Poloxamer 
188 and 20% Poloxamer 407, both from Spectrum Chemical, New Brunswick, NJ, USA, with 
68% distilled water), distilled water qs to 100%. The Wax + gel coat device was formulated 
similarly, except that DOPE was excluded from the formulation. The Wax device was 100% 
wax-based, and contained the following ingredients (% w/w): 10% letrozole; 10% Phospholipon 
90H; 5% cholesterol; and Suppocire D q.s. to 100%. 
7.3.4. In vivo testing of letrozole intravaginal devices 
The spine of a Cue-Mate (Bioniche Animal Health, Belleville, ON, Canada) with blank 
(progesterone-free) intravaginal pods was used as a support structure for the letrozole devices. 
Beef heifers were given intravaginal devices as follows: blank devices (control, n = 4), Wax 
(DOPE) + gel coat devices (n = 2), Wax + gel coat devices (n = 4), and Wax devices (no gel 
coat, n = 4). To determine the pharmacokinetics of the respective formulations, blood samples 
were taken at 0, 10, 20, 30 min, 1, 2, 3, 4, 6, 8, 12 and 24 h, twice daily until Day 4, and daily 
thereafter until Day 12 after device placement. Frequent sampling was performed using an 
indwelling jugular catheter as described [84]. Daily blood samples were collected by jugular or 
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coccygeal venipuncture into 10 mL heparinized vacuum tubes (Becton Dickinson Vacutainer 
Systems, Franklin Lakes, NJ, USA). 
Plasma samples were analyzed by LCMS/MS for letrozole concentration. Peak 
concentration in plasma (Cmax) and time to peak concentration (tmax) were determined using 
observed values. The area under the concentration-time curve until the final plasma sample 
(AUClast) was determined using the linear trapezoidal rule. Bioavailability was determined by 
comparing the respective AUCs of letrozole given intravaginally and intravenously (Chapter 5), 
corrected by dose. Relative bioavailability refers to the availability of one letrozole formulation 
as compared to another formulation. These measurements determine the effects of formulation 
differences on drug absorption [252]. 
7.3.5. Measurement of plasma letrozole concentration 
Letrozole concentration was determined using high performance liquid chromatography tandem 
mass spectrometry (LCMS/MS), as described previously [253]. Partial validation of the method 
was conducted as recommended when the same matrix but from different species is being 
analyzed (human plasma versus bovine plasma;[254]). Partial validation parameters included 
linearity, selectivity, accuracy and precision. 
Linearity was tested by running six standard curves independently. Ratio counts versus 
concentration were plotted and R-square values were calculated. The mean (± SEM) R-square 
value was 0.998 ± 0.0009. The calibration curve had to have a correlation coefficient (r
2) ≥ 0.99. 
The acceptance criterion for each calculated standard concentration was 15% deviation from the 
nominal value except lower limit of quantification (LLOQ) samples, which was set at 20% 
(Table 7. 2). 
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Selectivity, defined as the degree to which the response is unaffected by contributions from 
the matrix, was tested in six independent bovine plasma lots, spiked with one single value within 
the standard curve (30 ng/mL) and plotted against a non-extracted standard curve made on 
mobile phase. A pooled plasma sample was also included. The results (30.6 ± 0.19 ng/mL) 
showed that there was no significant difference for letrozole concentration among plasma 
sources. 
 
Table 7. 2. Precision and accuracy data of calculated concentrations of calibration samples for 
letrozole in bovine plasma (n=6). 
Concentration 
added (ng/mL) 
Concentration found 
(mean ± SD; ng/mL) 
Precision (%) Accuracy (%) 
0.2 0.75 ± 0.035 10.49 378.5 
0.4 0.93 ± 0.039 9.45 241.8 
2 2.28 ± 0.033 3.24 114.0 
8 7.96 ± 0.045 1.26 99.5 
25 22.92 ± 0.114 1.11 91.7 
50 48.80 ± 0.167 0.77 97.6 
75 77.50 ± 0.324 0.93 103.3 
100 99.25 ± 0.258 0.58 99.3 
 
Accuracy and precision were calculated by running four different concentrations of quality 
control (QC) samples (0.2, 0.5, 30, and 70 ng/mL) six times. Accuracy was calculated as 
percentage of the true concentration of letrozole recovered by the assay. Precision, expressed as 
the relative standard deviation was assessed using the following formula: %RSD = (STD DEV x 
100) / mean. The acceptance criteria of precision were ≤ 20% LLOQ and ≤ 15% for the 
remaining concentrations and for accuracy were 100 ± ≤ 20% for LLOQ and 100 ± ≤ 15% or 
higher for the remaining concentrations (Table 7.3). 
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Blank bovine plasma standards spiked with 0.2 and 0.4 ng/mL of letrozole did not meet the 
acceptance criteria for accuracy; therefore the lower limit of quantification was set at 2 ng/mL. 
Samples below 2 ng/mL were considered as 0 (zero). 
Table 7. 3. Precision and accuracy of the LCMS/MS method for determining letrozole 
concentrations in plasma samples 
Concentration 
added (ng/mL) 
Concentration found 
(mean ± SD; ng/mL) 
Precision (%) Accuracy (%) 
0.2 0.8 ± 0.04 12.1 398.2 
0.5 1.6 ± 0.05 6.8 325.7 
30 28.0 ± 0.16 1.3 93.4 
70 72.3 ± 0.24 0.7 103.3 
7.3.6. Statistical analyses 
Statistical analyses were done using the Statistical Analysis System software package (SAS 
Learning Edition 9.1, 2006; SAS Institute Inc., Cary, NC, USA). Time-series data (letrozole 
concentration) were analyzed by repeated measures, using the PROC MIXED procedure. The 
main effects were formulation, time, and their interactions. Single-point measurements (estradiol 
concentrations) were analyzed by ANOVA, and differences among more than two means were 
further analyzed by Tukey’s post-hoc test for multiple comparisons. Individual time point 
comparisons between treatment groups were performed using least significant difference (LSD) 
test. A probability of P ≤ 0.05 was used to indicate significance and probabilities between P 
>0.05 and P < 0.10 indicated that a difference approached significance. Data are presented as the 
mean ± SEM.  
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7.4. Results 
7.4.1. In vitro testing of different inhibitors of estradiol production:  
Aromatase activity in bovine granulosa cell culture after estradiol synthesis inhibitor treatment 
was determined in three replicates. Results are shown in Figure 7. 1. Letrozole and anastrozole 
were the most effective in reducing estradiol secretion by granulosa cells in vitro. Concentration 
of estradiol following 20 and 200 ng/mL of letrozole, and 200 and 2000 ng/mL of anastrozole 
did not differ from that of the negative control (no FSH stimulation). Febendazole, at the levels 
tested did not reduce estradiol secretion significantly by FSH-stimulated granulosa cells.  
7.4.2. Diffusion chamber study results: 
Letrozole concentrations obtained with each formulation on the vaginal mucosa in diffusion 
chamber studies are shown in Figure 7. 2. Although not statistically different, the wax-based 
formulation released letrozole at a consistent rate as indicated by the minimum changes in 
letrozole concentration over time. On the contrary, the sudden increase followed by a decrease in 
letrozole concentration observed in the liposome-based vehicle indicates that by the 12 h point 
most letrozole had been released and absorbed through the vaginal mucosa, after which letrozole 
concentrations dropped due to dilution. 
The absorbability of the gel coating had been tested previously using diffusion chamber 
trials for a prototype intravaginal device (Chapter 6). The procedure was performed as described 
herein; except that temperature setting of the chambers was 38.0°C, and samples were collected 
hourly for 12 h. Results from that study are presented in Figure 7. 3 to illustrate the rapid release 
of letrozole from the gel formulation. 
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Figure 7. 1. Effect of three different inhibitors of estradiol production on estradiol secretion by 
bovine granulosa cells in culture. Cells were cultured in vitro for 6 days under non-luteinising 
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conditions without treatment (negative control), or treatment with FSH alone (positive control) 
or with letrozole (A), anastrozole (B) or fenbendazole (C) at 1/10 x standard, standard or 10 x 
standard doses Data are presented as the mean ± SEM estradiol concentrations in three 
independent replicate cultures for each inhibitor. 
ab
 Values with no common superscript are 
different (P<0.05). 
 
 
Figure 7. 2. Letrozole concentrations in saline during diffusion chamber trial for 24 hours. 
Letrozole was prepared in a liposome- or a wax-based vehicle and its diffusion through bovine 
vaginal mucosa was tested in diffusion chambers using phosphate buffered saline as perfusion 
buffer. Data from three diffusion chambers per formulation are presented as mean ± SEM. 
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Figure 7. 3. Letrozole concentrations in saline during diffusion chamber trial for 12 hours. 
Letrozole was prepared in a gel vehicle and its diffusion through bovine vaginal mucosa was 
tested in diffusion chambers using phosphate buffered saline as perfusion buffer. Data from two 
diffusion chambers per formulation are presented as mean ± SD.  
7.4.3. In vivo testing of letrozole intravaginal devices: 
All devices remained in place for 8 days. Although a mild vaginitis was observed at the time of 
device removal, general health of the heifers was not compromised and was considered to be 
optimal by an attending veterinarian (JY). 
The formulations coated with gel delivered letrozole more rapidly than that without a gel 
coating. There was no difference among formulations in mean letrozole concentrations over the 
first 12 h or during the 12 day observational period. However, when multiple comparisons 
among groups were performed by hour during the first 12 h, devices containing gel coat had 
significantly higher concentration of letrozole in plasma by 3 h post-device insertion compared 
to the wax alone group (Figure 7. 4). Letrozole concentration profiles over 12 days following 
device insertion are showed in Figure 7. 5. Wax alone group reached concentration similar to the 
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gel coating devices (wax (DOPE) + gel coat and wax + gel coat) by 60 h, although concentration 
achieved with the wax (DOPE) + gel coat devices were significantly lower than the other two 
formulations after 4 days from device insertion. Pharmacokinetic parameters for the three 
formulation tested are summarized on Table 7. 4 and Table 7.5. 
 
 
Figure 7. 4. Letrozole concentrations in plasma (mean±SEM) during the first 12 h following 
treatment with a letrozole-containing intravaginal device in heifers. Letrozole devices were 
prepared in three formulations: Wax (DOPE) + gel coat (n=2), Wax + gel coat (n=4), Wax only 
(n=4). 
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Figure 7. 5. Plasma letrozole concentrations in heifers (mean ± SEM) over 12 days following 
treatment with a letrozole-containing intravaginal device. Letrozole devices were prepared in 
three formulations: Wax (DOPE) + gel coat (n=2), Wax + gel coat (n=4), Wax only (n=4). 
ab
 On 
indicated days, values differed among groups (P≤0.05). 
 
Table 7. 4. Cmax and tmax (mean±SD) in cattle after treatment with different letrozole-containing 
intravaginal devices: Wax (DOPE) + gel coat (n=2), Wax + gel coat (n=4) and Wax (n=4).  
Parameter Wax (DOPE) + gel 
coat 
Wax + gel coat Wax 
Cmax (ng/mL) 214 ± 29.3 240 ± 91.4 225 ± 25.7 
tmax (h) 42 ± 25.5 72 ± 27.7 90 ± 12.0 
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Table 7. 5. Blood plasma letrozole content (AUClast) in cattle after treatment with different 
letrozole-containing intravaginal devices: Wax (DOPE) + gel coat (n=2), Wax + gel coat (n=4) 
and Wax (n=4). 
Area under the curve (AUClast) (hours x ng/mL) 
Wax (DOPE) + gel coat Wax + gel coat Wax 
18424 36485 24783 
 19453 20151 20693 
 - 35397 31519 
 - 18815 24816 
Mean 18938 27712.0 25452.9 
SD 727.5 9528.2 4483.5 
Bioavailability 43% 63% 58% 
Relative Bioavailability 68% 100% 92% 
 
7.5. Discussion: 
We tested the efficacy of three compounds (letrozole, anastrozole and fenbendazole) for 
inhibiting estradiol production by bovine granulosa cell cultures in vitro. Results showed that 
letrozole and anastrozole were efficacious in reducing estradiol production to levels found in 
non-FSH-stimulated granulosa cells. Fenbendazole, however, did not reduce estradiol 
concentrations significantly. This is consistent with reports that letrozole and anastrozole are 
very specific inhibitors of the aromatase enzyme [181, 255], while the mechanism by which 
fenbendazole impairs estrogen synthesis in mammals remains unclear. However, it has been 
reported that albendazole, a benzimidazole anthelmintic drug closely related to fenbendazole, 
can inhibit the activity of cytochrome P450 enzymes (CYP enzymes) in vitro in rat and mouflon 
sheep [256, 257], a family of enzymes of which aromatase is a member [258]. It is possible that 
fenbendazole may have had a direct, although mild, effect on P450 aromatase activity in the 
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bovine granulosa cells in vitro. In comparing relative potencies, letrozole was more potent than 
anastrozole; estradiol synthesis was reduced to that of non-FSH-stimulated cells at a lower dose 
for letrozole than anastrozole (20 ng/mL vs 200 ng/mL, respectively). This observation is in 
agreement with a previous report that letrozole was several orders of magnitude more potent than 
anastrozole in vitro using cell culture from tissues of different origins [259]. 
Results obtained from the diffusion chamber trials indicated that a wax-based formulation 
was the most suitable for the development of a prolonged-release vehicle for administration of 
letrozole. The wax-based vehicle released letrozole at a steady rate. The profile (letrozole 
concentration over time) from the liposome-treated chambers indicated rapid liquefaction and 
absorption of the letrozole-containing vehicle through the vaginal mucosa. Letrozole 
concentrations peaked at 12 h and began to decrease by 24 h post-treatment. This pattern of rapid 
release of letrozole from the vehicle was also observed in a previous study in which a prototype 
intravaginal device with a polymer-based vehicle was tested in cattle (Chapter 6). In the 
prototype study, plasma letrozole concentrations increased rapidly by 24 h after device insertion, 
but declined rapidly thereafter, likely as a result of rapid and complete liquefaction of the vehicle 
and loss via vulvar discharge. 
An increased interest in aromatase inhibitor-based protocols to control ovarian function in 
mammals creates the need for the development of effective routes and vehicles of administration 
to ensure the desired biological effects are achieved. Regarding prolonged treatment in farm 
animals, the intravaginal route is preferable for the administration of aromatase inhibitor because 
it is well-tolerated by the animals, it reduces handling and stress, it is user-friendly, there is a 
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high retention rate (which varies with device design), it is easy applied, and it enables controlled 
withdrawal [243]. 
After selection of the wax-based vehicle for further development, three different 
formulations of intravaginal devices were tested. The addition of DOPE to the wax-based 
mixture was to determine whether it would enhance absorption through the vaginal mucosa by 
enhancing the fusion of the liposomes to the cellular membrane [260]. However, the addition of 
DOPE to the formulation greatly increased the cost of the devices and hastened the elimination 
of letrozole (2 days after device insertion vs. 4 days in the other groups). Compared to the wax-
only device, the addition of the gel coat hastened the initial increase in plasma letrozole 
concentrations (maximum concentration at 12 h vs. 3 days).  
Bioavailability was calculated using historical AUClast data obtained in earlier studies using 
an intravenous route of administration (Chapter 5). We concluded that the Wax + gel coat device 
provided the highest bioavailability, followed closely by the Wax-only device. Although the total 
amount of letrozole delivered (AUClast) did not differ between the Wax + gel coat device and 
Wax-only device, the characteristics of the delivery during both the first 12 hours and 12 days 
did differ.  
Partial validation of the LCMS/MS method to measure letrozole levels in bovine plasma was 
required. The results of validation indicated that samples below 2 ng/mL could not be quantified 
by the method employed in this study given that accuracy did not meet the required criteria for 
blank bovine plasma standards spiked with 0.2 and 0.4 ng/mL of letrozole. However, all the 
other parameters investigated during partial validation (precision, linearity, and selectivity) fell 
within acceptable ranges. 
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In summary, among the aromatase inhibitors tested, letrozole was the one that had greatest 
potency, as determined by inhibition of estradiol production in vitro. Furthermore, a wax-based 
vehicle, with a higher melting point than the polymer-based vehicle used in a previous study, 
provided steady and continuous delivery of the active compound over the treatment period. 
Finally, the addition of a letrozole-containing gel coating increased initial absorption and 
hastened the increase on plasma concentrations of the active ingredient, while the letrozole-
containing wax-based vehicle prolonged drug-delivery from the intravaginal device. The 
biological response to these pharmacokinetic differences remains to be tested in vivo by 
assessment of estradiol inhibition and ovarian function. 
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CHAPTER 8: EFFECT OF AROMATASE INHIBITOR INTRAVAGINAL 
DEVICES ON OVARIAN FUNCTION IN CATTLE 
 
 
 
Relationship of this study to the thesis: 
To develop an efficient non-steroidal aromatase inhibitor-based method to synchronize ovulation 
in the bovine model, we need to be able to manipulate the duration of exposure of the animals to 
the active ingredient (letrozole). To this end, prolonged-release letrozole-containing intravaginal 
devices were formulated (Chapter 7). The biological response to these devices is assessed in the 
present chapter with the aim of determining the most suitable formulation to be applied in a 
letrozole-based protocol for synchronization of ovulation in cattle. 
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8.1 Abstract 
A study was designed to determine the biological response to two letrozole intravaginal device 
formulations by assessment of estradiol inhibition and changes in ovarian function in vivo. 
Heifers in which a CL was detected during an initial examination were treated intramuscularly 
(im) with 500 µg of cloprostenol to synchronize ovulation. At the time of ovulation (Day 0), 
heifers were assigned randomly to three groups and given an intravaginal device containing wax 
+ gel formulation (3 g of letrozole per device, n=4), wax formulation (3 g of letrozole per device, 
n=4), or a blank device (control, n=4). Intravaginal devices were inserted on Day 3 and kept in 
place for 8 days. Transrectal ultrasound examinations were done and blood samples were taken 
daily. The dominant follicle diameter profile was larger in heifers treated with the wax + gel coat 
letrozole-containing intravaginal device, and the interwave interval was prolonged in heifers in 
both letrozole-treated groups (P<0.001). Plasma estradiol concentrations were reduced 
significantly in the letrozole-treated groups. Although no differences were observed in corpus 
luteum diameters were detected among treatment groups, plasma progesterone concentrations 
were lower (P<0.02) in heifers given the wax formulation. We concluded that letrozole-
impregnated intravaginal devices formulated with a wax base plus gel coat vehicle is most 
suitable for the application of a letrozole-based protocol for the synchronization of ovulation in 
cattle. It effectively reduced estradiol production resulting in prolonged dominant follicle growth 
and lifespan, without adversely affecting progesterone production. 
8.2 Introduction 
Control of the estrous cycle in animal species of commercial interest, such as cattle, impacts the 
efficiency and economy of meat and milk production. Numerous treatments and protocols have 
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been used to control reproductive events [107, 235, 236]; however, many of these protocols 
involve the administration of steroid hormones in food producing animals. The reproductively 
active steroid hormones, such as estradiol, are perceived as having a particularly negative impact 
on consumer health [22, 237, 238]. This internationally shared opinion has led to a ban on the 
use of steroid hormones in food producing animals and in specific categories of animals (e.g., 
lactating dairy cattle) in many countries (i.e., European Union, New Zealand, and Australia; [23, 
24]). 
Recently, non-steroidal aromatase inhibitors have been investigated as an alternative for 
controlling ovarian function using a bovine model [39, 40]. The studies have focused on the use 
of letrozole, a non-steroidal aromatase inhibitor that inactivates the aromatase enzyme 
responsible for the synthesis of estrogens by reversibly binding to the “heme” group of the P450 
subunit [192]. Letrozole is used as an adjuvant or first-line treatment for hormone-dependent 
breast cancer in post-menopausal women [33]. It has also been used in women because of its 
potential for removing the negative feedback effect of estradiol on FSH secretion [34, 35, 215]. 
For ovarian stimulation in women, letrozole is commonly used at a dose of 1 to 5 mg per day for 
5 days [35, 216], and has been used in higher or increasing doses for ovarian superstimulation 
[36, 37]. 
Using the bovine model, we have found that letrozole treatment extends the lifespan of the 
dominant follicle and thereby delays emergence of the next follicle wave and/or ovulation 
(Chapter 6). Letrozole treatment also had a luteotrophic effect; that is, larger CL and/or higher 
concentrations of progesterone were detected in letrozole-treated heifers (Chapter 6). The 
luteotrophic effect of letrozole treatment has important implications for the purposes of 
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enhancing embryo development and reducing embryonic loss [39, 40]. Finally, biologically 
active concentrations of letrozole have been achieved via intravenous, intramuscular or 
intravaginal administration ([39, 40] Chapters 5 and 6). Collectively, these results provide the 
impetus for the development of aromatase inhibitor-based synchronization and fertility 
treatments in cattle. 
The intravaginal route of administration of letrozole is of particular interest because it 
permits extended treatment periods, is minimally invasive for the animal, reduces animal 
handling and associated stress, and is most likely to be accepted by practitioners and producers 
[243]. In a previous study (Chapter 6), we tested a prototype of an intravaginal letrozole-
releasing device, but circulating concentrations of letrozole declined within 24 h after device 
insertion as a result of rapid release from the formulation (Chapter 6). In a follow-up study, two 
intravaginal devices were developed (wax + gel coat and wax alone) and tested in cattle to 
determine their pharmacokinetic characteristics. The wax-based vehicle resulted in steady and 
continuous delivery of letrozole over the treatment period in heifers. Further, the addition of a 
letrozole-containing gel coating increased initial absorption and hastened the increase of plasma 
concentrations of the active ingredient while the letrozole-containing wax-based vehicle 
maintained the prolonged delivery from the intravaginal device (Chapter 7).  
The present study was designed to determine the effects of recently developed letrozole 
intravaginal device on circulating estradiol concentrations and ovarian function. We 
hypothesized that differences in the release and absorption characteristics of the intravaginal 
formulations would induce differential effects on ovarian function in cattle.  
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8.3 Materials and Methods  
8.3.1 Cattle 
Hereford-cross beef heifers (n=12), 15 to 20 months of age and weighing between 342 and 592 
kg (457 ± 17.7 kg), were chosen from a herd of 50 heifers maintained in outdoor corrals at the 
University of Saskatchewan Goodale Research Farm (52° North and 106° West). Heifers were 
fed alfalfa/grass hay and grain to gain approximately 1.3 Kg per day and had water available ad 
libitum during the experimental period from August to September. Heifers were initially 
examined by transrectal ultrasonography (MyLab5, Canadian Veterinary Imaging, Georgetown, 
Ontario Canada) to confirm that they were post-pubertal as indicated by the presence of a CL 
[217]. Animal procedures were performed in accordance with the Canadian Council on Animal 
Care and were approved by University of Saskatchewan Protocol Review Committee. 
8.3.2 Treatments and examinations 
The spine and blank pods (progesterone-free) of a commercially available intravaginal device for 
cattle (Cue-Mate, Bioniche Animal Health, Belleville, ON, Canada) were used as a support 
structure for the administration of letrozole. Device formulations and pharmacokinetic 
parameters have been described elsewhere (Chapter 7). Briefly, one device type (wax + gel coat) 
was prepared using a wax-based vehicle containing 2 g of letrozole per device, coated with a gel-
based formulation containing 1 g of letrozole (total of 3 g of letrozole per device). The second 
device type (wax) was compounded entirely of the wax-based formulation so as to contain 3 g of 
letrozole per device. 
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Heifers in which a CL was detected during the initial examination were treated 
intramuscularly (im) with 500 µg of cloprostenol (PGF, Estrumate, Schering-Plough Animal 
Health, Pointe-Claire, QC, Canada) to synchronize ovulation [220]. On Day 0 (ovulation), 
heifers were assigned randomly to three groups (n=4 per group) and given an intravaginal device 
containing the wax + gel formulation, wax formulation, or no letrozole (blank intravaginal 
device, control) starting at Day 3. The intravaginal device was left in place for 8 days. 
8.3.3 Ovarian ultrasonography 
Observations from daily ultrasound examinations were recorded on a sketch sheet in which each 
ovary and its structures (CL and follicles ≥ 4 mm in diameter) were represented by size and 
location [73]. Ovulation was defined as the disappearance of any follicle ≥8 mm between 
consecutive examinations, and was confirmed by the subsequent development of a CL [217]. 
Follicular wave emergence was taken as the day of ovulation, or determined retrospectively as 
the day when the dominant follicle was first identified at a diameter of 4 or 5 mm [45, 64]. If the 
dominant follicle was not identified until it reached 6 or 7 mm, the previous day was considered 
the day of the follicular wave emergence [87]. The dominant follicle of a wave was defined as 
the largest follicle of the wave [221]. The day of onset of follicular or luteal regression was 
defined, in retrospect, as the first day of an apparent progressive decrease in diameter [45].  
8.3.4 Collection of blood samples 
Blood samples were collected by coccygeal venipuncture into 10 mL heparinized vacuum tubes 
(Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA). Samples were collected daily 
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from pre-treatment ovulation (Day 0) to Day 15. Blood samples were centrifuged at 1500 x g for 
20 min, and plasma was separated and stored in plastic tubes at -20 °C. 
8.3.5 Hormone assays 
Plasma concentrations of estradiol were determined in duplicate using a commercial RIA kit 
(Double Antibody Estradiol; Diagnostic Products, Los Angeles, CA, USA). The procedure was 
carried out at the Department of Animal Health and Biomedical Sciences, University of 
Wisconsin – Madison, as described elsewhere [79, 223], with the following modifications: 
Standards (0.78–100 pg/mL) were prepared in steroid-free (charcoal-treated) bovine plasma. The 
standards (250 µL in duplicate) and plasma samples (500 µL in duplicate) were extracted with 3 
mL of diethyl ether, frozen in a dry-ice/methanol bath, decanted into assay tubes, and dried 
overnight under a fume hood. The dried samples and standards were re-suspended with 100 µL 
of assay buffer (0.1% gelatin in PBS). The intra-assay and inter-assay coefficients of variation 
were 10.5% and 10.6% for high reference samples (mean 11.1 pg/mL), and 14.8% and 12.3% for 
low reference samples (mean 2.6 pg/mL), respectively. The sensitivity of the assay was 0.1 
pg/mL. 
Plasma progesterone concentrations were determined in duplicate using a commercial solid-
phase kit (Coat-A-Count; Diagnostic Products Corporation, Los Angeles, CA, USA). The range 
of the standard curve was 0.1 to 40.0 ng/mL. All samples were analyzed in a single assay; the 
intra-assay coefficients of variation for samples assayed in duplicates were 4.0% for low 
reference samples (mean, 0.74 ng/mL) and 1.1% for high reference samples (mean, 8.57 ng/mL).  
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8.3.6 Statistical analyses 
Statistical analyses were done using the Statistical Analysis System software package (SAS 
Learning Edition 9.1, 2006; SAS Institute Inc., Cary, NC, USA). Serial data (hormone and 
follicle profiles) were compared by analysis of variance for repeated measures using the PROC 
MIXED procedure to determine the effects of device formulation (wax + gel coat, wax, or 
control), time, and their interactions. When a main effect or interaction was detected, individual 
comparisons among groups and days were performed using least significant differences (LSD). 
Single-point measurements (inter-wave interval and dominant follicle diameter at treatment) 
were compared among groups by analysis of variance. Significance was defined as P ≤ 0.05. 
8.4 Results 
The intravaginal devices were inserted on Day 3 (Day 0 = ovulation), and the mean diameter 
of the dominant follicle at the time of placement did not differ among groups ( 
Table 8. 1). The day-to-day diameter profile of the dominant follicle during treatment was 
greatest (P<0.05) in the wax + gel coat group, intermediate (P<0.05) in the wax group, and 
smallest (P<0.05) in the control group (Figure 8. 1). The inter-wave interval was longest in the 
wax group, intermediate in the wax + gel coat group, and shortest in the control group (P<0.001,  
Table 8. 1). 
Table 8. 1. Effects of letrozole-containing intravaginal devices on ovarian function in heifers 
(mean±SEM). 
 
Control 
(n=4) 
Wax+gel 
(n=4) 
Wax 
(n=4) 
Dominant follicle diameter (mm) at device 
insertion (Day 3) 
9.7 ±0.5 11.2 ± 0.5 9.2 ± 0.1 
Inter-wave interval (days) 10.2 ± 0.4
a
 12.2 ± 0.4
b
 14.3 ± 0.4
c
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abc 
Within rows, values with no common superscript are different (P<0.05) 
 
 
Figure 8. 1. Dominant follicle diameter profiles (mean±SEM) in heifers treated with a blank 
intravaginal device (control, n=4), or a letrozole-containing device with wax + gel coat (n=4) or 
wax only (n=4). Devices were inserted on Day 3. 
abc
 On indicated days, values with no common 
subscripts are different (P≤0.05).  
Plasma estradiol concentrations in the letrozole-treated groups (wax + gel coat and wax) 
were lower than in the control group from the first post-treatment sample (P=0.002, Figure 8. 2). 
No difference was detected in estradiol concentrations between the wax + gel coat and wax 
groups.  
Corpus luteum diameter profiles were not different among groups (P=0.36, Figure 8. 3). 
However, progesterone concentrations were lower in the wax group than in the other groups 
from Day 9 to Day 12 (P<0.05, Figure 8. 4). 
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Figure 8. 2. Plasma estradiol concentrations (mean±SEM) in heifers treated with a blank 
intravaginal device (control, n=4), or a letrozole-containing device with wax + gel coat (n=4) or 
wax only (n=4). Devices were inserted on Day 3. 
 
 
Figure 8. 3. Corpus luteum diameter profiles (mean±SEM) in heifers treated with a blank 
intravaginal device (control, n=4), or a letrozole-containing device with wax + gel coat (n=4) or 
wax only (n=4). Devices were inserted on Day 3.  
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Figure 8. 4. Plasma progesterone concentrations (mean±SEM) in heifers treated with a blank 
intravaginal device (control, n=4), or a letrozole-containing device with wax + gel coat (n=4) or 
wax only (n=4). Devices were inserted on Day 3. 
8.5 Discussion 
Two letrozole-containing formulations were tested in the present study. Our hypothesis that 
differences in the release and absorption characteristics of the intravaginal formulations would 
induce differential effects on ovarian function in cattle was supported. The only difference 
between the two letrozole preparations was the presence of a gel coating on one; the total amount 
of letrozole (3 g) in each device did not differ (Chapter 7). The letrozole-containing gel coating 
has a lower melting point than the wax-based vehicle, allowing for rapid liquefaction and 
absorption of the formulation once the device was inserted into the vagina (Chapters 6). The wax 
plus gel coat formulation resulted in an early rise in plasma letrozole concentrations and a steady 
concentration by 24 h after device insertion. However, following insertion of wax-based 
intravaginal devices, steady plasma letrozole concentrations were reached 60 h after treatment 
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(Chapter 7). The biological response detected in the present study was consistent with 
pharmacokinetic differences detected in earlier studies, 
Increased LH secretion and larger dominant follicle profiles have been observed following 
the administration of letrozole in previous studies [39, 40]. Although circulating gonadotropin 
concentrations were not measured in the present study, the differences in the pharmacokinetic 
characteristics of the formulations tested likely resulted in differences in gonadotropin secretion (i.e., 
earlier increase of LH secretion in the wax + gel coat group), and thus, differences in dominant 
follicle profiles. This is consistent with larger dominant follicle diameter profiles in letrozole-treated 
heifers, and the progressively longer interwave interval in letrozole-treated heifers given wax plus gel 
coat and those given the wax-only formulation.  
The two letrozole formulations reduced plasma estradiol concentrations significantly and to 
a similar extent; estradiol concentrations differed from the control group by 12 h after device 
insertion. The plasma letrozole concentrations 12 h after device insertion, measured in the 
previous study to be 176.7 ± 11.70 ng/mL in the wax plus gel coat group and 71.2 ± 7.61 ng/mL 
in the wax group (Chapter 7), were both adequate to suppress estradiol production. Perhaps the 
amount of letrozole contained in the intravaginal devices may be reduced without compromising 
the efficacy in reducing estradiol concentrations. However, the lesser efficacy of the wax only 
formulation in affecting ovarian function suggests that the amount of letrozole required to elicit a 
detectable reduction in estradiol concentration may not be the same as that required to affect 
ovarian function, especially during the first hours after device insertion. 
Letrozole treatment did not affect CL diameter profiles in the present study, regardless of the 
formulation used. The significantly lower plasma concentrations of progesterone observed in the 
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wax-based letrozole impregnated device group were unexpected. Based on the results of 
previous studies [39, 40], we expected letrozole treatment to suppress estradiol secretion and 
increase LH release, which in turn resulted in increased CL diameter profiles and/or increased 
progesterone secretion. Further research is needed in to clarify this finding. 
Letrozole is a potent inhibitor of estradiol production in the bovine species (Chapters 5 and 
6). Hence, there is increased interest in the development of letrozole-based protocols for the 
control of ovarian activities in cattle. Based on previous studies, we concluded that the 
lengthened duration of letrozole treatment would have impact on ovarian function ([39, 40], 
Chapters 5 and 6). Therefore, it is not surprising that formulation and pharmacokinetic 
characteristics played a key role in the success of a letrozole-based regimen for the control of 
reproductive phenomena in the present study. In summary, we observed that the vehicle used to 
deliver letrozole with an intravaginal device (wax + gel coat vs wax alone) differentially affected 
ovarian function in cattle. We concluded that letrozole-impregnated intravaginal devices 
formulated with a wax base plus a gel coat vehicle effectively delivered elevated concentrations 
of letrozole to the animal and reduced estradiol production resulting in increased follicular 
growth and lifespan, without adversely affecting progesterone production. 
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CHAPTER 9: SYNCHRONIZATION OF OVULATION IN CATTLE WITH 
AN NON-STEROIDAL AROMATASE INHIBITOR-BASED PROTOCOL: 
A PILOT STUDY 
 
 
 
 
 
 
Relationship of this study to the thesis: 
Based on the results of experiments included in Chapters 5, 6, 7 and 8, a non-steroidal 
aromatase inhibitor-based protocol for the control of ovulation in cattle is presented in Chapter 
9. The improved understanding of the effects of route of administration, vehicle, and the type and 
duration of aromatase inhibitor treatment on ovarian function permitted evidence-based 
estimation of the timing of letrozole treatment, in combination with other treatments (PGF and 
GnRH), to synchronize ovulation using the bovine model.   
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9.1. Abstract 
The present study was designed to test the hypothesis that the addition of a letrozole-impregnated 
intravaginal device in a PGF / GnRH-based protocol will induce ovulation synchrony in cattle 
regardless of the stage of the estrous cycle in which treatment is given. Forty-eight heifers were 
treated intramuscularly (im) with 500 µg of cloprostenol (PGF) followed by 100 µg of GnRH 24 
h later to synchronize ovulation. Daily ultrasound examinations determined the interval to 
ovulation which served as control data for the synchronizing effect of aromatase inhibitor 
treatment in the same animals. At the time of ovulation (Day 0), heifers were assigned randomly 
and given an intravaginal device containing 3 g of letrozole for 4 days starting on Days 0, 4, 8, 
12, or 16. At the time of device removal, heifers were given PGF followed by GnRH 24 h later. 
Ultrasound examinations were performed daily, from two days prior to device insertion, 
continuing for 9 days after the post-treatment ovulation. The pre-ovulatory follicle diameters 
after letrozole treatment were larger in Day 4 group compared to Day 0 and Day 16 groups, and 
intermediate in Day 8 and Day 12 groups (P<0.0006). The percentage of heifers that ovulated 
(87.1% vs 69.4%, respectively) and synchrony of ovulation was greater following letrozole 
treatment compared to letrozole-free control data. No effect of group (day of treatment) on 
ovulation rate was detected. Although estradiol levels did not differ among the letrozole-treated 
groups, estradiol levels in Groups 0 and 4 were lower than their respective controls, while 
Groups 8 and 12 did not differ from their respective controls, mostly due to low estradiol 
concentration in the control samples. Corpus luteum diameter profiles and progesterone 
production were not affected by group. A small breeding trial was done using the letrozole-PGF-
GnRH protocol; from the 43 heifers that were fixed-time inseminated 24 h after the 
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administration of GnRH, 3 were confirmed pregnant 35 days post-AI. In summary, the addition 
of a letrozole-impregnated intravaginal device for 4 days, combined with PGF treatment at 
device removal and GnRH 24 later resulted in a greater proportion of heifers ovulating more 
synchronously. Results suggest that treatment can be initiated effectively at random stages of the 
estrous cycle. However, the effects of letrozole treatment on CL lifespan and subsequent fertility 
were unexpected and must be studied in more detail. 
9.2 Introduction 
A conservative estimate of the worldwide use of AI is 83 million cows per year – estimated to 
represent about 20% of the breedable cattle population (25% in North America) [1]. Worldwide, 
53% of cows artificially inseminated are of dairy breeds and 39% are of beef breeds, but in 
Canada, the gap is much wider: 94% in dairy and 6% in beef. Regarding ET, just over 120,000 
donor cows are collected each year worldwide and 800,000 embryos are transferred [261]. In 
Canada, those numbers do not exceed 13,500 and 55,000, respectively [3]. Estrogen-based 
protocols for controlling follicle development and synchronizing ovulation in cattle have been 
instrumental in modern breeding practices. These protocols enabled producers to control the 
timing of ovulation reliably, enabling efficient use of time, labour and resources by allowing pre-
scheduled artificial insemination. Estradiol-based protocols optimized the productivity of 
superovulation and embryo transfer programs due to their effectiveness in synchronizing 
follicular wave emergence prior to the initiation of superstimulation treatment [4-8]. However, 
the use of estradiol has been banned in many countries (i.e., European Union, New Zealand, and 
Australia) [23, 24]. This situation has created a void in treatments that efficiently control ovarian 
dynamics for the purpose of fixed-time insemination and embryo transfer in cattle. 
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Aromatase inhibitors have been investigated as a tool with which the estrous cycle in cattle 
might be controlled with the same precision as the older estradiol-based protocols but with the 
advantage of being a steroid-free alternative. Studies conducted in cattle have focused on the use 
of letrozole, a non-steroidal aromatase inhibitor that inactivates the aromatase enzyme 
responsible for the synthesis of estrogens by reversibly binding to the “heme” group of the P450 
subunit. Letrozole is used as an adjuvant or first-line treatment for hormone-dependent breast 
cancer in post-menopausal women [33], and has been used in assisted reproduction in women 
because of its potential effect on removing the negative feedback of estradiol on FSH secretion 
[34, 35, 215].  
The intravaginal route of administration of letrozole is of particular interest because it 
enables extended treatment periods, is minimally invasive, reduces animal handling and stress, 
and is most likely to be accepted by practitioners and producers [243]. In an earlier study 
(Chapter 6), we tested a prototype of an intravaginal device for providing an extended treatment 
with letrozole. However, letrozole was released too rapidly with the formulation used, and 
plasma concentrations were near base-line within 24 h after device insertion (Chapter 6). We 
modified the vehicle formulation and two variant intravaginal devices were developed and tested 
in cattle to determine their pharmacokinetic characteristics (Chapter 7). A wax-based vehicle 
with a higher melting point than the gel-based vehicle previously tested provided a steady and 
continuous delivery of letrozole over a 5-day treatment period in heifers. The addition of a 
letrozole-containing gel coating to the wax vehicle resulted in more rapid initial absorption and 
hastened the increase in plasma concentrations of the active ingredient (Chapter 7). In a 
following study (Chapter 8), the wax-based plus gel coat letrozole-containing device suppressed 
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estradiol production resulting in increased follicular growth and lifespan without adversely 
affecting progesterone production in the extant CL. We concluded that letrozole-impregnated 
intravaginal devices formulated with a wax base plus a gel coat vehicle was most suitable for the 
application of a letrozole-based protocol for the synchronization of ovulation in cattle.  
To date, the main findings of studies in cattle are that letrozole treatment 1) extends the 
lifespan of the dominant follicle, 2) delays emergence of the next follicle wave and/or ovulation, 
and 3) is luteotrophic (i.e., larger CL and/or more progesterone) ([39, 40], Chapters 5 and 6). 
Collectively, these results provide compelling justification for the development of aromatase 
inhibitor-based synchronization and fertility treatments in cattle. 
The present study was designed to test the hypothesis that the addition of a letrozole-
impregnated intravaginal device in a PGF / GnRH-based protocol will induce ovulation 
synchrony in cattle regardless of the stage of the estrous cycle in which treatment is given. The 
principal objective of the study was to determine the ovulation rate and synchrony in heifers 
treated with a letrozole-based synchronization protocol at different stages of the estrous cycle 
(Experiment 1). A follow-up experiment was done as a pilot study to determine the pregnancy 
rate in heifers artificially inseminated following synchronization with the letrozole-based 
protocol initiated at random stages of their estrous cycle, would increase the percentage and 
synchrony of ovulations without adversely affecting pregnancy rates.the estrous cycle 
(Experiment 2).  
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9.3 Materials and Methods  
9.3.1 Experiment 1  
9.3.1.1 Cattle 
Hereford-cross beef heifers (n=49), 15 to 20 months of age and weighing between 379 and 667 
kg (mean of 505 ± 8.6 kg), were chosen from a group of 51 heifers maintained in outdoor pens at 
the University of Saskatchewan Goodale Research Farm (52° North and 106° West). Heifers 
were fed alfalfa/grass hay and grain to gain approximately 1.3 Kg per day and had water 
available ad libitum during the experimental period from December to February. Heifers were 
initially examined by transrectal ultrasonography (MyLab5 VET, Canadian Veterinary Imaging, 
Georgetown, Ontario Canada) to confirm that they were post-pubertal, as indicated by detection 
of a CL [217]. Animal procedures were performed in accordance with the guidelines of the 
Canadian Council on Animal Care and were approved by University of Saskatchewan Protocol 
Review Committee. 
9.3.1.2 Treatments and examinations 
Heifers in which a CL was detected during the initial examination (n=49) were treated 
intramuscularly (im) with a luteolytic dose of prostaglandin (500 µg cloprostenol, Estrumate, 
Schering-Plough Animal Health, Pointe-Claire, QC, Canada) followed by 100 µg of GnRH 
(Fertiline, Vetoquinol, Lavaltrie, QC, Canada) 24 h later to induce ovulation [220]. Daily 
ultrasound examinations were performed to determine the interval from GnRH treatment to 
ovulation to use as control data for the synchronizing effect of letrozole in the same animals. At 
the time of ovulation (Day 0), heifers were assigned randomly to the following five groups (n=8-
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10/group) and given an intravaginal device with a wax-based plus gel coat formulation 
containing 3 g of letrozole (Chapter 7) for 4 days starting on Day 0, 4, 8, 12, or 16. At the time of 
device removal, heifers were given 500 µg PGF followed by 100 µg of GnRH 24 h later. The 
treatment schedule is summarized in Figure 9. 1.  
 
 
Figure 9. 1. Synchronization treatment schedule for Experiment 1. Heifers (48) were treated im 
with PGF followed by GnRH 24 h later to synchronize ovulation. Ultrasound examinations (U/S) 
were done daily to detect ovulation,(Day 0) and heifers were given an intravaginal device 
containing 3 g of letrozole for 4 days starting on Days 0, 4, 8, 12, or 16. At the time of device 
removal, heifers were given PGF followed by GnRH 24 h later. Ultrasound examinations were 
performed daily, from two days before device insertion to 9 days after the post-treatment 
ovulation.  
Ultrasound examinations were performed daily from two days before device insertion to 
9 days after post-treatment ovulation. Observations from ultrasound examinations were recorded 
on a sketch sheet in which each ovary and its structures (CL and follicles ≥ 4 mm in diameter) 
were represented by size and location [73]. Ovulation was defined as the disappearance of a 
follicle ≥8 mm between successive examinations after GnRH treatment and was confirmed by 
the subsequent detection of a CL [217]. The time of follicular wave emergence was defined as 
the day of ovulation or retrospectively as the day when the dominant follicle was first identified 
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at a diameter of 4 to 5 mm [45, 64]. If the dominant follicle was not identified until it reached 6 
or 7 mm, the previous day was considered day of the follicular wave emergence [87]. The 
dominant follicle of a wave was defined as the largest antral follicle of the wave [221]. The day 
of onset of follicular and luteal regression was defined as the first day of an apparent progressive 
decrease in follicular and luteal diameters, respectively [45].  
9.3.1.3 Collection of blood samples 
Blood samples were collected by coccygeal venipuncture into 10 mL heparinized vacuum tubes 
(Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA). Samples were collected at 
the time of device removal for estradiol measurement, and at 3, 6 and 9 days following the post-
treatment ovulation to determine progesterone concentrations. Additionally, blood samples were 
collected on Days 4, 8, 12, and 16 from heifers in the Day 16 group (Day 0 = ovulation) to serve 
as control data for comparison of estradiol concentrations at the time of device removal in other 
treatment groups. As such, the Day 16 group did not have a control sample for comparison of 
estradiol concentrations at the time of device removal. Blood samples were centrifuged at 1500 x 
g for 20 min and plasma was separated and stored in plastic tubes at -20 °C until assayed. 
9.3.1.4 Hormone assays 
Plasma concentrations of estradiol were determined using a commercial radioimmunoassay kit 
(Double Antibody Estradiol; Diagnostic Products, Los Angeles, CA, USA). The procedure was 
carried out in the Department of Animal Health and Biomedical Sciences, University of 
Wisconsin-Madison, as described [79, 223], with the following modifications: Standards (0.78–
100 pg/mL) were prepared in steroid-free (charcoal-treated) bovine plasma. The standards (250 
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µL in duplicate) and plasma samples (500 µL in duplicate) were extracted with 3 mL of diethyl 
ether, frozen in a dry-ice/methanol bath, decanted into assay tubes, and dried overnight under a 
fume hood. The dried samples and standards were re-suspended with 100 µL of assay buffer 
(0.1% gelatin in PBS). The intra- and inter-assay coefficients of variation were 10.5 and 10.6%, 
respectively for high reference samples (mean 11.1 pg/mL), and 14.8 and 12.3%, respectively for 
low reference samples (mean 2.6 pg/mL). The sensitivity of the assay was 0.1 pg/mL. 
Plasma progesterone concentrations were determined using a commercial solid-phase kit 
(Coat-A-Count; Diagnostic Products Corporation, Los Angeles, CA, USA). The range of the 
standard curve was 0.1 to 40.0 ng/mL. Samples were analyzed in a single assay. The intra-assay 
coefficient of variation for samples assayed in duplicates was 4.0% for low reference samples 
(mean, 0.74 ng/mL) and 1.1% for high reference samples (mean, 8.57 ng/mL). 
 
9.3.2 Experiment 2 - Artificial insemination pilot study  
Forty five heifers were selected from the group used previously for the artificial insemination 
(AI) trial. Three heifers were excluded due to their low body condition. Two weeks after the end 
of the first experiment, the protocol described previously was applied as follows: a new 
letrozole-releasing intravaginal device was placed in all heifers on random days of the estrous 
cycles for 4 days. At device removal, PGF was given followed by GnRH 24 h later. Heifers were 
artificially inseminated 24 h after GnRH treatment. The semen used for the artificial 
inseminations was collected from five beef bulls located at a community pasture during their 
annual breeding soundness evaluation. Fresh semen was classified as good based on breeding 
soundness exam standards [262] with more than 400 million sperms/mL and more than 70% 
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individual progressive motility (Dr Anzar, personal communication). Semen from the five bulls 
was pooled prior to freezing. The straws contained a total of 25 million sperm /mL and 
Computer Assisted Semen Analysis (CASA) resulted in post-thaw cell motility and progressive 
motility of 49% and 44%, respectively. Pregnancy was diagnosed by transrectal ultrasonography 
35 days after insemination. 
9.3.3 Statistical analyses 
Statistical analyses were done using the Statistical Analysis System software package (SAS 
Learning Edition 9.1, 2006; SAS Institute Inc., Cary, NC, USA). Time-series hormone data and 
follicular diameter profiles were analyzed by repeated measures, using the PROC MIXED 
procedure to determine the main effects of treatment and time, and their interactions. Individual 
time-point comparisons were made using the least significant difference (LSD) test. Single-point 
measurements (dominant follicle diameter at device insertion, pre-ovulatory follicle diameter, 
CL diameter 9 days after the post-treatment ovulation and interval from GnRH treatment to 
ovulation) were compared among groups by one-way analysis of variance. The ovulation rate 
was compared among groups by Chi-Square test. The degree of synchrony between groups was 
calculated by analysis of variance of the residuals of the interval from GnRH to ovulation. 
Significance was defined as P ≤ 0.05. 
9.4 Results 
9.4.1 Experiment 1 
As expected, the diameter of the dominant follicle at the time of device placement was larger in 
the Day 4 and 12 groups compared to the Day 0 and 16 groups, and intermediate in the Day 8 
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group (Table 9. 1). Similarly, the maximum diameter of the ovulatory follicle after letrozole 
treatment was greater in Day 4 group compared to the Day 0 and 16 groups, and intermediate in 
Day 8 and 12 groups (Table 9. 1). The day-to-day dominant follicle diameter profiles during 
treatment were larger in the Day 4 group compared to the Day 0 and 16 groups, and intermediate 
in the Day 8 and 12 groups (P<0.001). 
Table 9. 1. Effects of a letrozole-containing intravaginal device in combination with PGF and 
GnRH on ovarian function in heifers (mean±SEM). 
Treatment group 
Dominant follicle diameter (mm) CL diameter 
(mm) 
at 9 days post-
ovulation 
At device 
placement 
At day before 
ovulation 
Day 0 (n=10) 5.7 ± 0.35 
a
 12.8 ± 0.58 
a
 20.9 ± 1.09 
a
 
Day 4 (n=9) 11.9 ± 0.59 
b
 16.4 ± 0.78 
b
 25.2 ± 1.65 
ab
 
Day 8 (n=8) 7.2 ± 1.76 
abc
 14.5 ± 0.83 
ab
 20.8 ± 1.88 
ab
 
Day 12 (n=11) 10.1 ± 0.74 
bc
 14.2 ± 0.48 
ab
 21.7 ± 0.99 
ab
 
Day 16 (n=10) 6.0 ± 1.56 
ac
 11.7 ± 0.59 
a
 26.8 ± 2.69 
b
 
abc 
Within columns, values with no common superscript are different (p<0.05) 
The percentage of heifers that ovulated after GnRH treatment was higher when a letrozole-
releasing intravaginal device was added to the PGF plus GnRH (control) protocol (P = 0.05, 
Table 9. 2). No effect of group on synchrony of ovulation was detected; hence data were 
combined into a single letrozole group. The interval from GnRH treatment to ovulation was 
longer in the control group compared to the combined letrozole-treated groups (P = 0.008, Table 
9. 2). The degree of ovulation synchrony was greater in the combined letrozole-treated groups 
than in the control group (P = 0.01, Table 9. 2 and Table 9. 3). The distribution of the ovulations 
in the letrozole-treated and control groups is summarized in Table 9. 3. 
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Table 9. 2. Effect of addition of letrozole to a PGF-GnRH-protocol on ovulation in heifers. 
 
Control Letrozole P-value 
Ovulation percentage 69.4% (34/49) 87.1% (42/48) 0.05 
Days from GnRH treatment to ovulation 2.4 ± 0.18 1.9 ± 0.08 0.01 
Degree of synchrony 0.68 ± 0.13 0.24 ± 0.07 0.01 
 
 
Table 9. 3. Distribution of ovulation in heifers given a letrozole-releasing intravaginal device for 
4 days beginning on different days of the estrous cycle, followed by a luteolytic dose of 
prostaglandin and an ovulation-inducing dose of GnRH. 
 
Ovulation in relation to GnRH 
Treatment group Before* 
Synchronized
* 
Ovulation 
failure* 
Day 0 0 10 0 
Day 4 3 7 0 
Day 8 0 7 1 
Day 12 0 10 1 
Day 16 3 5 1 
Letrozole total 6 (12%)
a
 39 (81%)
a 
3 (6%)
a 
Control total 7 (14%)
a 
28 (57%)
b 
14 (28%)
b
 
*Before = ovulation between PGF and GnRH treatments; Synchronized = ovulation within 48 
hours after GnRH treatment; Ovulation failure = no ovulation between PGF treatment and 48 
hours after GnRH treatment. 
ab 
Within columns, values with no common superscript are different 
(p<0.05) 
Plasma estradiol concentrations at the time of device removal in Groups 0, 4, 8, and 12 were 
compared to samples collected from heifers in Group 16 at equivalent time points before 
letrozole treatment in that group. Group 16 lacked a comparable control group due to the 
experimental design. Estradiol concentrations at device removal were lower in Groups 0 and 4, 
compared to their respective controls (P = 0.02 and P = 0.05, respectively; Figure 9. 2), and 
estradiol concentration tended to be lower following letrozole treatment in Group 8 (P = 0.1, 
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Figure 9. 2). Estradiol concentrations were low in Group 12 and not different from Day 12 
controls (P = 0.9, Figure 9. 2). 
  
Figure 9. 2. Plasma estradiol concentration (mean ± SEM) at letrozole device removal in heifers 
treated with a 4-day regimen of letrozole intravaginally compared to untreated controls. Devices 
were placed on Days 0 (n=10), 4 (n = 10), 8 (n = 8), 12 (n=11) or 16 (n=9; Day 0 = ovulation). 
Control samples were obtained from heifers in the Group 16 at Days 4, 8, 12 and 16, prior to 
treatment with letrozole on Day 16. Hence, Day 16 group lacked of a control group at device 
removal. 
Corpus luteum diameter profiles were not different among treatment groups (P = 0.45, 
Figure 9. 3). Similarly, progesterone concentrations were not different among treatment groups 
during the 9 days following ovulation (P = 0.33, Figure 9. 4). 
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Figure 9. 3. Corpus luteum diameter profiles (mean ± SEM) in heifers after treatment with 
letrozole-releasing intravaginal device for 4 days followed by PGF at device removal and GnRH 
24 h later. Devices were placed on Days 0 (n=10), 4 (n = 10), 8 (n = 8), 12 (n=11) or 16 (n=9; 
Day 0 = ovulation).  
 
Figure 9. 4. Plasma progesterone (P4) profiles (mean ± SEM) in heifers after treatment with 
letrozole-releasing intravaginal device for 4 days followed by PGF at device removal and GnRH 
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24 h later. Devices were placed on Days 0 (n=10), 4 (n = 9), 8 (n = 8), 12 (n=11) or 16 (n=10; 
Day 0 = ovulation). 
Two subsets of animals were identified based on lifespan of the CL resulting from the post-
treatment ovulations. One group included heifers with CL of normal lifespan which were 
actively growing or static 9 days after the post-treatment ovulation (7/10 in Group 0, 4/10 in 
Group 4, 4/8 in Group 8, 10/11 in Group 12, and 5/9 in Group 16). The remaining heifers had CL 
of short lifespan which were either regressing or had already regressed by 9 days after the post-
treatment ovulation [263]. Corpus luteum diameter profiles were not different among treatment 
groups within the two sub-populations (P = 0.62 and P = 0.41, for normal and short lifespan CL, 
respectively). Similarly, progesterone concentrations were not different among treatment groups 
within each sub-population during the observational period (P = 0.88 and P = 0.40, for normal 
and short lifespan CL, respectively). 
9.4.2 Experiment 2 - Artificial insemination trial 
The percentage of heifers that ovulated following treatment in the artificial insemination trial 
was 80% (36/45). Two heifers were not inseminated because it was not possible to reach the 
uterine lumen in order to deposit the semen. From the total number of heifers inseminated 
(n=43), three were confirmed pregnant 35 days post-AI. 
9.5 Discussion 
Studies of the effect of different letrozole treatment regimens on ovarian function in cattle have 
provided evidence of the potential of aromatase inhibitors as a tool to manipulate ovarian 
function in this species ([39, 40] Chapter 5, 6 and 8). The data presented herein further support 
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this notion by confirming our hypothesis that extended letrozole treatment using intravaginal 
devices, combined with a single PGF and GnRH treatment, increases the percentage of heifers 
that ovulated and the synchrony of ovulation, regardless the stage of the estrous cycle at 
initiation of the protocol. However, letrozole-PGF-GnRH-based protocol for ovulation 
synchronization resulted in poor pregnancy rates 
The percentage of heifers that ovulated was increased by the addition of a 4-day regimen of 
letrozole to a PGF plus GnRH protocol as compared to PGF plus GnRH alone (87.1% vs 69.4%, 
respectively). This increase in ovulatory response and synchrony of ovulation after the addition 
of letrozole may involve more follicles responding to the GnRH treatment and a decrease in 
early ovulations (ovulations that occurred prior to GnRH treatment). We have reported 
previously that letrozole induced growth and prolonged the lifespan of dominant follicles by 
increasing circulating plasma LH concentrations ([39, 40] Chapters 5 and 6). We speculated that 
the addition of letrozole to the PGF plus GnRH protocol would allow for smaller, less competent 
follicles, which otherwise would not have responded to GnRH treatment, to reach the necessary 
diameter and LH receptor populations to acquire ovulatory capacity and ovulate within 48 h post 
GnRH treatment. In addition to promoting follicular growth, letrozole treatment likely prolonged 
the lifespan of the static dominant follicles that otherwise would have become atretic by the time 
of GnRH treatment ([39, 40], Chapter 8). The reduction in early ovulations is supported by the 
observation that letrozole prevents estradiol secretion (Chapters 5, 6 and 8) thus minimizing the 
occurrence of a pre-ovulatory rise in estradiol concentration and a LH surge prior to 
administration of GnRH. The improved ovulatory response and synchrony of ovulation after 
GnRH indicated that letrozole could be applied for the development of a FTAI protocol. 
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Pregnancy rates were low in the small breeding trial; only 3 of 43 inseminated heifers were 
pregnant 35 days post-AI. The effect of letrozole treatment on fertility was unexpected. We have 
reported that letrozole treatment affects the plasma hormone profile and steroidogenesis, thus it 
is also expected to alter other aspects of reproductive function such as the duration of follicle 
dominance, oocyte age and activation, the process of fertilization, embryo quality, and CL 
lifespan. However, it is possible that other factors unrelated with the non-steroidal aromatase 
inhibitor treatment may also have influenced the pregnancy outcome obtained in this study. 
The impact of duration of dominance of the pre-ovulatory follicle on timing of ovulation and 
fertility has been reported [264, 265]. Prolonged dominance of the ovulatory follicle has been 
associated with reduced pregnancy rates. The decrease in fertility was more profound after 9 
days of dominance (35 to 70% reduction in pregnancy rates) compared to after 2 days of 
dominance [264]. Duration of dominance is related to increased LH levels [266] and early 
activation of oocytes (resumption of meiosis) has been associated with decreased fertility [264, 
266-268].  
During the present study, we attempted to design a minimal duration of follicle dominance 
in the pre-ovulatory follicles by adjusting the length of letrozole treatment to 4 days. The 
duration of dominance of the pre-ovulatory follicles among groups was estimated based on the 
average day of emergence of the follicle that became the ovulatory follicle - follicles typically 
reach dominant status by 3 days post-wave emergence (2.8 days) [65]. It would follow that the 
duration of dominance in Day 0 and 4 groups were 4 and 8 days, respectively. Day 8 group 
contained heifers that would have had follicles from the first follicular wave (n=4) and heifers 
with follicles originating from the second follicular wave (n=4). Hence, heifers in this group 
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would have had follicles in which dominance would have been 4 days or 12 days at the time of 
ovulation. Day 12 group should have had follicles that originated from only the second wave, 
and would have been dominant for about 4 days before ovulation. Day 16 group would have had 
follicles originating from either the second or third wave of follicular growth and the duration of 
dominance in this group would have been 4 and 12 days (4 and 6 heifers, respectively). As 
evidenced by these numbers, heifers between Days 7 and 9 (Day 8 ± 1) and between Days 15 
and 17 (Day 16 ± 1; Day 0 = ovulation) would be at risk of developing an ovulatory follicle that 
had been dominant for approximately 12 days and would likely have an aged and/or prematurely 
activated oocyte. However, we must consider the possibility that increased LH secretion (caused 
by letrozole treatment [39, 40]) may also cause premature activation of oocytes and a reduction 
in fertility, even if duration of dominance of the pre-ovulatory follicle was within normal range 
(1 to 5 days, [268]).  
Estradiol concentrations were reduced in heifers in Groups 0 and 4, tended to be reduced in 
Group 8, while Group 12 did not differ from their respective controls. Considering that estradiol 
concentration at device removal did not differ among letrozole-treated groups and averaged 2.1 ± 
0.24 pg/mL, the differences noted between letrozole-treated heifers relative to their controls were 
attributed to changes in estradiol concentration in the control samples. Estradiol concentration in 
the control heifers Days 4, 8, 12 and 16 were consistent with those obtained previously: basal 
estradiol concentrations have been reported to be around 2 pg/mL, with a small rise between 
Days 4 and 7 post-LH peak and no significant changes in estradiol concentration thereafter until 
the next pre-ovulatory estradiol rise [55]. It is possible, however, that the presence of a newly 
recruited wave of follicular development (third wave) was responsible for the low estradiol 
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concentration observed in the control heifers on Day 16. In other words, the high estradiol 
concentration expected with the presence of a growing (estrogen-active) follicle from the second 
wave (potentially an ovulatory wave) may have been obscured by the coexistence of atretic 
(estrogen-inactive) follicles from the second follicular wave with newly recruited follicles which 
have not yet reach their maximal estrogen production potential.  
There is some controversy regarding the requirement of estradiol for final follicular 
maturation and the presence of fertilizable oocytes in mammals. In rhesus monkeys, aromatase 
inhibitor treatment during the late follicular phase did not alter the number nor the pattern of 
growth of follicles although oocyte activation and in vitro fertility was reduced [139]. While 
some studies reported that addition of estradiol in in vitro maturation protocols impaired bovine 
oocyte nuclear maturation and subsequent embryo development [269, 270], others found that 
estradiol was essential for normal in vitro maturation [271], especially of early antral follicle-
derived oocytes [272]. However, data on the effects of estradiol deprivation on bovine oocyte 
maturation in vivo are not available, most likely due to the lack of an efficient treatment regimen 
to mimic such a condition. Although not directly assessed in this study, we can presume that 
follicular environment has been affected by treatment, affecting oocyte quality by disturbing 
meiosis. However, treatment with anastrozole, another non-steroidal aromatase inhibitor, did not 
impair follicular growth, ovulation nor fertilization in vivo and embryo development in vitro 
using a mouse model [273]. In addition, there are several important extra-gonadal effects of the 
estradiol produced by growing pre-ovulatory follicles, such as the development of receptive 
endometrium, the production of the cervical mucus, and sperm transport [274]. All these 
processes could be negatively affected by letrozole-induced estradiol inhibition. This notion is 
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further supported by the observation that heifers showed normal signs of estrus after initial PGF 
and GnRH treatment (control ovulations) but did not exhibit any estrous behaviour (i.e., 
mounting, standing to be mounted, vaginal mucus) following PGF and GnRH treatment after 
letrozole treatment. 
The effect of letrozole treatment on CL lifespan in this study was also unexpected. In 
previous studies, letrozole treatment resulted in larger CL which secreted higher levels of 
progesterone [39, 40] (Chapters 5 and 6). Thirty out of 48 (62.5%) heifers treated had CL 
considered to be of normal diameter at last observation (9 days post-letrozole treatment 
ovulation), while 18 (37.5%) heifers underwent luteolysis prior to the last observation at 9 days 
after ovulation. Progesterone production was not affected by group and its profile corresponded 
to CL lifespan (i.e., normal vs short lifespan). The reason for these differences on CL lifespan 
within groups remains unclear. There appeared to be no relationship between duration of 
follicular dominance and lifespan of the resulting CL. Short-lived CL have been described 
following hCG-induced ovulation of the dominant follicle of the first follicular wave in cattle, 
suggesting that pre-ovulatory changes intrinsic to the treatment may be responsible for the 
abnormal CL function [275].  
Another possible explanation for the observed short lifespan CL is related with the 
occurrence of early luteolysis. Short luteal phases in 33% of cows [276] and 47 % of heifers have 
been reported [277] when GnRH treatment was given 24 h after PGF. The short luteal phases 
were related to early release of PGF2α from the endometrium [278]. Reduced estradiol 
concentration during the proestrus has also been linked to short luteal lifespan. It has been 
hypothesized that high estradiol concentrations during proestrus are needed in order to induce an 
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adequate number of progesterone receptors, thus allowing progesterone to regulate the uterine 
secretion of PGF [263, 279]. Therefore, low estradiol concentration induced by letrozole 
treatment may impair the inhibitory effect that progesterone has on PGF secretion by allowing 
the increase in number of estrogen and oxytocin receptors in the endometrium and early release 
of PGF2α [280]. 
An important limitation of the present AI trial is the lack of a letrozole-free control group. 
Therefore, it is difficult to determine the impact that factors such as AI technician, semen quality 
and semen handling had on pregnancy rates. Another important factor to consider is the timing of 
the inseminations. Heifers were inseminated 24 h after GnRH based on an earlier study in which 
it was reported that ovulations occurred between 24 and 32 h after GnRH treatment [94, 98]. 
However, it is unknown if letrozole treatment alters the window of time between GnRH 
treatment and ovulation. Daily ultrasound examinations did not allow the determination of the 
time of ovulation precisely in the present study. Finally, the presence of the short lifespan CL 
during the AI trial also needs to be considered, which would reduce the proportion of heifers that 
could have remained pregnant. Post-AI ultrasound examinations were not performed until 
pregnancy check; hence, no information on CL lifespan is available for this set of animals. 
In summary, the addition of a letrozole-impregnated intravaginal device for 4 days, 
combined with PGF treatment at device removal and GnRH 24 h post-device removal increased 
the percentage of ovulations and synchrony of ovulation in cattle, regardless the stage of the 
estrous cycle at initiation of treatment. Reduced luteal lifespan after letrozole treatment was 
unexpected and requires further investigation in order to elucidate the mechanism responsible for 
this observation. Although the results obtained in the AI trial are unfavorable, we consider that 
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this portion of the study needs to be repeated with the inclusion of control group and in vitro 
fertilization trials in order to draw more meaningful conclusions on the impact that letrozole 
treatment has on oocyte competence and fertility. Adjustments of timing of AI, interval from 
PGF to GnRH treatment and even in vitro assessment of oocyte fertizability after estradiol 
deprivation may be considered. Finally, the letrozole treatment regimen presented herein has 
potential as a model to investigate the effect of estradiol deprivation on oocyte maturation and 
fertility in vivo. 
We conclude that the addition of letrozole to a GnRH plus PGF protocol can be used to 
increase the number of animals ovulating and the synchrony of ovulation, but additional studies 
are needed in order to elucidate the mechanisms related to reduced fertility observed herein.  
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CHAPTER 10: GENERAL DISCUSSION 
The ban of the use of estrogens in livestock and lack of commercially available estrogenic 
preparations negatively impacts the implementation of reproductive biotechnologies that depend 
on the use of estrogens in cattle production systems, limiting potential reproductive efficiency 
and genetic improvement provided by the use of AI or MOET programs [24]. In this context, the 
development of alternative methods for controlling ovarian function and improvement of fertility 
in cattle, with efficacy and predictability comparable with that of estrogen plus progesterone 
treatments [5], and with no harmful effects on human and animal health is needed. Non-steroidal 
aromatase inhibitors, such as letrozole, prevent the body from producing estrogens by reversibly 
binding to the heme group of the P450arom. Letrozole, have been administered to premenopausal 
women for the purpose of follicular stimulation, induction of ovulation, and ovarian 
superstimulation [36, 37]. We hypothesized that letrozole could be used to manipulate ovarian 
follicular wave dynamics, synchronize ovulation and improve post-breeding and embryo transfer 
fertility in cattle. Five experiments were conducted to test this hypothesis. We examined: 1) the 
effect of route and vehicle of letrozole treatment on ovarian function in cattle (Chapters 5, 6, and 
7), 2) the effect of type of aromatase inhibitor on ovary function in cattle (Chapter 7), 3) the 
effect of duration of aromatase inhibitor treatment (short vs prolonged) on ovarian follicles in 
cattle (Chapters 5, 6 and 8), and 4) the efficacy of an aromatase inhibitor-based protocol to 
synchronize ovulation in cattle (Chapters 8 and 9). Finally, a small breeding trial was conducted, 
in an attempt to obtain preliminary data and understanding of the effects of aromatase inhibitors 
treatment on pregnancy outcomes (Chapter 9). 
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To the best of our knowledge, these are the first studies on non-steroidal aromatase 
inhibitors for control of reproduction in cattle. Although studies on the effects of letrozole on 
ovarian function in women suggested that aromatase inhibitor-stimulated follicular growth was 
driven by increased FSH secretion as a result of removal of the negative feedback effects of 
estrogen [34, 141], current results in cattle suggest that it was LH rather than FSH that was 
responsible for the effects of letrozole [39, 40]. The objective of this general discussion is to 
summarize and integrate the results obtained from the experiments presented in Chapters 5, 6, 7, 
8 and 9 of this thesis to current information available in the literature.  
10.1 Effects of non-steroidal aromatase inhibitor in estradiol concentration 
Plasma estradiol concentrations were significantly reduced by letrozole administration in vivo 
(Chapters 5, 6, 8 and 9) and in vitro (Chapter 7). The duration and magnitude of the reduction in 
estradiol concentrations after letrozole treatment was affected by route and vehicle of 
administration (in vivo) and by type and dose of aromatase inhibitor (in vitro). The vehicle 
formulated for intramuscular administration of letrozole (Chapter 5) appeared to have a depot 
effect, delaying and prolonging drug release from the injection site. Hence, plasma estradiol 
concentrations in heifers treated intramuscularly took 24 h longer than in those treated 
intravenously to reach minimum values, and remained low 6 days after treatment. In the 
intravenous letrozole group, estradiol levels reached the minimum concentration rapidly 
(between 12 and 24 h after treatment) but returned to placebo-treated control levels within 2 
days. After insertion of letrozole-impregnated gel-based intravaginal devices (Chapter 6), 
estradiol concentrations were reduced, and the preovulatory rise in estradiol concentrations 
occurred 24 h later than in the control group. However, the duration of estradiol inhibition was 
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relatively short and was related with the rapid release of letrozole from the devices and the early 
drop in letrozole plasma concentration. Addition of a wax matrix to the formulations in order to 
prolong the release of letrozole from the intravaginal devices (Chapter 7) affected the extent and 
duration of estradiol inhibition as discussed in Chapters 8. Both letrozole formulations (Wax plus 
gel coat and Wax alone) significantly reduced plasma estradiol concentrations to a similar extent 
in treated heifers, and estradiol concentrations differed from the control group by 12 h after 
device insertion. In Chapter 9, estradiol concentrations were reduced after insertion of the wax 
plus gel coat letrozole-containing intravaginal device in heifers treated from Days 0 to 4, and 
from Days 4 to 8, and tended to be reduced in heifers treated from Days 8 to 12 (Days 0, 4 and 8 
groups, respectively. Day 0 = ovulation).  
As compared to their respective controls, estradiol concentration were reduced by 56% and 
45% with im and iv letrozole administration, respectively (Chapter 5), by 45% with the gel-based 
letrozole intravaginal device (Chapter 6) and by 60% with the wax-based letrozole intravaginal 
devices (Wax plus gel coat and Wax alone combined, Chapters 8 and 9). These levels of 
inhibition in estradiol production following the administration of letrozole in cycling heifers 
were similar to that reported for cycling females in other species. Reduction in estradiol 
concentration of about 50% were reported in premenopausal bonnet monkeys treated with 3.5 
mg/day of letrozole over 7 days (from Days 7 to 14 of the menstrual cycle) [281], and in 
premenopausal women treated with 5 mg/day of letrozole from Days 3 to 7 of the menstrual 
cycle [225]. It appears, however, that estradiol inhibition by letrozole treatment is more profound 
in males and in post-menopausal women than in cycling cattle, and premenopausal women and 
non-human primates. When given to boars at a dose of 0.1 mg/kg body weight, letrozole 
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treatment reduced estrogen levels by 90% at 24 hours and levels remained low for at least 168 
hours post-treatment [282]. In post-menopausal women, estrogen suppression was 97 to 99% 
[33, 187], and 30% with the lowest (0.02 mg) and 90% with the highest (30 mg) dose of 
letrozole tested in healthy human males [182]. It is recognized that differences in doses and 
regimens of administration of letrozole, as well as methods used for the determination of 
estradiol levels in plasma or serum must be taken into consideration in the interpretation of these 
findings. Furthermore, the inherently low circulating estradiol concentration in non-pregnant 
cattle, compared to females of other species such women and the mare, represents an obstacle for 
the determination of an effect of letrozole treatment on estradiol secretion in cattle. 
Our in vitro-generated data on the effects of type of aromatase inhibitor (letrozole, 
anastrozole and fenbendazole) using bovine granulosa cells in culture revealed that letrozole and 
anastrozole were efficacious in reducing estradiol production to levels found in non-FSH-
stimulated granulosa cells (Chapter 7). Fenbendazole, however, did not reduce estradiol 
concentrations significantly. These observations are consistent with reports in which letrozole 
and anastrozole were found to be strong and selective inhibitors of the P450arom [181, 255]. In 
comparing relative potencies, estradiol synthesis was reduced to that of non-FSH-stimulated cells 
at a lower dose with letrozole than with anastrozole (20 ng/mL vs 200 ng/mL, respectively) 
which is in agreement with a previous report that letrozole was several orders of magnitude more 
potent than anastrozole in vitro using cell culture from different tissues such as hamsters ovarian 
tissue fragments, normal human adipose tissue fibroblasts and the JEG-3 human 
choriocarcinoma cell line [259]. Albendazole, a benzimidazole anthelmintic drug closely related 
to fenbendazole, inhibited the activity of cytochrome P450 enzymes (CYP enzymes; a family of 
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enzymes of which aromatase is a member) in vitro in rat and mouflon sheep [256-258].[256, 
257], [258]. Therefore, fenbendazole may have had a direct, although mild, effect on P450arom 
activity, or it may have affected estradiol production indirectly, through non-specific inhibition 
of other P450 enzymes in the bovine granulosa cells in vitro. 
10.2 Effects of non-steroidal aromatase inhibitor treatment on follicular dynamics 
The timely control of wave emergence and ovulation has been instrumental for the successful 
application of reproductive technologies in cattle and other species. The outcome of a 
superstimulation treatment is strongly influenced by the stage of follicular development at the 
time of initiation of treatment, with optimal ovarian responses being obtained when 
superstimulatory treatments were initiated at the time of follicular wave emergence [5, 109]. 
Similarly, FTAI eliminates the need for estrus detection but requires synchronous growth and 
ovulation of a viable dominant follicle in order to be successful. The effect of non-steroidal 
aromatase inhibitors on non-ovulatory follicle growth and wave emergence in cattle has been 
assessed previously [39, 40] and in Chapters 5 and 8 of the present thesis. The effect of letrozole 
treatment on pre-ovulatory follicles and ovulation was the subject of Chapter 6 and 9. 
We were able to determine the changes in ovarian dynamics after letrozole treatment during 
experiments reported on in Chapters 5, 6, 8 and 9. In general terms, letrozole had a stimulatory 
effect on the growth and lifespan of the non-ovulatory dominant follicle which was consistent 
with earlier reports [39, 40]. Furthermore, intravaginally administered letrozole treatment during 
the pre-ovulatory follicular wave also resulted in a greater diameter and prolonged lifespan of the 
ovulatory follicle, delaying ovulation by 24 h (Chapter 6). Likewise, it has been shown that 
women treated with letrozole from Days 3 to 7 of the menstrual cycle had larger ovulatory 
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follicles than untreated controls [224]. However, formulation and route of delivery of letrozole 
affected the extent of this effect. For example, letrozole given im or iv (Chapter 5) did not result 
in significantly larger dominant follicles. However, despite the effect of aromatase inhibitor 
treatment on dominant follicle diameter, the prolonged interval from treatment to new wave 
emergence (Chapter 5 and 8) and from treatment to ovulation (Chapter 6), indicates that letrozole 
administration prolonged the functionality of the dominant follicle, which may be even more 
meaningful. This observation was also supported by the outcomes of the synchronization trial 
(Chapter 9). The higher proportion of ovulations observed in the letrozole-treated group was 
attributed to smaller, less competent follicles (which otherwise would not have responded to 
GnRH treatment) reaching the necessary diameter and LH receptor populations to acquire 
ovulatory capacity and ovulate within 48 h post GnRH treatment. In addition to promoting 
follicular growth, letrozole treatment likely prolonged the lifespan of the dominant follicle (as 
documented in Chapters 5 and 8, and in [39, 40]) making it possible to maintain the viability of 
static follicles that otherwise would have become atretic by the time of GnRH treatment. As a 
result, the addition of letrozole to a PGF plus GnRH protocol increased ovulatory response 
(87.1% vs 69.4%, respectively) and the synchrony of ovulation. The prolonged dominance 
resulting after letrozole treatment resembles that observed in beef cows following exogenous 
pulsatile administration of LH [283] or that obtained after increased LH pulsatility by induction 
of sub-luteal progesterone concentration in cattle [16]. 
The effect of letrozole treatment on follicles prior to selection was assessed in experiments 
described in Chapters 6 and 9. We hypothesized that letrozole treatment initiated prior to the 
onset of pre-ovulatory dominant follicle selection would result in the development of multiple 
  
150 
 
dominant follicles. This hypothesis was based on earlier research in cattle [40] and results 
obtained from women undergoing ovarian stimulation [36, 37, 216]. In cattle, the initiation of a 
3-day regimen of letrozole given iv prior to follicular selection resulted in the development of 
two co-dominant follicles, one of which regressed immediately after interruption of letrozole 
administration [40]. Similarly, a mild superovulatory response was described in women 
following the use of letrozole in increasing doses (step-up protocol) and after a 5-day letrozole 
regimen of 5 or 7.5 mg/day, and it was concluded that increased FSH secretion may have been 
responsible for multi-follicular growth [36, 37, 284]. However, the results obtained in the current 
studies (Chapters 6 and 9) failed to support our hypothesis. Although non-steroidal aromatase 
inhibitor treatment was initiated before dominant follicle selection in Chapter 6, it is possible that 
the low bioavailability of letrozole resulting from the intravaginal formulation accounted for the 
lack of co-dominance. In the experiments described in Chapter 9, the letrozole formulation used 
in the intravaginal devices prolonged release and therefore increased letrozole bioavailability. 
Nevertheless, no superstimulatory response occurred. We speculate that the delay of the increase 
in plasma letrozole concentration due to absorption through the vaginal mucosa (Chapter 7) may 
have interfered with the superstimulatory effect. The formerly reported co-dominance was 
obtained after intravenous letrozole administration; immediate and complete bioavailability of 
letrozole may have favored the mild ovarian superstimulation observed in that study [40].  
10.3 Effects of non-steroidal aromatase inhibitor treatment in CL function 
Studies in cattle indicated luteotrophic effects on the existing CL after treatment with a single or 
a 3-day regimen of letrozole; circulating LH was increased while FSH remained unchanged [39, 
40]. Similar findings have been reported in women, where enhanced luteal function was 
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associated with increased circulating LH concentrations but no difference in FSH concentrations 
[225]. Non-steroidal aromatase inhibitors exerted a luteotrophic effect when given during the 
diestrous and proestrous in beef heifers (Chapters 5 and 6, respectively). The effect was 
evidenced by larger CL diameter profiles and/or increased plasma progesterone concentrations in 
letrozole-treated heifers. In Chapter 5, the luteotrophic influence on the extant CL appeared to be 
more evident when letrozole was given intramuscularly than when given intravenously. 
Intravaginally administered letrozole treatment during the growing phase of the ovulatory wave 
(Chapter 6) resulted in the ovulation of a larger dominant follicle but this did not result in larger 
CL as it has been previously reported [116, 118, 285]. Interesting, despite the lack of an increase 
in CL size, elevated plasma progesterone profiles were observed over the first 12 days post-
ovulation in the letrozole-treated group. We speculated that preovulatory letrozole treatment may 
have affected the number or proportion of large luteal cells (granulosa cell origin) and small 
luteal cell (thecal cell origin) contained within the CL [230], resulting in an increase in 
progesterone production per CL volume. Small and large luteal cells are normally present in the 
bovine CL in a ratio of 7.6:1 [231]. Small luteal cells respond directly to LH stimulus to secrete 
progesterone [232, 233], while large luteal cells appear to be responsible for sustained secretion 
of progesterone in the absence of a stimulus [233]. Treatment of cows with equine chorionic 
gonadotropin resulted in increased density and number of large luteal cells which increased the 
capacity of the CL to produce progesterone without altering its volume [234]. We interpreted 
that the stimulatory effects of letrozole treatment during proestrous on the newly formed CL 
function has the potential of enhancing fertility by increasing circulating progesterone 
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concentrations during the first 7 days post-ovulation in cattle, which may be specially beneficial 
in dairy cows. 
In the experiments described in Chapter 9, we observed CL dysfunction following letrozole 
treatment for the first time. In this study, 18 out of 48 heifers (37.5%) ovulating after treatment 
with a wax plus gel coat letrozole-containing intravaginal device underwent early luteolysis 
(luteal regression observed during the first 9 days post-ovulation). Progesterone production 
profile corresponded to CL lifespan (i.e., normal vs short lifespan). This unexpected finding was 
unrelated to size and lifespan of the pre-ovulatory dominant follicle. Although we cannot rule out 
a direct effect of letrozole on CL steroidogenic machinery, other factors need to be taken into 
consideration in order to interpret this finding. Reduced estradiol concentration during the 
proestrus in cattle has been linked to short luteal lifespan, and it has been hypothesized that high 
estradiol concentrations during proestrus are needed in order to induce an adequate number of 
endometrial progesterone receptors, thus allowing progesterone to regulate the uterine secretion 
of PGF [44, 45]. Therefore, low estradiol concentration induced by letrozole treatment may have 
impaired the inhibitory effect that progesterone has on PGF secretion, allowing for an increase in 
the number of estrogen and oxytocin receptors in the endometrium and early release of PGF2α 
[46]. However, due to the lack of a contemporary untreated control group, we cannot fully 
determine whether the presence of short-lived CL in the non-steroidal aromatase inhibitor-treated 
group was entirely due to letrozole or there were other factors involved. Corpora lutea with a 
shortened lifespan have also been described following hCG-induced ovulation of the dominant 
follicle of the first follicular wave in cattle, suggesting that pre-ovulatory changes intrinsic to the 
treatment may be responsible for the abnormal CL function [40]. Short luteal phases in 33% of 
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cows [41] and 47 % of heifers have been reported [42] when GnRH treatment was given 24 h 
after PGF. The short luteal phases were related to early release of PGF2α from the endometrium 
[43]. Therefore, adjusting the timing of GnRH treatment in relation to PGF administration in our 
letrozole-based protocol may help to minimize the incidence of early luteolysis. Although 
letrozole-mediated estradiol deprivation early in the luteal phase and its impact of CL 
functionality has not been critically assessed, our observation of luteotrophic effects of 
aromatase inhibitor on the developing CL ([39, 40] and Chapter 5) indicate that letrozole 
treatment during this period may be the key to improving CL size and/or progesterone 
production.  
10.4 Effect of non-steroidal aromatase inhibitor treatment on gonadotropin secretion 
We have reported that letrozole induces an increase in plasma LH concentrations [39, 40]. 
However, the exact nature of the increase in LH concentration (i.e. increase basal secretion 
and/or increase LH pulsatility) after letrozole treatment was not evident from our data. None of 
the studies presented herein were designed to characterize the influence of letrozole on LH 
pulsatility. Although measurement of LH and FSH concentrations were attempted in Chapter 5 
and 6, daily and 12 h sampling frequency has limitations when measuring gonadotropin 
concentrations and attempting to correlate them to ovarian dynamics. Several studies in which 
analysis of LH pulse frequency was their main endpoint used sampling frequencies of 10 to 15 
minutes [286-289]. Sampling intervals of 20 min have been considered inadequate to 
consistently detect changes in LH pulsatility [13].  
The findings summarized in this thesis further support the hypothesis that treatment with 
aromatase inhibitor resulted in an increase in LH secretion which in turned resulted in greater 
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dominant follicle diameter and lifespan, and increased CL diameter and/or increased 
progesterone secretion. In Chapter 5, a surge on LH concentration was observed on the day of 
wave emergence in the letrozole im group while no such increase was detected in the letrozole iv 
or combined placebo-treated control groups. We were unable to detect an increase in LH 
concentration in Chapter 6, although the delay in ovulation led us to speculate that the LH surge 
was also delayed by letrozole treatment. The effect of aromatase inhibitor treatment on 
gonadotropin secretion was not included among the endpoints studied in the experiments 
reported in Chapters 8 and 9.  
Several research groups have generated information on the aromatase inhibitor-induced 
changes in gonadotropin secretion in other species. Our results are in agreement with the study 
by Cortínez et al. [225] in which a larger follicular size in letrozole-treated women was attributed 
to the higher levels of LH found in the circulation. Similarly, long-term letrozole treatment in the 
stallion resulted in a 9-fold increase in LH secretion, while FSH concentrations did not differ 
from that of control stallions [290]. Increased LH concentration after letrozole treatment, without 
significant changes in FSH, were also reported using a rat model [291]. Kisspeptin-secreting 
neurons contain ER and other sex steroid receptors and are located in close proximity to GnRH-
secreting cells in the hypothalamus [59, 60]. Reducing circulating E2 concentrations have been 
correlated with higher kisspeptin (Kp) mRNA levels and increased GnRH output [58]. 
Administration of 100 pmole/k of Kp in cattle, resulted in increased circulating LH 
concentrations during diestrous and proestrus, but not during estrous [61]which may assist in the 
interpretation of our findings: letrozole treatment (or reduced estradiol) resulted in increased 
follicular growth during diestrous (Chapter 5 and 8) and proestrous (Chapters 6 and 9), possibly 
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through increased Kp output and increased GnRH secretion, while during estrous (Chapter 6), 
letrozole treatment may have delayed the Kp increase and therefore the preovulatory LH surge. 
Regarding FSH, it is known that follicular factors other than estradiol influence the secretion of 
this gonadotropin [52, 53]. Inhibin secretion has been positively correlated with follicular growth 
and it has been associated with the drop in FSH secretion that encompasses follicular selection 
[54]. Therefore, levels of inhibin secreted by the dominant follicle may increase during letrozole 
administration and diminish the expected rises in FSH concentration. The potential action of 
inhibin on FSH secretion in part would explain the lack of a superstimulatory effect when 
letrozole treatment was initiated prior to selection (Chapters 6 and 9). Additional studies will be 
needed in order to clarify this concept. Measurement of inhibin concentration during letrozole 
treatment or combination of an aromatase inhibitor plus inhibin-blocking treatment (or using 
animals immunized against inhibin) may have to be considered for this purpose. 
10.5 Effect of non-steroidal aromatase inhibitor treatment on fertility in cattle 
A small breeding trial was included as part of the study reported in Chapter 9. Unexpectedly low 
pregnancy rates were obtained; only 3 of 43 inseminated heifers were pregnant 35 days post-AI. 
Although we were tempted to conclude that non-steroidal aromatase inhibitor treatment has a 
direct negative impact on oocyte competence, other factors inherent to the experimental design 
and resulting from the altered gonadotropin profiles obtained after letrozole treatment need to be 
considered.  
The requirement of estradiol for final follicular maturation and development of oocyte 
competence in mammals is not fully understood. While the inclusion of estradiol in in vitro 
maturation protocols impaired bovine oocyte nuclear maturation and subsequent embryo 
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development in some studies [269, 270], others report that estradiol is essential for normal in 
vitro maturation [271], especially of early antral follicle-derived oocytes [272]. In rhesus 
monkeys, aromatase inhibitor treatment during the late follicular phase did not alter the number 
nor the pattern of growth of follicles, although oocyte activation and in vitro fertility was reduced 
[139]. However, data on the effect of estradiol deprivation on bovine oocyte maturation in vivo 
are not available, most likely due to the lack of an efficient animal model or treatment regimen to 
mimic such a condition. Although not directly assessed in this study, we can presume that 
follicular environment may have been affected by letrozole treatment, potentially affecting 
oocyte quality by disturbing meiosis. However, a mouse model demonstrated that treatment with 
anastrozole did not impair follicular growth, ovulation nor fertilization in vivo and embryo 
development in vitro [273]. In addition, non-steroidal aromatase inhibitor treatment may have 
had several important extra-gonadal effects; estradiol produced by the growing pre-ovulatory 
follicle has been shown to be associated with the development of receptive endometrium, the 
production of the cervical mucus, and sperm transport [274]. Clinical studies in humans, 
however, denote that the main advantage of the use of letrozole over other estradiol suppressors 
used in ovarian stimulation (such as clomiphene citrate, CC) is that uterine maturity does not 
seem to be compromised [200, 201, 203]. The improved endometrial thickness obtained after 
letrozole treatment compared to that of CC-treated patients has been attributed to the relatively 
short half-life of letrozole and the reversible nature of letrozole interaction with the P450arom 
[200, 201, 203]. An interesting observation made during the experiments included in Chapter 9 
supports, in part, the notion of alteration in reproductive organs other than the ovaries after non-
steroidal aromatase inhibitor treatment in cattle. Heifers showed normal signs of estrus after 
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initial PGF and GnRH treatment (control ovulations), but failed to exhibit estrus signs or 
behaviour (i.e., mounting, standing to be mounted, vaginal mucus discharge) once letrozole was 
included to the PGF-GnRH protocol. 
Other factors that need to be examined to understand the pregnancy outcomes presented in 
Chapter 9 include duration of dominance, and incidence of oocyte aging and/or activation. The 
impact of duration of dominance of the pre-ovulatory follicle on timing of ovulation and 
subsequent fertility has been reported [265, 292]. Prolonged dominance of the ovulatory follicle 
has been associated with increased LH pulsatility [266]. Additionally, early activation of oocytes 
(resumption of meiosis) driven by increased LH pulsatility has been considered the main cause 
of decreased fertility following the use of progestogens in synchronization protocols [268, 292-
294]. During the breeding trial, heifers in which treatment was initiated between Days 7 and 9 
and between Days 15 and 17 (Day 0 = ovulation) may have been at risk of developing an 
ovulatory follicle which was dominant for approximately 12 days and would likely have had an 
aged and/or prematurely activated oocyte (Chapter 9). We must also consider the possibility that 
increased LH secretion (potentially caused by letrozole treatment [39, 40]) may have led to 
premature activation of oocytes and a reduction in fertility, even in those heifers in which 
duration of dominance of the pre-ovulatory follicle was within normal range (1 to 5 days, [268]). 
Finally, another factor which could have accounted for the low pregnancy rates is the occurrence 
of short-lived CL, previously discussed. Unfortunately, post-AI ultrasound examinations were 
not performed until pregnancy check 35 days later; hence, no information on CL lifespan was 
available for this set of animals. 
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Deficiencies in the experimental design and limited resources (number of heifers available) 
introduced additional confounding factors to the interpretation of the results of the AI trial 
included in Chapter 9. The lack of a letrozole-free control group made it difficult to determine 
the impact that factors such as AI technician, semen quality and semen handling may have had 
on pregnancy rates. Although semen quality was deemed to be satisfactory in terms of post-thaw 
motile cells and progressive motility (49% and 44%, respectively) ensuring the present of at least 
12 million progressively motile sperm cells per insemination dose, previous evidence of the 
fertility of the semen was not available. Another important factor to consider is the timing of the 
inseminations. Heifers were inseminated 24 h after GnRH and this was based on an earlier study 
in which it was reported that ovulations occurred between 24 and 32 h after GnRH treatment [94, 
98]. However, it is unknown if letrozole treatment alters the timing between GnRH treatment and 
ovulation. Daily ultrasound examinations did not allow the determination of the time of 
ovulation precisely during the studies included in Chapter 9. In the Ovsynch protocol, the second 
GnRH treatment is normally administered 48 h post PGF, and cows are inseminated 16 to 18 h 
later [295]. A study showed that GnRH treatment 24 h post-PGF resulted in lower pregnancy 
rates that when GnRH was given 48 h post-PGF, with both groups being inseminated 24 h post-
second GnRH [94]. As discussed previously, it is conceivable that increasing the interval 
between PGF and GnRH from 24 h to 48 h could be beneficial not only to prevent short-lived CL 
as previously discussed, but also for oocyte competence and fertility. Furthermore, adjusting the 
timing of insemination using a letrozole-PGF-GnRH based protocol may also result in improved 
pregnancy rates.  
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10.6 Pharmacokinetics of letrozole in cattle 
The pharmacokinetic parameters estimated during this thesis work are in accordance with those 
reported previously in cattle [40], and differ to some extent from those described humans [184, 
185]. Letrozole appears to have a shorter half-life in cattle (on average, 33 h) than in humans (48 
h). Mean residence time (MRT) value represents the average duration of persistence of the drug 
in the body and, although it was numerically similar to that reported in humans (60.5 h in heifers 
(Chapter 6) vs 58.7 h in women [184]), direct comparisons cannot be made since two different 
methods where used for the calculation of this parameter in each study. Finally, the volume of 
distribution observed in the heifers (8 L/kg) was higher than that reported in women (2 L/kg) 
[184], suggesting that letrozole has higher tissue distribution in this species as compared to 
humans. Since the half-life of a drug not only depends on elimination, the difference in tissue 
distribution may be in part responsible for the shorter half-life of letrozole estimated in cattle as 
compared to humans. 
Bioavailability can been defined as the amount of a drug given by any route, other than 
intravenously, that reaches general circulation and is available at the site of action [227]. In this 
thesis, bioavailability was calculated using AUClast data obtained using the intravenous route of 
administration of letrozole in Chapter 5. In Chapter 6, the low bioavailability of letrozole 
obtained with the intravaginal devices (16%) may be explained by the melting point of the gel-
vehicle used. This gel-based vehicle is commonly used for intravaginal suppositories for women, 
in which body temperature is lower than that of cattle (37° vs 39° C) [228, 229]. As previously 
discussed, rapid liquefaction and release of the formulation from the intravaginal devices may 
have caused the loss of most of the formulation through the vulvar opening. After in vivo testing 
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of newly formulated intravaginal devices in Chapter 7, we concluded that the wax plus gel coat 
device provided the highest bioavailability (63%), followed closely by the wax-only device 
(58%). The addition of DOPE as a absorption enhancer to the device formulation may have 
decreased its melting point causing loss of the device contents to the outside a decreasing its 
bioavailability (43%). 
The increasing interest in aromatase inhibitor-based protocols to control ovarian function in 
mammals created the need for the development of effective routes and vehicles of administration 
to ensure the desired biological effects are achieved. Our hypothesis that the formulation and 
route of administration used to provide letrozole treatment in heifers will have an important 
influence on the changes in ovarian function was supported by the experiments presented in this 
thesis. Since half-life and volume of distribution are inherent to the chemical characteristics of 
drug of interest and, in our studies these parameters were relatively independent of vehicle, 
variations in the ovarian effects among experiments were attributed to differences in the 
absorption pattern among formulation and routes of administration. In Chapter 5, the oil-based 
intramuscular vehicle used for letrozole administration appeared to act as a depot, releasing 
letrozole from the injection site at a slow and steady rate, and the effects on ovarian function 
were more consistent and reliable that those obtained with following intravenous administration. 
In another example, the profile of letrozole concentration over time reported in Chapter 6 was 
affected primarily by the rapid liquefaction and release of the formulation from the intravaginal 
devices. This rapid release may have interfered with absorption of letrozole, due to most of the 
formulation being lost through the vulvar opening. Therefore, letrozole was released from the 
intravaginal devices for 24 h post-insertion, but elimination took place locally and absorption and 
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plasma clearance took place thereafter. The duration of estradiol inhibition may have been 
influenced by the pharmacokinetic characteristics of this intravaginal formulation, and could 
account for the 24 h delay in the estradiol rise observed in the letrozole-treated group. The 
intravaginal devices tested in Chapter 7 indicated that, although the total amount of letrozole 
delivered (AUClast) did not differ between the wax plus gel coat device and wax-only device, the 
characteristics of the delivery during both the first 12 hours and 12 days did differ. The wax plus 
gel coating formulation resulted in an early rise in plasma letrozole concentrations, reaching a 
steady plasma concentration by 24 h after device insertion. Plasma letrozole concentrations did 
not reach values similar to that in the wax plus gel coat group until 60 h after treatment following 
insertion of wax-only intravaginal devices (Chapter 7). Although these pharmacokinetic 
differences were expected, their biological relevance was confirmed in Chapter 8. Both letrozole 
formulations significantly reduced plasma estradiol concentrations to a similar extent in treated 
heifers, and estradiol concentrations differed from the control group by 12 h after device 
insertion. However, the lesser efficacy of the wax only group in affecting ovarian function may 
indicate that the amount of letrozole required to reduce estradiol concentrations is not necessarily 
the same as that required to affect ovarian function, especially in the first few hours after device 
insertion. 
Drug administration by the intramuscular route in large animals is commonly used. 
However, the fact that withdrawal of the circulating concentration of the active compound 
depends entirely on absorption and clearance makes it is difficult to manipulate the length of the 
effect. This remains to be an important limitation for this route of administration, particularly 
when the length of exposure to a given drug greatly impacts the success of the treatment, as is 
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the case for synchronization of ovulation for breeding purposes. When it comes to prolonged 
treatment in farm animals for reproductive management, the intravaginal route of administration 
is preferable because it is well-tolerated by the animals, reduces handling and stress, is user-
friendly and easily applied, there is a high retention rate (which varies with device design), and it 
enables controlled withdrawal [243].  
10.7 Summary 
In summary, our results demonstrate that route of administration, or more precisely, the nature of 
the vehicle used for the administration of letrozole (intravenous, intramuscular depot, short 
release intravaginal or prolonged release intravaginal) has an impact on the effects of letrozole 
on hormonal profiles and ovarian dynamics. The intramuscular route appeared to provide a 
prolonged release of letrozole from the injection site which had a marked effect on estradiol 
production, dominant follicle lifespan, and CL form and function (Chapter 5). Letrozole 
treatment during the ovulatory follicle wave by means of a gel-based intravaginal releasing 
device resulted in more rapidly growing dominant follicles and a larger ovulatory follicles, 
delayed ovulation (by 24 h) of a single follicle and formation of a CL that secreted higher levels 
of progesterone (Chapter 6). A wax-based vehicle, with higher melting point than the polymer-
based vehicle used in Chapter 6, allowed for a steady and continuous delivery of the active 
compound over the treatment period. The addition of a letrozole-containing gel coating increased 
the rate of initial absorption and hastened the increase on plasma concentrations of the active 
ingredient, while the letrozole-containing wax-based vehicle prolonged drug-delivery from the 
intravaginal device (Chapter 7). When tested in vivo, we confirmed that letrozole-impregnated 
intravaginal devices formulated with a wax base plus a gel coat vehicle was most suitable for the 
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application of a letrozole-based protocol for the synchronization of ovulation in cattle, since it 
effectively delivered elevated concentrations of letrozole, reduced estradiol production resulting 
in increased follicular growth and lifespan, without adversely affecting progesterone production 
(Chapter 8). The addition of a letrozole-impregnated intravaginal device for 4 days, combined 
with PGF treatment at device removal and GnRH 24 h post-device removal increased the 
percentage of ovulations and synchrony of ovulation in cattle, regardless the stage of the estrous 
cycle at initiation of treatment (Chapter 9). As observed in previous studies [39, 40], the effects 
observed could be associated with an increase in circulating LH concentrations. However, the 
effects of treatment on gonadotropin concentrations are inconclusive, possibly due to inadequate 
sampling frequency. The impact of letrozole treatment of oocyte fertility remains unknown. 
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CHAPTER 11: GENERAL CONCLUSIONS 
The general objectives of this thesis included the determination of the effect of route and vehicle 
of letrozole treatment on ovarian function in cattle (Chapters 5, 6, and 7), the effect of type of 
aromatase inhibitor on ovary function in cattle (Chapter 7), the effect of duration of aromatase 
inhibitor treatment (short vs prolonged) on ovarian follicles in cattle (Chapters 5, 6 and 8), and 
the efficacy of an aromatase inhibitor-based protocol to synchronize ovulation in cattle (Chapters 
8 and 9). The chapter-specific conclusions are summarized as follows: 
1) Chapter 5: Effects of vehicle and route of administration of a non-steroidal aromatase 
inhibitor on ovarian function in a bovine model. 
a. Route of administration and the nature of the vehicle used for the administration 
of letrozole (depot vs intravenous) have an impact on the effects of letrozole on 
ovarian dynamics and hormonal profiles. 
b. Intramuscular route provides a prolonged release of letrozole from the injection 
site. 
c. Letrozole treatment given intramuscularly on Day 3 post wave emergence 
lengthens the lifespan of the dominant follicle, delays post-treatment wave 
emergence, and has a luteotrophic effect as evidenced by a larger CL and higher 
circulating progesterone concentrations. However, the same dose of letrozole 
given intravenously is not effective in altering ovarian function.  
d. The effects of letrozole on ovarian function are associated with an increase in 
circulating LH concentrations. 
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e. Due to the extremely prolonged release of letrozole from the injection site when 
given im, am alternative route of administration that allows for controlled 
termination of letrozole exposure may be needed to effectively control estradiol 
production and ovarian function in cattle. 
f. Results further support the working hypothesis that letrozole has potential as a 
steroid-free option for the control of ovarian function for the purposes of fixed-
time artificial insemination and embryo transfer. 
2) Chapter 6: Non-steroidal aromatase inhibitor treatment with an intravaginal device and its 
effect on pre-ovulatory ovarian follicles in a bovine model. 
a. Letrozole treatment during the ovulatory follicular wave results in more rapidly 
growing dominant follicles and larger ovulatory follicles. 
b. Letrozole treatment during the ovulatory follicular wave by means of a gel-based 
intravaginal device delays ovulation of a single follicle by 24 h.  
c. Letrozole treatment during the ovulatory follicular wave by means of a gel-based 
intravaginal device results in the formation of a CL that secreted higher levels of 
progesterone. 
d. Letrozole treatment during the ovulatory follicular wave by means of a gel-based 
intravaginal device significantly reduces estradiol secretion and delays pre-
ovulatory surge in estradiol. 
e. A sustained-release intravaginal device has potential in the development of an 
aromatase inhibitor-based protocol for control of ovulation for herd 
synchronization.  
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f. The stimulatory effects of letrozole treatment on CL function has the potential of 
enhancing fertility by increasing circulating progesterone concentrations during 
the first 7 days post-ovulation in cattle. 
3) Chapter 7: Formulation and testing of an intravaginal device for aromatase inhibitor 
delivery in cattle. 
a. Among the aromatase inhibitors tested (letrozole, anastrozole and fenbendazole) 
letrozole has greatest potency, as determined by inhibition of estradiol production 
in vitro.  
b. A wax-based vehicle, with higher melting point than the polymer-based vehicle 
used in Chapter 6, allows for a steady and continuous delivery of the active 
compound over the treatment period. 
c.  Addition of a letrozole-containing gel coating improves initial absorption and 
hastens the increase on plasma concentrations of the active ingredient, while the 
letrozole-containing wax-based vehicle prolonged drug-delivery from the 
intravaginal device. 
4) Chapter 8: Effect of aromatase inhibitor intravaginal devices on ovarian function in 
cattle. 
a. The vehicle used to deliver letrozole with an intravaginal device (wax plus gel 
coat vs wax alone) in cattle differentially affects ovarian function. 
b. Letrozole-impregnated intravaginal devices formulated with a wax base plus a gel 
coat vehicle effectively delivers elevated concentrations of letrozole in heifers and 
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reduces estradiol production resulting in increased follicular growth and lifespan, 
without adversely affecting progesterone production 
c. Letrozole-impregnated intravaginal devices formulated with a wax base plus a gel 
coat vehicle is most suitable for the application of a letrozole-based protocol for 
the synchronization of ovulation in cattle. 
5) Chapter 9: Synchronization of ovulation in cattle with an aromatase inhibitor-based 
protocol: a pilot study. 
a. Addition of a letrozole-impregnated intravaginal device for 4 days, combined 
with PGF treatment at device removal and GnRH 24 h post-device removal 
increases the percentage of ovulations and synchrony of ovulation in cattle, 
regardless the stage of the estrous cycle at initiation of treatment.  
b. Reduced luteal lifespan after letrozole treatment is reported for the first time. 
Further investigation is needed in order to elucidate the mechanism responsible 
for this observation.  
c. Although the results obtained in the AI trial are disappointing, additional studies 
are needed in order to elucidate the mechanisms related with reduced fertility after 
letrozole-based synchronization of ovulation.  
d. Adjustments of timing of AI and interval from PGF to GnRH treatment may need 
to be considered in order to improve pregnancy rates after letrozole-based 
synchronization protocols. 
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e. Letrozole treatment regimen presented in Chapter 9 has potential as a model to 
investigate the effect of estradiol deprivation on oocyte maturation and fertility in 
vivo. 
 
The results of the experiments included in this thesis and the related literature lead us to 
conclude that the general hypothesis that letrozole has potential as a steroid-free option for the 
control of ovarian function for the purposes of fixed-time artificial insemination and embryo 
production was supported. However, further research will be needed in order to elucidate the 
effects of estradiol deprivation and letrozole treatment during the proestrous on oocyte 
competence and fertility of the resulting ovulations in cattle. 
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CHAPTER 12: FUTURE STUDIES 
Based on the conclusions drawn and the limitations identified during the work presented in this 
thesis, I raise the following research questions for future consideration: 
 Which non-steroidal follicular factors, if any, are preventing the increase in FSH secretion 
before and after follicular selection? Is inhibin involved in the lack of FSH surge after 
letrozole-induced estradiol deprivation in cattle? 
 Is there a critical timing for the luteotrophic effects of letrozole to become evident? Is 
letrozole, given at different stages on the estrous cycle, detrimental to luteal function? 
 Can a long-term treatment with letrozole stimulate the growth of subordinate follicles to 
ovulatory size? Can these subordinate follicles be induced to ovulate? 
 Can aromatase inhibitors be used in order to reduce the amount of exogenous gonadotropin 
needed for ovarian superstimulation in cattle? 
 Is estradiol required for the normal growth and maturation of the dominant follicle? Are the 
concentration of intrafollicular factors different between letrozole treated and untreated 
animals? 
 How does estradiol deprivation alter gonadotropin secretion patterns? Does it affect it at 
hypothalamic level? At pituitary level? 
 Does inhibition of estradiol secretion during proestrus affect oocyte competence? Are those 
oocytes matured in vivo under low estradiol fertilizable in vitro? 
 Does inhibition of estradiol secretion during proestrus affect sperm transport post-service? 
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 Does inhibition of estradiol secretion during proestrus alter uterine environment and embryo 
survival? Does pre-ovulatory treatment with letrozole in recipient cows affect embryo 
survival? 
 Can these results obtained in heifers be replicated in other farm animals or women? 
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